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EQUIPMENT TO ADDRESS INFRASTRUCTURE AND HUMAN RESOURCE
CHALLENGES FOR RADIOTHERAPY IN LOW-RESOURCE SETTINGS
Abstract

Rachel Elizabeth McCarroll, B.S.

Advisory Professor: Laurence E. Court, Ph.D.

Millions of people in low- and middle- income countries (LMICs) are without access to
radiation therapy and as rate of population growth in these regions increase and lifestyle
factors which are indicative of cancer increase; the cancer burden will only rise. There are a
multitude of reasons for lack of access but two themes among them are the lack of access to
affordable and reliable teletherapy units and insufficient properly trained staff to deliver high
quality care. The purpose of this work was to investigate to two proposed efforts to improve
access to radiotherapy in low-resource areas; an upright radiotherapy chair (to facilitate lowcost treatment devices) and a fully automated treatment planning strategy.
A fixed-beam patient treatment device would allow for reduced upfront and ongoing
cost of teletherapy machines. The enabling technology for such a device is the
immobilization chair. A rotating seated patient not only allows for a low-cost fixed treatment
machine but also has dosimetric and comfort advantages. We examined the inter- and intrafraction setup reproducibility, and showed they are less than 3mm, similar to reports for the
supine position.
The head-and-neck treatment site, one of the most challenging treatment planning,
greatly benefits from the use of advanced treatment planning strategies. These strategies,
however, require time consuming normal tissue and target contouring and complex plan
optimization strategies. An automated treatment planning approach could reduce the
additional number of medical physicists (the primary treatment planners) in LMICs by up to
v|Page

half. We used in-house algorithms including mutli-atlas contouring and quality assurance
checks, combined with tools in the Eclipse Treatment Planning System®, to automate every
step of the treatment planning process for head-and-neck cancers. Requiring only the patient
CT scan, patient details including dose and fractionation, and contours of the gross tumor
volume, high quality treatment plans can be created in less than 40 minutes.
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Chapter 1: Introduction
Cancer is a worldwide and growing epidemic; projected to kill nearly 13 million people
by 2030. It is a fallacy that cancer is a disease only of the developed world; the most recent
statistics showed more than two thirds of cancer-related deaths occur in low- and middleincome countries (LMICs)(1). As the population of LMICs ages and as risk factors such as
smoking, poor dietary habits, and sedentary lifestyles increase, the cancer burden will only
rise(2).
Though colloquially referred to as a single disease, cancer is a class of diseases
which share common traits, and, therefore, the treatment of cancer is necessarily very varied.
Treatment options often involve one or more of three common techniques; surgery,
chemotherapy, and/or radiation therapy. Surgical intervention has the longest history with
records dating back to Greek physicians in the first and second centuries A.D.(3) and may be
required for up to 80% of cancer patients(4). Surgery, however, is often insufficient for
metastatic disease. Chemotherapy, introduced at the beginning of the 20th century, uses
drugs to combat cancer growth and spread at the molecular level and can only be
administered if sufficient laboratory facilities are also available (5). Finally, radiation therapy,
introduced at the end of the 19th century and available for both the palliative and curative
treatment of cancer uses energetic subatomic particles due induce DNA damage and kill
cancer cells(6). Radiotherapy is required for the treatment of more than 50% of the cancer
population (7).
Radiation and its use in medicine have been intertwined from the start; in late 1895
Wilhelm Röntgen designed an experiment to identify the source of flouresence on a painted
cardboard screen and it was only two weeks later he took the famed first radiograph of his
wife’s hand, which he included in the first manuscript describing this new kind of rays(8). The
use of radiation to treat cancers came shortly thereafter, for stomach cancer in 1896, for basal
15 | P a g e

cell carcinoma in 1899, and many others to follow(9). Radiation therapy has advanced quickly
since its introduction and an improved understanding of how to harness the biological effect of
radiation on cancer cells, improvements in the safe and accurate delivery of radiation
throughout the body, and, more recently, advances in computing power and have led to rapid
changes in treatment delivery and improved patient outcomes.
Radiation therapy has been shown to be cost-effective for both palliative and curative
cancer treatment in LMICs (10, 11); one study showed that the cost of an entire course of
radiation therapy in Senegal is only $300USD (12). However, due in part to the substantial
capital investment and the ever-increasing pace of technological advancements, the practice
of radiation oncology in developed and less developed regions rapidly is rapidly diverging. In
low- and middle-income countries, defined as those countries with a gross national income
per capita less than $12,235 USD and where 84% of the world’s population (13) and 57% of
the cancer population lives(1), there exist only 30% of the world’s radiation therapy equipment
(14). It is not only the equipment for treatment that is lacking – so too are trained personnel
required to safely and effectively deliver treatment. It is estimated that by 2020 LMICs will
need an additional 9,169 radiation therapy machines (3.2 times what was available in 2014),
9,915 medical physicists (3.9 times 2014 availability), 12,149 radiation oncologists (2 times
2014 availability), and 29,140 radiation therapists (3.7 times 2014 availability)(15). In order to
bridge the gap in cancer care around the world, and to provide safe, effective, and possibility
lifesaving treatment to 6.3 million people, urgent and innovative solutions are needed.
In order to address the overwhelming demand for radiotherapy, a multi-thronged
approach is necessary. Efforts should seek to utilize technology and ideas at the forefront of
the field, should be developed in concert with professionals for which the solutions are aimed,
and should utilize and build upon previous efforts. Current initiatives underway to bridge the
gap in radiotherapy needs worldwide include efforts to provide necessary equipment and
ancillary supplies to less developed regions, programs for the training (initial and ongoing) of
16 | P a g e

radiotherapy professionals, systems for peer-to-peer collaborations which encourage
professional growth and promote high quality care, the development of low-cost and effective
solutions, and there are many others. Despite these efforts, there remains a significant
challenge to provide radiotherapy services worldwide. The work herein represents two
proposed efforts; an upright radiotherapy chair and a fully automated treatment planning
strategy.

An Upright Radiotherapy Chair
External beam radiation therapy machines have been in use since the 1950s and
early treatments had reports of patients treated in lying, seated, and standing positions (16,
17). The invention of the computed tomography (CT) scanner in 1972 gave physicians the
ability to accurately visualize each patient’s anatomy and, in the context of radiation therapy,
optimize treatment delivery. The incorporation of CT image acquisition for treatment planning
represented a breakthrough in radiation therapy and the acquisition of pre-treatment CT
scans for use in treatment planning has become routine practice in radiation oncology clinics.
The orientation of CT scanners is such that the patient lies, generally supine, on a treatment
couch inside a bore with a diameter of up to 90cm (18), and this effectively requires that
radiation treatment plans are developed for and delivered to patients in a lying position.
Further, it requires that teletherapy machines accommodate this treatment position.
Unfortunately, some patients, particularly those with head-and-neck or lung cancers, may
develop orthopnea, dyspnea, dysphagia, or other conditions that make lying flat for the
duration of treatment difficult or impossible. Further, it has been shown that dosimetric
advantages can be had in other position; for example, when patients assume a seated or
upright position lung volume and motion are reduced, allowing for sparing of normal tissues
and fewer radiation-induced symptoms (19-21).

17 | P a g e

To accommodate the lying position during treatment delivery radiotherapy machines
most commonly feature a rotating gantry around a stationary isocenter and this contributes
greatly to the considerable cost of teletherapy units. In an effort to reduce the cost of
teletherapy treatment machines and with added benefits of patient comfort and limited
dosimetric improvement; we propose the development and validation of a treatment chair for
use in radiation therapy. The use of treatment chair which rotates around the patient’s axis
would allow for a fixed radiation field and tremendously reduce machine cost. In addition,
such a treatment paradigm would allow for a reduction in cost due to shielding, set-up,
treatment delivery, machine downtime, and other factors of which are currently under
investigation (22-24). This lower cost machine is of interest to machine vendors and would be
highly applicable in areas with limited resources.
The work herein represents an important step in the assessment of the clinical utility of
a radiotherapy treatment chair; set-up reproducibility. As radiation treatment often occurs in
small fractions over the course of many weeks and the prescribed treatment is developed
from a single pre-treatment image it is critical that the patient be positioned in very similar
positions each day; this is known as inter-fraction set-up reproducibility. Further, as radiation
treatment, especially advanced techniques, may take more than ten minutes for delivery(25) it
is important the patient maintains the same position for the duration of treatment; this is
known and intra-fraction reproducibility. Both inter- and intra- fraction reproducibility are
important aspects when considering the implementation of new patient positions into clinical
practice. The traditional supine position has been shown to have inter- and intra- fraction
reproducibility less than 5mm on average for treatment of the breast (26, 27), prostate (28),
head and neck (29), and whole brain (30). The main goal of this study was to assess the
setup reproducibility of a novel treatment chair design, paving the way for clinical use and
supporting further investigation into a fixed-beam low-cost radiotherapy treatment machine.
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Automated Treatment Planning
Treatment planning is a mainstay in the field of radiation oncology. During the required
treatment planning process a representation of the patient, most often a simulation CT, is
used to design or select beam arrangements, shapes, energies, and combinations which will
best deliver the prescribed therapeutic dose to the target volume while sparing as much
normal tissue possible. The practice of treatment planning has evolved quite dramatically in
the past thirty years. In the 1990s the practice of acquiring a computed tomography scan of
the patient, on which the target and organs at risk are delineated and the dose delivery is
visualized and optimized, became common practice. Compared to conventional techniques,
3D conformal treatment allowed tumor dose to be escalated without a significant increase in
normal tissue dose (31), thus improving tumor control (32, 33) while reducing normal tissue
complication (34). The use of 3D conformal techniques did, however, also increase the cost,
complexity, burden on equipment and personnel, and time needed to plan and deliver
radiation therapy (31, 35, 36).
Treatment planning and delivery further improved with the introduction of intensity
modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) which rely
on the use of non-uniform beam fluences and an inverse approach to the dose optimization
problem. Through the use of optimization criteria and a search algorithm beam parameters
are optimized in order to meet the constraints set by the user through the minimization (or
maximization) of an objective function. The beam fluence variations in IMRT and VMAT offer
distinct advantages over simpler beam shaping devices for irregularly shaped targets and
those in close proximity to critical organs at risk. The advantages of these advanced
techniques is underlined in the treatment of cancers in the head-and-neck. Cancers in this
region are in close proximity of up to 25 organs at risk, and advanced planning techniques
have been shown to significantly increase planned target coverage and conformality while
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decreasing normal tissue complications including xerostomia and fibrosis (37-40). More than
two thirds of the head-and-neck cancer population lives in less developed regions(1) where
access to these advanced techniques is severely limited and while, for many clinics, the lack
of advanced equipment is the primary barrier in the delivery of advanced treatments, there
are many others for whom the machinery exists but treatment delivery is limited due to
staffing considerations, this is the scenario for our partner clinics in South Africa and the
Philippines.
In low-resource areas the time and cost required for treatment planning, especially for
these advanced techniques, contribute to the limited number of patients able to receive
advanced treatment (41). The cost of personnel, including highly skilled treatment planners,
while less than in high-income countries, represent 10% of the total cost of radiotherapy (6).
Combined with the well documented “brain drain” on human resources in low-income areas
(42) the need for tools which can relieve part of the staffing burden while maintaining a
standard of care is tremendous.
The increasing complexity of treatment planning has also brought other challenges.
Complex treatments often involve many decisions and tradeoffs during the planning process
and it has been shown that every IMRT and VMAT treatment plan may not offer the same
benefits; in a study on treatment plan quality investigators found the plan quality was not
significantly correlated with the treatment planning system, modality of delivery, plan
complexity, education or certification of the planner, planner confidence or experience, the
number of beams, or the number of monitor units. Instead, it was concluded, plan quality was
most contributable to general “planner skill” (43). An automated planning strategy may also
standardize treatment plan quality which are prone to significant variability; this variability
represents a significant challenge when comparing patient outcomes (44) and when
optimizing plan delivery parameters. Additionally, these advanced IMRT and VMAT

20 | P a g e

techniques come with a significant increase in technical burden including infrastructure
required for plan development, quality assurance checks, and delivery.
We propose a solution which would automate the treatment planning process for
head-and-neck cancers; removing a time intensive aspect of the treatment planning process;
standardizing treatment across patients, and relieving highly trained staff for other duties,
ultimately reducing the tremendous deficit in the numbers of these staff.
Automated methods are emerging throughout the radiotherapy process. From beam
commissioning to patient plan checks, researchers and vendors alike are exploring
automated methods of improving radiotherapy (45, 46), and this includes treatment planning
(47-49). At the forefront of automated plan optimization is knowledge based planning (KBP)
which uses information gathered from previously treated patients to generate treatment plans
for new patients and was first reported in 1990 for its potential to organize and harness the
current state of knowledge of treatment planning in order to improve treatment planning (50).
With technological advancement and improved computing power, the interest in KBP has
increased dramatically and has found recent success in the planning of breast, prostate and
head-and-neck cancer showing an improvement in plan quality and a reduction in plan
variability (51-54). Unfortunately, these studies fall short of full plan automation, as often
these KBP algorithms require manual inputs. One of the most time intensive requirements of
advanced planning techniques is the delineation of normal tissues and targets. The automatic
contouring of these structures is an area of ongoing research; technologies ranging from
traditional atlas based deformable solutions to newer deep learning pixel-wise classification
methods are finding success in the contouring of both normal tissues and targets for a variety
of treatment sites (55-57). These approaches, however are limited in scope and are not fully
integrated into routine clinical practice. The full validation of automatic contouring for clinical
use and oversight of the use of an autocontouring technique in an automated treatment
planning system has not yet been presented in the literature. Together automatic plan
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optimization and autocontouring represent a majority of the tasks required for treatment
planning.
Ideally, a fully automated planning approach would eliminate the need for human
intervention, would produce clinically acceptable or superior plans, would include methods to
assure the quality and safety of each step, and would do so while reducing the time and
human effort needed for planning. Such an automated planning technique would not only be
tremendously helpful in low resource areas but would prove an essential tool in all clinics,
may improve the standard of care, and would be a reliable tool for comparing planning
techniques within and among patients.
Towards realizing the benefits of full automation in treatment planning, we propose a
fully automated treatment planning approach for head-and-neck cancer. This system would
decrease the time required to generate a high quality plan, would reduce the training needed
for plan production, would reduce plan variability, and may facilitate the transition to advanced
planning techniques. We envision a system for which the user must only provide an approved
CT scan, patient information including information about the prescribed dose and
fractionation, and the identification of the primary target through the contouring of either a
high dose CTV or gross tumor volume(s) including both the primary and nodal disease as
indicated. The system would then use this information to generate a treatment plan through
many, validated steps including plan preparation, automatic contouring of normal tissues,
automatic contouring of target volumes, plan optimization, dose calculation, and plan
finalization. Secondary and independent checks of each step should be implemented for
redundancy and to ensure the safe use of an automated system. An overview of the system
can be seen in Figure 1. The work herein represents validation and development of three key
components, the knowledge based plan optimization, the contouring of normal tissues and
the generation of targets volumes.
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Required Information

1. Patient Information
2. Patient CT Scan

3. Primary and Nodal GTVs

Radiation Planning Assistant
Preliminary Steps
Marked Isocenter Detection
Treatment Isocenter Selection
Couch removal
Contouring
Normal Tissues
Targets
Planning Structures
Plan Optimization
Knowledge Based Optimization
Dose Calculation
Plan Normalization

Result

Treatment Plan

Plan Documentation

Plan Finalization
Plan Documentation
Final Plan Checks

Figure 1. Schematic of the proposed automatic treatment planning strategy. Presented in this work are the development and validation
of automatic contouring of both normal tissues and targets and the knowledge based plan optimization technique and associated quality
assurance checks.
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Chapter 2: Purpose and Central Hypothesis
Central Hypothesis
Equipment can be developed which may partially alleviate the staff and infrastructure burden
of radiotherapy in low- resource settings and are feasible and clinically appropriate.

Specific Aim 1: An Upright Radiotherapy Chair
Aim: To preclinically validate the use of an upright radiotherapy chair for head-and-neck
patients
Hypothesis: An upright radiotherapy chair has clinically acceptable inter- and intra- fraction
reproducibility
Experiment 1.1: Establish the inter- and intra- fraction setup variation of an upright
radiotherapy chair
Experiment 1.2: Assess patient experience in an upright radiotherapy chair

Specific Aim 2: A Fully Automated Treatment Planning Strategy
Aim: To develop and validate a single optimization treatment planning strategy for the headand-neck
Hypothesis: Single optimization head and neck treatment plans perform with equal quality to
clinically acceptable plans and 90% are accepted by radiation oncologists for use without edit.
Experiment 2.1: Quantitative and physician review of treatment plan quality

Specific Aim 3: Automatic Delineation of Normal Structures in the Head-andNeck
Aim: The assess the feasibility of the use of automatically contoured normal structures in the
head and neck in a fully automated treatment planning strategy
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Hypothesis: Automatically contoured normal structures can be used for treatment planning
purposes without significant impact on plan quality.
Experiment 3.1: Evaluation of automatic contouring algorithms for normal structures
in the head and neck
Experiment 3.2: Clinical use of an autocontouring algorithm for normal structures in
the head and neck
Experiment 3.3: Development of a random forest model for assessment of
anatomical errors in autocontours of normal structures in the head and neck
Experiment 3.4: Assessment of dosimetric impact of using autocontoured normal
structures for treatment planning in the head and neck

Specific Aim 4: Automatic Delineation of Target Volumes in the Head-and-Neck
Aim: To assess the feasibility of the use of automatically countered intermediate and low
dose target volumes in the head and neck
Hypothesis: Automatically contoured clinical target volumes can safely be safely used for
treatment planning purposes.
Experiment 4.1: Quantitative and physician review of an automatically contoured
clinical target volumes in the head and neck
Experiment 4.2: Assessment of dosimetric impact of using autocontoured clinical
target volumes for treatment planning in the head and neck
Experiment 4.3: Development of a method to ensure quality of autocontoured clinical
target volumes

25 | P a g e

Chapter 3: An Upright Radiotherapy Chair
A substantial portion of this chapter is written or based on the following publication:
McCarroll RE, Beadle BM, Fullen D, Balter Pa, Followill DS, Stingo FC, Yang J, Court LE.
Reproducibility of patient setup in the seated treatment position: A novel treatment chair design.
Journal of Applied Clinical Medical Physics. DOI: 10.1002/acm2.12024 Volume 18, Issue 1, Pages
223-229 © John Wiley & Sons
The permission for reuse of this material was obtained from John Wiley & Sons ©.

In this chapter we describe the results for Specific Aim 1 which pertains to the
development and clinical validation of an upright treatment approach. Our working
hypothesis is that an upright radiotherapy chair has clinically acceptable inter- and
intra- fraction reproducibility equal to or less than that in the traditional supine position.

Introduction
The majority of patients treated with radiation therapy are positioned supine on the
treatment couch, with a small proportion prone. These positions are supported by decades of
experience and are suited for the routine practice of 3-dimensional treatment planning with
imaging from computed tomography (CT) scanners which utilize horizontal bores. However,
some patients, particularly those with head-and-neck or lung cancers, may develop
orthopnea, dyspnea, dysphagia, or other conditions that make lying flat for the duration of
treatment difficult or impossible. Further, an upright treatment allows for an increase in lung
volume and decrease in lung motion which allow for the sparing of normal tissues and fewer
radiation-induced symptoms (19-21). In addition to the comfort and dosimetric advantages of
treatment in the upright position, this treatment position could allow for the development of a
treatment paradigm centered on a fixed treatment beam and seated rotating radiotherapy
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patient. This delivery approach would prove advantageous in the development of a low-cost
linear accelerator system, applicable to low- and middle- income countries. Advantages of this
approach in terms of cost, shielding, set-up, treatment delivery, machine downtime, and
others factors are under investigation (22-24). Interest from vendors in a fixed beam system
has further supported this work.
Historically, chairs for radiation therapy are used primarily as an exception for patients
unable to tolerate the lying position and have involved temporary replacement of the
treatment couch with an upright unit(58-60) Additionally, these previous studies are from an
era in which treatment planning was carried out primarily using 2D image acquisition(61-63)
and margins which were much more tolerant of positional inaccuracies. The degree of these
uncertainties is not well documented in the literature; only one description of an upright
system included an assessment of the reproducibility of patient position(61) and found that for
all patients shifts of the treatment blocks of at least 5mm were required.
Concerning treatment planning in the upright position, traditional CT scanner
geometries do not allow for image acquisition in the seated position. Recent studies, however,
have explored the feasibility of acquiring cone beam CT (CBCT) scans of seated patients
using the on-board imaging capabilities of modern medical linear accelerators by positioning
the gantry at 0° degrees, and then rotating the patient couch instead of the gantry (64, 65).
Studies have also demonstrated the feasibility of using cone beam CT images acquired at the
treatment unit for treatment planning (64, 66-68). This work supports our expectation that we
will soon be able to take CBCT images of patients in an upright position for the purpose of
treatment planning, by rotating the treatment couch. It has been reported that acquisition of a
field of view of 40 cm x 26 cm at isocenter is possible (64).
Given the above, we have developed a treatment chair suitable for use with standard
gantry based linear accelerator geometries for head-and-neck cancer regions, incorporating
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measures designed to optimize the reproducibility of inter- and intra- fraction patient setup.
Herein we report the details of the chair design, inter- and intra- fraction reproducibility
measurements for five head-and-neck cancer patients under simulated treatment scenarios,
and patient feedback and discuss considerations for future development.
Preclinical validation of a treatment chair is necessary for the development of a
treatment approach centered on treatment chair and paired with a fixed radiation beam; such
a treatment paradigm could greatly reduce the upfront and ongoing cost of radiation therapy
make the treatment more available in low-resource settings.

Methods
Chair Design
The chair was initially designed by engineering students at Rice University (Houston,
TX), with major refinement to improve patient comfort and ease of patient positioning. The
general concept was based on a massage chair, as the forward leaning position was
expected to give better stability than a regular chair design. Additionally, this forward leaning
position is beneficial for patients with an excess accumulation of saliva. The chair was
constructed in two major parts: (i) the seat with the back rest was constructed such that it slid
onto the end of the treatment couch and was securely fastened to avoid shifts in position, and
(ii) a unit consisting of footrests (15 x 30 x 2 cm acrylic), a chest plate (T-shaped acrylic), a
face piece, and a wooden support post. Once the patient sat down, the second unit slid into
position between the patients’ legs and securely tightened into position. Having the chair
attach to the couch allowed us to make use of the couch’s remote motions to correct patient
position based on pre-treatment imaging. Additionally, set-up of the chair fits smoothly into
patient treatment workflow, where therapists gather and position any accessories needed for
treatment shortly before the patient enters the treatment vault. The chair allows for many
positional variations due to patient size, height, and comfort. Figure 2 shows the available
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chair adjustments, including adjustment of the seat depth (A), the chest plate height (B), the
chest plate angle (C), the face piece angle (D), and the footrest height (E). The chair was
manufactured in-house, primarily from wood and acrylic materials. Limiting the use of metal
was important to avoid affecting beam or imaging quality. Further, the construction allowed for
easy maneuverability into position. For setup and reproducibility, indexing measures including
notches and angle identifiers were incorporated.

Figure 2. Treatment chair setup. For
simulation, a flattop bench was used to
mimic the treatment couch in the
treatment vault. For image acquisition,
the seat was securely fastened to the
treatment couch. The setup is
adjustable for patient size and comfort
including adjustment of the seat depth
(A), chest plate height (B), chest plate
angle (C), face piece angle (D), and
footrest height (E).

Intra- and Inter-Fraction Imaging
Six head-and-neck cancer patients undergoing radiotherapy (in a supine position)
were accrued with approval from our institutional review board. Five patients completed the
study and are included in the analysis. The seated patients were first set-up in the treatment
chair outside of the treatment room using a flattop bench in lieu of the treatment couch
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(Figure 2). For setup, the chair position was established and a Vac-Lok cushion (MTVLG35C;
Civco Medical Solutions, Coralville, IA) and thermoplastic head mask (MTAPU; Civco Medical
Solutions, Coralville, IA) were made. The Vac-Lok cushion was used to fill any space between
the patient’s chest and the chest piece, to create pseudo arm rests for patient comfort, and to
facilitate set-up reproducibility, especially lateral stabilization (Figure 3). The head mask was
secured over the back of the patient’s head, in contrast to typical head-and-neck cancer
treatment for which a thermoplastic mask is generally placed over the patient’s face and
secured to the treatment table. Additionally, the patients were assessed for the need of
additional accessories, including an A-bar for arm and hand positioning and comfort and a
pillow behind the back for added support.

Figure 3. Patient setup for lateral image
acquisition in the treatment vault , with kV
imagers extended and couch positioned at 0°.
The Vac-Lok cushion was shaped so as to
create armrests for patient comfort, the head
mask was secured of the back of the patient’s
head.
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For imaging, the chair position was duplicated in the treatment vault. For two patients,
acrylic shims were needed to loosen the thermoplastic mask at the face, after the mask had
hardened. A TrueBeam® linear accelerator (Varian Medical Systems, Palo Alto, CA) was
used for this study, primarily due to the couch end load limit of 200 kg, which allows for
positioning of the treatment seat and patient at the couch’s end. With the gantry at 330°,
kilovoltage imagers retracted, and the patient couch lowered to the full extent and positioned
at 270°, the patient was set up as in simulation. The gantry rotation to 330° was necessary to
improve access in this relatively tight space. We also inserted a custom tray into the physical
wedge slot to protect the exit window in case of accidental contact.
The longitudinal table position was selected so that the patient’s vertebrae were
approximately at the beam’s isocenter. Using orthogonal lasers, the patient’s position was
marked on the thermoplastic mask. The gantry was rotated to 0° and kilovoltage imagers
were extended outward. The position of kilovoltage imagers varied between patients due to
patient size and couch location, to which the chair was attached. The superior-inferior, leftright, and anterior-posterior positions of the imagers relative to the patient ranged 10, 3, and
5cm respectively. The position of the imagers was such that anatomical regions captured in
the image were similar between patients. Posterior-anterior images were acquired first (couch
at 90°, gantry at 0°, kV imagers extended), the couch was rotated to 0° and then lateral
images were acquired. All mechanical motions occurred under supervision inside the
treatment vault.
After image acquisition and under supervision, the couch was rotated for 5 minutes to
simulate treatment delivery. Two additional images (lateral and P-A) were then acquired.
Image registration of these two sets of images was used to calculate the first intra-fraction
reproducibility measurement. The patient then got out of the treatment chair and rested for a
few minutes, and the process was repeated to acquire 2 more sets of images, providing one
inter-fraction reproducibility measurement and one additional intra-fraction measurement.
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Upon completion, the patient was asked to complete a questionnaire (see supplemental
materials, page 180) regarding both their supine treatments and their experience in the chair.

Image Registration
The head-and-neck region has many degrees of motion, so inter- and intra-fraction
alignment was evaluated for several sub-regions of the acquired images. We used a method
similar to that used previously to evaluate setup reproducibility in patients with head-and-neck
cancer after cone beam CT guidance (69). Sub-regions of interest on kV projection lateral
images were cervical vertebrae 1-3 (C1C3), C3C5, the mandible, and the occipital bone. The
sub-regions of interest on P-A images were the left temporomandibular joint and the nasal
sinuses. These regions were chosen to facilitate accurate evaluation of patient motion, to
match those studied previously (69), and to obtain high visibility on the acquired images. The
images were processed via histogram normalization and sub-regions were chosen by hand to
include the area of interest, see Figure 4. Rigid 3-dimensional image registration (bidirectional translation and rotation) was carried out between the two 2-dimensional kilovoltage
images in Matlab (MathWorks, Natick, MA) using the gradient descent method with the mean
square error as the registration metric. All registration results were verified visually.

32 | P a g e

Occipita
l Bone
C1C

Mandibl

C3C

Figure 4. Histogram-normalized kilovoltage image of a representative patient , outlining the
sub-regions selected on the lateral image (A) and PA image (B) for registration. C1C3 and
C3C5, cervical vertebrae 1–3 and 3–5, respectively.

Simulated Image Guidance
The use of image guidance for patient positioning and tumor localization in head-andneck cancer patients receiving radiotherapy is a routine procedure in many clinics and is
necessary for the delivery of advanced treatment techniques such as IMRT and VMAT. We
therefore simulated the use of image guidance in our inter-fraction displacement images, as
done by others, which were acquired without patient realignment prior to the simulated
treatment delivery. The two images were first registered according to the position of C1C3
(lateral images) or the spinal column (posterior-anterior images). Then, the remaining subregions were registered as previous. This approach provided a measure of the residual error
in inter-fraction displacement given the use of image guidance.
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Measurement of Registration Uncertainty
To best approximate the possible uncertainty in the rigid registration, we placed an
Alderson Radiation Therapy phantom (ART-210, Radiology Support Devices, Ramsey, NJ) in
the treatment chair, and images were acquired within the range of imaging parameters used
to acquire patient images. The chair and phantom were shifted by a known amount and the
images were registered. The difference between the registration and the true table positon
provides a measure of the uncertainty in our rigid registration technique.

Development of an Updated Chair
Results from this study and feedback from the patient questionnaire indicated several
features of the current chair design which could be improved for both patient comfort and
radiotherapeutic use. A second treatment chair was developed in-house using primarily
acrylic pieces and an increased number of indexing options.

Results
Patient Cohort
The 5 patients in this study were all male, with a median age of 65 years (range: 55–
78 years), mean height of 181.1 cm (range: 180–183 cm), and mean weight of 88 kg (range:
76–111 kg). Female subjects (n > 8) were positioned in the chair during trial development and
found no difficulties in positioning or comfort. On the basis of the feedback from the first two
patients imaged, the face piece was changed from the bolus-based chin-and-forehead piece,
to a suctionable cushion which conforms to the patient’s face (Figure 5). Further, a small
piece of loop fastener was applied to the top of the face piece as a barrier between the seam
of the plastic and the patient’s forehead.
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Figure 5. Face piece of the chair before and after the change implemented after feedback
from the first two patients. Before the change, the chin and forehead pieces were covered
with bolus material for comfort, and the inferior chin piece was arched for anatomical
conformity.

Image Registration
Table 1 lists the intra- and inter- fraction displacement for the 6 sub-regions measured.
Rotation displacement was found to be small, ranging between -0.2° and 0.7°. The error in
the registration, as measured with the phantom measurements was found to be no more than
0.4 mm. Average intra- fraction displacements were less than 2 mm across all patients.
Average inter-fraction displacements were less than 3 mm. The largest displacements were
seen in the anterior-posterior direction. Image guidance improved inter-fraction patient set-up
in the anterior-posterior and left-right directions by an average of 1mm.
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Table 1. Intra-fraction and inter-fraction displacements with and without image guidance in the treatment chair
Mean displacement (mm) ± SE [Range] (n=5)
Inter-fraction

Intra-fraction

C1C3

C3C5

Mandible

Occipital Bone

Nasal Cavity

Left TMJ

S-I

A-P

0.1±1.2

Without IGRT
L-R

S-I

A-P

1.2±2.5

0.5±2.0

-2.5±5.3

[-1.8-1.9]

[-3.3-4.7]

[-1.8-3.3]

-0.1±1.1

1.2±3.3

[-1.8-1.1]

With IGRT
L-R

S-I

A-P

L-R

[-6.8-6.1]

Used for
IGRT

Used for
IGRT

0.2±2.4

-2.0±5.7

-0.3±0.7

0.3±0.5

[-4.9-5.9]

[-3.2-3.4]

[-6.8-7.1]

[-1.3-0.4]

[-0.1-1.0]

0.1±1.1

0.5±1.6

1.0±1.8

-1.2±4.3

0.5±1.3

1.1±3.6

[-1.1-2.3]

[-1.7-3.6]

[-1.1-3.7]

[-7.1-4.0]

[-1.6-2.0]

[-2.1-7.0]

0.2±1.4

0.3±2.5

-0.3±2.3

-2.7±4.3

-0.8±0.4

-0.4±2.6

[-2.3-1.6]

[-5.5-3.5]

[-3.2-3.0]

[-7.4-1.5]

[-1.4--0.3]

[-4.6-2.3]

0.4±1.8

-0.7±1.2

0.4±2.0

2.1±3.4

-1.1±0.9

1.7±6.8

[-3.2-2.4]

[-3.2-1.0]

[-1.9-3.5]

[-1.0-7.3]

[-1.9-0.3]

[-9.1-7.6]

0.6±1.6

-0.8±1.8

0.3±1.9

3.0±4.1

-1.3±1.1

2.6±4.5

[-2.5-3.0]

[-4.7-1.2]

[-2.1-3.0]

[-1.5-8.4]

[-2.4--0.1]

[-4.0-7.8]

SE, standard error; S-I, superior-inferior; A-P, anterior-posterior; L-R, left-right; IGRT, image-guided radiation therapy; C1C3 and
C3C5, cervical vertebrae 1–3 and 3–5, respectively; TMJ, temporomandibular joint
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Table 2. Comparison of inter-fraction displacements in the seated and supine treatment
positions for simulated image guidance with respect to cervical vertebrae 1–3
Mean displacement (mm) ± SE
Supine position
Region of interest

Upright position
(this study)

Kapanen et al(70)*

van Kranen et
al(69)

C3C5

-0.3 ± 0.7

1.2*

0.10 ± 0.00

Mandible

0.5 ± 1.3

2.9

1.30 ± 2.50

Occipital bone

-0.8 ± 0.4

1.3

0.60 ± 2.0 0

C3C5

0.3 ± 0.5

3.1*

0.10 ± 0.50

Mandible

-1.1 ± 3.6

2.2

-0.30 ± 1.20

Occipital bone

-0.4 ± 2.6

1.9

0.30 ± 0.60

Cranial-caudal

Anterior-posterior

*Standard errors (SE) were not reported by Kapanen et al. Additionally, cervical vertebrae 1–
2 (C1C2) were used as a reference, and C5C7 data were reported instead of C3C5 data.

Patient Questionnaire
Patients were asked to rate various aspects of their treatment in the supine and
seated positions by completing a questionnaire consisting of 15 items. Fourteen of the fifteen
resultant comparisons were less than one point apart on a 6 point (0-5) scale. In Figure 6, the
questions separated by 4 tenths of a point or more are illustrated. Regarding comfort in the
arms during treatment, patients preferred the seated position over the supine position, with a
mean score of 4.6, compared with 3.6 for the supine position (a score of 5 corresponded to
“perfectly comfortable”). Patients also had the opportunity to provide written and verbal
feedback about the treatment experience. Verbal feedback included discomfort at the chin
and lips, which was partially alleviated with the change in the face piece, as indicated by
fewer verbal reports of discomfort after the change was made. Pressure from the head mask
and pressure at the chest from the Vac-Lok cushion were also noted. Several patients
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expressed the expected benefit of a deeper seat cushion. One patient requested a strap
around the back to help prevent slouching and to remind the patient to relax forward into the
chair.

Patient Response

6
5
4
3
2
1
0

Upright Chair
Traditional Supine

Patient Feedback

I felt like I
Getting on the needed to
chair was easy move not at
all

I felt calm

I felt stable
My neck was My arms were My back was and supported
perfectly
perfectly
perfectly
on the chair
comfortable comfortable comfortable
(strongly
agree)

4

4.4

4

3.8

4.6

4.6

4

4.6

4

3.6

4.4

3.6

4.2

4.8

Figure 6. The results of the patient questionnaire. Only questions separated by an average of
0.4 points (5 point scale) or more are shown. The full questionnaire can be found in the
supplemental materials. The questionnaire alternated the score assigned to a positive
response. For example, a rating of 5 was assigned to answers of “I felt calm” and “Getting on
the chair (couch) was difficult”. In this figure all positive responses are correlated to a ratings
of 5 and text has been altered for clarity.

Development of an Updated Chair
We modified the chair design to reflect patient feedback and our accumulated
experience. Changes include an increase in seat depth (from 23 cm to 45 cm), the
footrest/chest/face piece no longer attaches to of the seat portion between the patients’ legs
but rather on the outside of one’s hips, and for dosimetric consideration the thick supportive
materials at the chest piece were removed. A schematic and picture of the new treatment
chair can be found in Figure 7.
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A

B

C
a

c

b

d

Figure 7. New radiotherapy chair design. Shown are the pre-build schematic (panel A) and
photos of the seat only (Panel B) and the full chair (Panel C). The new chair design features
adjustments for the angle of the face piece (a), a back strap for patient comfort (b),
adjustments for chest plate depth and angle (c), and adjustments for chest plate height (d).

Discussion
As radiation therapy treatment planning has moved almost entirely to 3-dimensional
methods, the acquisition of CT scans for planning has become routine in many clinics around
the world. The horizontal bore of such scanners is a limiting factor for possible patient
positions and therefore nearly all patients are treated lying in a prone or supine position.
However, this position may not be suitable for all patients, especially those suffering from
orthopnea, dyspnea, or dysphagia. Further, dosimetric considerations may indicate upright or
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seated patient positioning. As techniques for image acquisition at the treatment unit continue
to advance, for treatment paradigms still reliant on 2-dimensional planning techniques, for
patients unable to tolerate a lying treatment position, and for the development of a fixed-beam
low-cost system an upright treatment chair may prove optimal for treatment. We have
designed a treatment chair compatible with current linear accelerator geometries and have
tested patient intra- and inter- fraction displacement for the head and neck region. Patient
displacement was on average less than 2 mm in the intra- and 3 mm in the inter- fraction
scenarios. These raw inter- fraction measurements prove much better than those found for a
previous upright setup for mantle treatments, for which all patients required block shifts of at
least 5 mm, and 35% requiring shifts greater than or equal to 1 cm(61).
We also evaluated inter-fraction displacements in a scenario of simulated image
guidance. While in clinical scenarios the radiation therapist would typically compare the whole
acquired image to a planning image for use in image guidance, we have used only a subregion of the acquired image to simulate image guidance. This approach is consistent with
techniques used previously (69) and both the mean and standard deviation of inter-fraction
displacement in the seated position in our study are on the same order as those reported for
the traditional supine-position techniques (Table 2).
There are limitations to this technique. One patient was not able to complete the
testing, and review of his images before the trial was aborted suggests that he had significant
intra-fractional displacement (up to 3.3 cm). This was likely due to the fact that he was falling
asleep and not feeling well, resulting in significant positional changes. While this only
affected one patient, this may be more widespread; our attempts to create a treatment chair
that is better tolerated than the supine position may not be tolerated by some patients.
Furthermore, we largely enrolled “healthy” patients who tolerated the supine position quite
well, and they also tolerated the upright position quite well. It remains to be seen how
patients with significant medical issues (for instance, orthopnea, dyspnea, thick secretions)
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and for patient nearing the end of treatment may tolerate the upright treatment, and whether it
reflects an improvement over the supine position. These issues will be investigated in future
studies.
The tight geometry of the gantry system and the chair tested in our study is partially a
result of a minimum vertical height of the treatment couch and seat height; therefore, care
must be taken when positioning the patient. We estimate that by the sixth patient setup took
approximately 8 minutes including marking of lasers on head mask, similar to that for supine
positioning. A complete assessment of the shift accuracy of the used registration algorithm
was completed. However, while the rotational displacement of patient images was small, less
than 1°, a similar analysis was not completed for the rotational accuracy of the registration
algorithm and is potential source of error in this study.
The ability to acquire treatment planning images in the upright position, mirroring that
of treatment, is an important aspect of the complete treatment process in the upright position.
Using onboard imaging systems or other techniques, the acquisition of planning images in the
treatment position is possible. Herein we have explored the set-up reproducibility of the
upright treatment position in an in-house built chair. The results show the chair to have interand intra- fraction set-up reproducibility similar to current supine techniques. This works
support the further investigation of the use of this position in the development of a fixed beam
and rotating patient treatment paradigm. Such a position could dramatically reduce the
upfront and ongoing cost of radiotherapy machines which may aide in their implementation in
low-resource and LMIC settings.

Conclusion
In conclusion, our preliminary tests indicate that it is feasible to create an upright
treatment chair with geometry suitable for 3-D imaging (with cone beam CT) and robust
reproducible patient position between and within radiotherapy fractions. This work supports
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this vision of the a system whereby patients can be simulated and treated in an upright
position without degradation of a conformal, modern radiation treatment plan towards a fixedbeam low-cost radiotherapy system.
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Chapter 4: A Single Optimization Treatment Planning
Strategy in the Head-and-Neck
In this chapter we describe the results for Specific Aim 2 which pertains to the
development of a fully automated single optimization head-and-neck treatment planning
approach. Our working hypothesis is that a single optimization head-and-neck treatment
planning approach produces plans which perform with equal quality to clinically acceptable
plans and 90% of which are accepted by radiation oncologists for clinical use without edit.

Introduction
Towards a fully automated treatment planning approach for the head-and-neck an
optimized and validated plan optimization approach is the most important aspect. The
treatment of head-and-neck tumors; in close proximity of up to 25 organs at risk and divided
into multiple target dose levels, represents one of the most challenging sites in treatment
planning. Interest in automated plan optimization strategies has increased dramatically and
researchers have identified several approaches which have found success for prostate, lung,
and the head-and-neck cancers (54, 71-74). These approaches, however are subject many
limitations, including their evaluation for only a small subset of patients, the need for manual
adjustment or fine-tuning after automatic optimization, and the need for manual input
including beam parameters or patient-specific dose parameters.
We seek to develop a fully automated planning strategy in the head-and-neck which
produces plans of equal or superior quality compared to clinically treated plans, does not
require the user to select beam angles, or modify the final treatment plan. Such a technique
could dramatically reduce the human effort needed to generate treatment plans and ultimately
reduce the deficient of highly trained radiotherapy staff in LMICs and represents a critical
component of a fully automated treatment planning system.
43 | P a g e

Methods
Patient Cohort
For this analysis, 54 patients treated at The University of Texas MD Anderson
Cancer Center selected as to represent seven head-and-neck subsites; larynx,
nasopharynx, oral cavity, oropharynx, paranasal sinuses and cavity, and salivary
glands and 30 patients from other institutions treated on a clinical trial were
retrospectively collected. The clinical trial data was obtained through The Cancer
Imaging Archive (75) and was originally derived from the Radiation Therapy Oncology
Group 0522 study (76). Selection criteria for both patient cohorts included a maximum
of three planned target volume dose levels, the use of IMRT or VMAT treatment
delivery, and availability of the treated dose distribution for comparison. Autoplans
were generated for each of the patients and compared against clinical plans at clinical
dose constraints and relevant endpoints. Additionally, 20 patient CTs, 10 collected
from each of 2 partner institutions in South Africa, were used to evaluate the single
optimization treatment planning approach but were not compared to the clinically
treated plans.

Planning Strategy
The planning strategy mirrors the clinical planning approach but competes each step
automatically and without human intervention.
Plan Initialization
Primarily developed by other members of our group, plan initialization steps includes
assignment of the target prescription dose levels, removal of the treatment couch, selected of
the treatment isocenter, initial setup of beam parameters, and contouring of any structures
(planning or otherwise) required for treatment planning but not included in the clinical
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treatment plan. Target prescription dose levels were matched to the clinically delivered plan.
The treatment isocenter was selected to be at the center of all combined planning target
volumes (PTVs). Either three or four 360-degree treatment arcs were selected depending on
target size and orientation. The collimator angles for the first two arcs were set to be 30 and
330 degrees and jaws were determined such that the entire target remained in the beam’s
eye view (BEV) as the gantry rotates through 360 degrees. If the field size exceeded 18 cm
in the x-direction (the direction of travel of the multi-leaf collimators (MLCs)) then the jaw was
set to be symmetric with a field size of 18 cm. This constraint was imposed on the jaw
settings due to mechanical constraints of the MLCs modeled in the treatment planning system
(Varian 2100 series linear accelerator, Millennium 120 MLCs) which have a maximum
distance of travel of 14.5cm, and in an effort to design a planning approach widely applicable
to many machine types which, for example, may not have jaw tracking capabilities. The
collimator was then set to 90 degrees and the jaws set such that all PTVs remained in the
field of view with a 1cm margin over 360 degrees of rotation. If this required that the x jaw size
exceed 18 cm, a fourth field was added such that the two fields cover the PTVs, one from the
most superior extent and from the most inferior and both with a maximum size of 18cm.
Structures required for plan optimization which were not included in the original treatment
plan, including planning and normal structures, were automatically contoured using an inhouse multi-atlas deformable image registration technique, details of which are described in
Chapter 5.
Dose Optimization and Knowledge Based Planning
A knowledge based treatment planning module, RapidPlan®, has been implemented
and is available for clinical use in the Eclipse Treatment Planning system (Varian Associates,
Palo Alto, CA). Using a number of previously treated plans, from which both the geometries of
the targets and organs at risk as well as the planned dose distributions are extracted, DVH
estimation models are used to parameterize a DVH estimation algorithm which sets the
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constraints for new patients. The methodology employed by the proprietary RapidPlan®
software is based primarily on work from Duke University Medical Center which characterizes
inter-patient organ at risk sparing (77). To estimate the DVH for each organ at risk,
quantitative metrics are used which include the distance to target histogram, the relative
relationship between the OAR and the targets, and additional anatomical features including;
the relative volume overlap, the relative out-of-field volume, the absolute OAR volume and the
absolute target volume (78). In RapidPlan® the user has the capability to create their own
DVH estimation models based on patients selected by the user, though there are two vendor
provided DVH estimation models for the head-and-neck – the “CancerCare Manitoba Head
and Neck” and the “Washington University Head & Neck models”. The latter served as the
basis for this work. The details of the data set used to develop the Washington University
Head & Neck Model can be found in the provided model description. In short, the model was
trained and tested on plans with targets delineated in the nasopharynx, oral cavity,
oropharynx, hypopharynx, larynx, or other unknown head-and-neck primary anatomical
locations. The model allows for one, two, or three targets and estimates the DVH curve for the
brain, brainstem, upper esophagus, larynx, lips, spinal cord, mandible, middle ear, oral cavity,
parotid glands, pharyngeal constrictors, and submandibular glands. Provided in the model
description are contouring guidelines for both targets and organs at risk. The model was
trained and validated on unilateral and bilateral cases planned as head first, supine, 6-9 field
IMRT cases with 6x photons, couch rotation of 0 degrees and fields with allowable gantry
angles in increments of 40 degrees from 0 to 320 degrees. The objectives and relative
priorities used for clinical training cases can be found in the model description.
For this study we used the model-provided line constraints for normal structures and
modified or added new templated constraints for both structures with model provided line
constraints and other structures. Through iterative testing structure constraints and priorities
were optimized based on quadrative analysis and physician feedback. The final constraints
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used for the planning strategy presented here can be found in the Appendix. As is currently
mandatory in the Eclipse TPS when using RapidPlan®, the Photon Optimizer (PO) algorithm
(version 13.5.35) was used to optimize VMAT plans. Dose was calculated using the
anisotropic analytic algorithm (version 13.5.35) implemented in the Eclipse treatment planning
system.
To ensure adequate coverage of each target autoplans were normalized such that
95% of the target volume received at least 98% of the prescribed dose. To reduce plan
sensitivity to normalization, normalization criteria were implemented. Structures with volume
less than 20cc, which can greatly effect plan normalization especially if the structure is in a
high gradient area, and structures with more than 20% of the target volume having Hounsfield
unit less than -800, in which high doses are not theoretically achievable and the uncertainty in
dose calculation algorithms is high, were excluded for normalization purposes, unless it was
the only target.

Quantitative Plan Analysis
For evaluation, 4 patient groups were considered; (1) all patients with corresponding
clinical plans, (2) only patients treated at MD Anderson, (3) only patients treated at other
institutions as part of a clinical trial, and (4) only patients from partner institutions in South
Africa for which corresponding clinical plans were not available. The autoplans were
evaluated at typical clinical constraints and those outlined in RTOG protocol 1016. Autoplans
were assessed as the mean, standard deviation, minimum and maximum values across
patients at dosimetric points of interest, and the percentage of plans meeting the clinical
constraint.
For plans with corresponding clinically delivered plans, autoplans were also compared
against the corresponding clinical plans at many DVH endpoints using the Wilcoxon signed
rank test, a nonparametric statistical hypothesis test based on rank orders for two planning
groups. The two planning techniques were also compared using the Brown-Forsythe test, a
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non-parametric test which tests for the equality of the variances in the two planning groups by
examining the absolute distance of each point from the median of the distribution(79). For
both tests, significance was established as a p-value of less than 0.05. When comparing
plans using the Wilcoxon signed rank test, plans were normalized such that DVHs were
matched at the dose received by 95% of the high dose PTV, allowing for a fair comparison of
OAR sparing and target coverage.

Physician Review of Autoplans
Throughout the process, specialized head-and-neck radiation oncologists were
consulted concerning plan quality. Feedback was used to improve the planning strategy.
Once the planning strategy was finalized, plan review documents were created for 40
patients, 20 from the cohort of patients treated at MD Anderson and 20 from the cohort of
patients treated on a clinical trial. Review documentation included CT slices with overlaid
dose distributions, beam and field information, patient information and DVH curves for target
and normal structures. A head-and-neck radiation oncologist was asked to rate the plans on a
three point scale, either needing no edit for clinical use, needing minor edit, or needing major
edit.

Results
VMAT optimization of plans took 5.5 ± 2.0 minutes (average ± standard deviation) and
dose calculation took 9.0 ± 3.3 minutes, an additional 1 minute was required for additional
steps including opening the plan and setting the prescription. Other pre-planning activities
were not systematically recorded for this study, but for a sample of ten patients automated
tasks which include the removal of the treatment couch, detection of the body, selection of the
isocenter, determination of the field parameters, contouring of planning structures, data
format conversion, and import of DICOM files into Eclipse took 22.5±1.1 minutes, with the
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largest time commitment (on average, 18 minutes) coming from contouring. The entire
planning process is therefore estimated to require an average of 37 minutes.

Patient Cohort
Patient characteristics can be found in Table 3. One of the thirty patients collected and
treated on the clinical trial had a CT scan with variable slice spacing, which is not compatible
with the necessary autocontouring and was thus excluded from analysis.

Table 3. Characteristics of patients used to validate the treatment planning strategy. In
parenthesis are additional statistics of the 20 patients collected from the South African partner
institutions
Characteristic
Number of Target Dose
Levels
3
2
1
Gender
Male
Female
Unknown
Sub-site
Hypopharynx
Larynx
Nasopharynx
Oral Cavity
Oropharynx
Paranasal Sinuses
Salivary Glands
Unknown

Number
56 (4)
18 (9)
9 (7)
38
16
29 (20)
3(1)
12(3)
5(1)
12(3)
41(2)
5
5
20(10)

Quantitative Plan Analysis
Plans were normalized such that 95% of each of the PTVs received at least 98% of
the prescribed dose, excluding structures with volume less than 20cc or for which more than
20% of the PTV had Hounsfield unit less than -800, as previously discussed. Of 250 total
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targets, 2 had more than 20% of the volume with Hounsfield unit less than -800 (22% and
26%) and 8 had volume less than 20cc [range 4-19 cc]. All ten of these exceptions were from
the MD Anderson patient data set. Of the ten exceptions only four targets received less than
98% of the prescribed dose to 95% of the volumes after plan normalization. The structure
chosen for normalization as well as the percentage of dose covering 95% of the target volume
can be found for all targets in Figure 8. Forty six of the 103 autoplans were normalized to the
high dose PTV, 25 to the intermediate dose PTV, and 32 to the low dose PTV.
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MD Anderson data Set

South Africa data Set

Clinical Trial data Set

High Dose PTV
Intermediate Dose PTV
Low Dose PTV

Figure 8. Coverage of 95% of target volumes , used for normalization. High dose PTVs are
shown in red, intermediate dose in blue, and low dose in yellow. Patients from the MD
Anderson data set in squares, from the clinical trial data set are displayed as circles, and from
the South African data set in diamonds. The target receiving 98% of the prescription dose to
95% of the volume was chosen for normalization.
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Quantitative metrics describing the autoplan and corresponding clinical plans including
the mean, standard deviation, and minimum and maximum value at clinically relevant
dosimetric endpoints can be found in Table 4 and the fraction of both clinical and autoplans
meeting clinical constraints in Table 5. Clinical constraints were, on average, met in clinical
plans more often for patient cohort from MD Anderson (86%) than those treated on a clinical
trial (72%).
Constraints least often met were the mean dose less than 39 Gy the submandibular
glands, for which of 83 clinical plans 16% and 35% met for ipsilateral and contralateral
glands, respectively, and autoplans met less often with rates of 12% and 28%, respectively.
Next least often met was the clinical constraint of a mean dose less than 26 Gy to the parotid
glands, for which clinical plans met with a rate of 46% and 83% for contralateral and
ipsilateral glands respectively. Autoplans met these constraints more often at rates of 51%
and 88%.
Of the 103 autoplans, all but two had maximum spinal cord dose less than 45Gy. One
plan, from the MD Anderson data set had a spinal cord maximum dose of 45.1Gy and while
exceeding a 45Gy constraint, meets a constraint of less than 0.03cc with dose greater than
48Gy which has been reported in the literature(80, 81). The other plan not meeting this
constraint had the spinal cord contour within 1.3mm of the high dose PTV, and had a
maximum dose of 48.44Gy, this patient, from the cohort of patients from South Africa, did not
have a corresponding clinical plan. Similarly, two patients from the South African data set did
not meet the clinical constraint of brainstem maximum dose less than 54 Gy, having
maximum doses of 60.2 Gy and 57.4 Gy. For these patients the brainstem contour and high
dose PTV overlapped with volumes of 0.3 and 0.1cc. These patients failing to meet brainstem
and spinal cord constraints can be seen in Figure 9.
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Table 4. Quantitative evaluation of autoplans and corresponding clinical plans (when available) at clinically relevant dosimetric points.

Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)

AutoPlans
Clinical Plans
mean±std
[min-max]
mean±std
[min-max]
Spinal Cord, Maximum Dose [Gy]
39.2±5.2
[4.8-45.1]
32.2±11.6
[2.8-48.9]
38.0±6.2
[4.8-45.1]
26.0±9.6
[2.8-48.9]
41.1±0.8
[40.2-43.7]
43.7±3.0
[38.8-48.9]
41.0±3.8
[32.0-48.4]
Ipsilateral Parotid, Mean Dose [Gy]
27.6±16.2
[0.1-67.8]
30.4±17.7
[0.0-70.5]
26.6±18.8
[0.1-67.8]
27.4±19.6
[0.0-70.5]
29.5±9.9
[16.5-57.3]
36.0±12.1
[23.3-66.0]
38.5±17.7
[6.0-64.3]
Ipsilateral Parotid, Volume Receiving > 30Gy [%]
37.1±29.1
[0.0-100.0]
44.4±31.0
[0.0-100.0]
35.9±33.5
[0.0-100.0]
40.2±33.3
[0.0-100.0]
39.2±18.8
[16.5-57.3]
51.9±25.0
[12.7-100.0]
56.6±29.4
[6.0-64.3]
Ipsilateral Submandibular Gland, Mean Dose [Gy]
57.9±19.6
[0.5-72.4]
58.2±19.2
[0.5-74.9]
53.4±22.1
[0.5-72.4]
53.1±20.8
[0.5-72.3]
66.2±9.9
[20.2-72.3]
67.9±10.5
[17.3-74.9]
58.1±15.8
[26.4-75.3]
Cochleae, Maximum Dose [Gy]
13.1±15.1
[0.0-69.5]
13.6±14.8
[0.0-72.9]
14.8±17.2
[0.0-69.5]
10.0±13.5
[0.0-72.9]
10.1±9.2
[2.2-44.5]
20.5±14.6
[2.1-57.4]
19.6±23.5
[0.6-75.2]

AutoPlans
Clinical Plans
mean±std
[min-max]
mean±std
[min-max]
Brainstem, Maximum Dose [Gy]
33.6±15.3
[0.0-48.3]
28.6±18.5
[0.0-71.6]
29.3±16.7
[0.0-48.3]
18.5±14.5
[0.0-49.1]
41.6±7.3
[16.5-47.7]
47.2±6.9
[33.5-71.6]
28.7±20.2
[1.7-60.2]
Contralateral Parotid, Mean Dose [Gy]
16.5±7.6
[0.1-34.9]
16.1±9.8
[0.0-33.2]
14.0±7.5
[0.1-34.9]
11.0±7.9
[0.0-23.4]
21.2±5.1
[12.9-29.2]
25.6±4.6
[15.3-33.2]
24.3±14.2
[5.6-50.7]
Contralateral Parotid, Volume Receiving > 30Gy [%]
14.6±13.6
[0.0-52.7]
18.2±14.4
[0.0-49.0]
10.4±12.1
[0.0-52.7]
11.4±11.3
[0.0-32.6]
22.5±13.0
[0.8-43.0]
30.5±10.6
[3.7-49.0]
31.8±27.7
[0.0-86.7]
Contralateral Submandibular Gland, Mean Dose [Gy]
48.6±19.9
[0.4-72.1]
43.8±24.9
[0.5-73.0]
42.6±21.3
[0.4-72.1]
34.2±24.9
[0.5-72.1]
59.7±10.3
[23.6-71.9]
61.810.7
[19.7-73.0]
49.3±18.3
[11.9-73.0]
Brain, Maximum Dose [Gy]
38.2±19.1
[0.0-69.5]
41.019.9
[0.0-71.9]
35.6±22.1
[0.0-69.5]
34.521.4
[0.0-70.3]
43.2±9.9
[13.3-57.1]
53.27.5
[37.3-71.9]
34.2±9.9
[1.5-78.5]
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Table 4. Continued from previous page.
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)
Structure
All Patients (n=83)
MDACC Patients (n=54)
Clinical Trial Patients (n=29)
South Africa Patients (n=20)

Optic Chiasm, Maximum Dose [Gy]
5.1±10.0
[0.0-62.0]
4.9±10.5
[0.0-52.5]
6.6±12.2
[0.0-62.0]
6.2±12.0
[0.0-52.5]
2.1-0.9
[1.0-4.2]
1.4±1.2
[0.0-4.7]
9.8±16.6
[0.5-64.6]
Lens, Maximum Dose [Gy]
2.1±2.5
[0.0-15.6]
1.7±2.5
[0.0-12.2]
2.4±3.0
[0.0-15.6]
1.9±2.6
[0.0-12.2]
1.5±0.5
[0.7-3.4]
1.1±1.7
[0.0-7.1]
3.5±5.0
[0.3-21.4]
High Dose PTV, Dose Received by hottest 1cc [% of Rx]
106.4±2.1
[102.7-113.5] 106.6±2.7
[97.5-114.5]
106.7±2.3
[102.7-113.5] 105.2±1.5
[97.5-107.6]
105.9±1.5
[103.9-110.1] 109.1±2.5 [104.1-114.5]
108.7±3.4
[106.1-119.4]
Intermediate Dose PTV, Volume Receiving 95%Rx [%]
99.1±1.6
[91.8-104.0]
100.6±1.7
[93.3-106.6]
99.1±1.8
[91.8-103.1]
100.5±1.5
[93.3-102.7]
99.1±1.4
[98.0-104.0]
100.7±2.0
[97.5-106.6]
98.4±0.8
[98.0-100.6]

Optic Nerves, Maximum Dose [Gy]
5.5±11.2
[0.0-61.7]
5.6±12.2
[0.0-57.8]
7.4±13.5
[0.0-61.7]
7.2±13.8
[0.0-57.8]
2.1±0.8
[0.9-4.1]
1.2±1.3
[0.0-4.6]
12.5±22.1
[0.5-71.4]
Eyes, Maximum Dose [Gy]
5.4±10.8
[0.0-59.7]
4.8±10.0
[0.0-56.9]
7.1±13.0
[0.0-59.7]
6.3±12.0
[0.0-56.9]
2.2±1.1
[0.8-7.0]
1.9±2.3
[0.0-12.8]
8.7±14.6
[0.4-49.0]
High Dose PTV, Volume Receiving 95%Rx [%]
98.7±1.0
[98.0-102.8]
100.2±1.6
[89.8-102.0]
98.7±0.9
[98.0-101.6]
100.1±1.9
[89.8-102.0]
98.8±1.3
[98.0-102.8]
100.3±0.5
[99.0-101.1]
99.5±2.5
[98.0-107.5]
Low Dose PTV, Volume Receiving 95%Rx [%]
98.4±2.0
[87.5-105.7]
100.6±1.9
[93.0-107.7]
98.5±2.3
[87.5-105.7]
100.6±1.6
[93.0-107.7]
98.2±0.3
[98.0-99.0]
100.5±2.6
[97.2-107.7]
99.8±2.7
[98.1-103.8]
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Table 5. Fraction of clinical and autoplans meeting clinical dosimetric constraints
MDACC & CT Patients
Clinical Trial (CT)
(n=83)
Patients (n=29)
Clinical
Clinical
Structure
Constraint
Autoplans
Autoplans
Plans
Plans
Spinal Cord
Dmax<45Gy
88%
99%
66%
100%
Brainstem
Dmax<54Gy
96%
100%
90%
100%
Ipsilateral Parotid
Dmean<26Gy
46%
51%
24%
38%
Contralateral
Dmean<26Gy
Parotid
83%
88%
52%
76%
Ipsilateral Parotid
V30Gy<50%
64%
75%
55%
79%
Contralateral
V30Gy<50%
Parotid
100%
99%
100%
100%
Ipsilateral
Submandibular
Dmean<39Gy
Gland
16%
12%
3%
3%
Contralateral
Submandibular
Dmean<39Gy
Gland
35%
28%
3%
7%
Cochleae
Dmax<35Gy
91%
89%
83%
97%
Optic Chiasm
Dmax<54Gy
100%
99%
100%
100%
Optic Nerve
Dmax<54Gy
99%
99%
100%
100%
Lens
Dmax<7Gy
95%
95%
96%
100%
Eyes
Dmax<35Gy
98%
98%
100%
100%
Brain
Dmax<54Gy
70%
84%
59%
97%
High Dose PTV
V1cc<110%
87%
93%
62%
97%
High Dose PTV
V1cc<117%
100%
100%
100%
100%
High Dose PTV
V95%>95%
74%
24%
72%
17%
Intermediate Dose
V95%>100%
PTV
100%
100%
100%
100%
Intermediate Dose
V95>80%
PTV
71%
9%
43%
0%
Low Dose PTV
V95>100%
100%
100%
100%
100%
Low Dose PTV
V95%>78%
98%
100%
100%
100%

MDACC Patients
(n=54)
Clinical
Autoplans
Plans
100%
98%
100%
100%
57%
57%

South Africa
Patients (n=20)
Autoplans
90%
85%
25%

100%
69%

94%
72%

50%
40%

100%

98%

75%

22%

17%

20%

52%
95%
100%
98%
94%
97%
76%
100%
100%
76%

39%
85%
98%
98%
93%
97%
78%
91%
100%
29%

25%
73%
95%
89%
81%
88%
70%
85%
95%
100%

100%

100%

8%

81%
100%
96%

12%
100%
100%

100%
25%
100%
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High Dose PTV

Brainstem
Spinal Cord

Figure 9. Examples of normal structures not meeting clinical constraints . In only these three
patients did spinal and brainstem structures fail to meet clinical maximum dose constraints. In
all cases the critical structure in question was in very near proximity or overlapping with the
high dose target volume. In panel A, the spinal cord and high dose planning target volume are
separated by only 1.3mm, in panels B and C the brainstem overlaps with the high dose
planning target volume. These cases underline the need for sanity checks on contours prior to
plan optimization.

A paired Wilcoxon signed rank test was used to compare the clinical and autoplans for
three groups – all 83 patients with available clinical plans, 54 patients from MD Anderson, and
29 patients treated at on a clinical trial protocol. The p-value of the Wilcoxon signed rank test
for each DVH metric can be found in Table 6. Considering all 83 patients with corresponding
clinical plans, the autoplans significantly outperformed their clinical counterparts considering
the volume of spinal cord receiving more than 45 Gy, the maximum dose and the volume
receiving more than the clinical threshold of 54 Gy to the brain, the mean dose to the
ipsilateral parotid and volume receiving 30 Gy to the ipsilateral and contralateral parotids. The
clinical plans performed better considering the maximum dose to the spinal cord, brainstem,
optic chiasm, optic nerves, eyes, and lens. However, for all these the plans were not
significantly different considering the volume receiving more than the clinical maximum dose
threshold. The clinical plans had significantly better sparing of the submandibular glands with
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a lower average mean dose and significantly better coverage of the low dose PTVs at 95% of
the prescription dose and a lower dose to 1cc of the high dose PTV. Similarly, when
considering only the patients from the MDACC data set the clinical plans outperformed the
autoplans on all these categories. The autoplans only outperformed the cohort of patients
from MD Anderson considering the volume receiving more than 30Gy to the ipsilateral
parotid, the mean dose to the contralateral parotid, and the volume of the intermediate dose
PTV receiving more than 95% of the prescribed dose.
When considering the cohort of patients treated on a clinical trial, the autoplans
significantly outperformed the clinical plans for a majority of evaluated constraints. The
autoplans outperformed the clinical plans in terms of maximum dose and volume exceeding
the maximum dose to the spinal cord, brainstem, brain, and cochlea, mean dose and V30Gy
to both the contralateral and ipsilateral parotids, and dose to the hottest 1cc of the high dose
PTV. The only categories in which the 29 clinical plans treated on a clinical trial outperformed
the autoplans were the maximum dose to the optic nerves, chiasm, lens, and eyes, though for
none of these did the clinical plans outperform the autoplans when considering the volume of
the structure exceeding the clinical constraints and the maximum dose constraints were met
for all patients.
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Table 6. Comparison of autoplan performance to clinically treated plans. Shown are p-values
of the paired Wilcoxon signed rank test. In green are parameters for which the autoplans
outperformed the clinical plans, and in red which the clinical plans outperformed the
autoplans.

Structure
Spinal Cord
Brainstem
Ipsilateral Parotid
Gland
Contralateral Parotid
Gland
Ipsilateral
Submandibular Gland
Contralateral
Submandibular Gland
Cochleae
Optic Chiasm
Optic Nerves
Lens
Eyes
Brain
High Dose PTV
Intermediate Dose
PTV
Low Dose PTV

Test
Point
D_max
V_45Gy
D_max
V_54Gy
D_mean
V_30Gy
D_mean
V_30Gy

p-value, Wilcoxon signed rank
All Patients
Clinical Trial
MDACC Patients
(n=83)
Patients (n=29)
(n=54)
<0.01
<0.01
<0.00
<0.01
<0.01
1.00
<0.01
<0.01
<0.01
0.25
0.25
1.00
<0.01
<0.01
0.23
<0.01
<0.01
<0.01
0.27
<0.01
<0.01
<0.01
<0.01
0.39

D_mean

0.02

0.15

<0.01

D_mean

<0.01

0.28

<0.01

D_max
V_35Gy
D_max
V_54Gy
D_max
V_54Gy
D_max
V_7Gy
D_max
V_50Gy
D_max
V_54Gy
D_1cc
V_95%

0.51
0.11
<0.01
1.00
<0.01
0.50
<0.01
0.13
<0.01
0.50
0.01
0.01
<0.01
0.69

<0.01
0.01
<0.01
1.00
<0.01
1.00
<0.01
1.00
<0.01
1.00
<0.01
<0.01
<0.01
1.00

<0.01
<0.01
<0.01
1.00
<0.01
0.50
<0.01
0.08
<0.01
0.50
0.01
0.54
<0.01
1.00

V_95%

0.06

0.77

0.02

V_95%

0.02

0.07

0.26
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Considering the variance between the two planning strategies, the results of the
Brown-Forsythe test for all patient with corresponding clinical plans are shown in Table 7. A
significant p-value, as for maximum dose to the spinal cord and brainstem; and mean doses
to the contralateral parotid and submandibular glands, indicates that the two distributions
come from distributions with different variances. When considering all 83 patients, the
standard deviation across plans was less for autoplans than clinical plans, suggesting the
autoplanning technique provides plans with decreased inter-patient variability.

Table 7. Brown-Forsyth test of equal variance between autoplans and clinical plans. A
significant p-value (p<0.05, shaded green) indicate that the distributions of clinically relevant
DVH points have different variances. For each tissue the RPA plan distribution had a
significantly smaller variation than the clinical plans.
p value, Brown-Forsythe Test
Structure
Spinal Cord
Brainstem
Ipsilateral Parotid
Contralateral Parotid
Ipsilateral Submandibular Gland
Contralateral Submandibular Gland
Cochleae
Optic Chiasm
Optic Nerves
Lens
Eyes
Brain
High Dose PTV
Intermediate Dose PTV
Low Dose PTV

Test Point
D_max
D_max
D_mean
V_30Gy
D_mean
V_30Gy
D_mean
D_mean
D_max
D_max
D_max
D_max
D_max
D_max
D_1cc
V_95%
V_95%
V_95%

All Patients (n=83)
<0.01
<0.01
0.40
0.61
0.01
0.63
0.81
0.04
0.73
0.74
0.50
0.37
0.99
0.48
0.11
0.95
0.82
0.34
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Figure 10 describes the layout of Figure 11 in which the performance of the
autoplanning strategy against the corresponding clinical plan for all 83 patients is considered
at many clinically relevant dosimetric points. Over 83 patients and 18 structures, 4 bilaterally,
for a total of 1719 DVH points considered (36 target volumes did not exist, and 71 structures
were outside of the dose calculation region in the clinical plan), 610 (35%) had improved DVH
metric for the autoplans, but the improvement did not change the whether the plans met
clinical constraints. For 989 structures (58%), the clinical plan performed better at the
endpoint, but the difference was not beyond the clinical threshold. However, for 76 structures
(4%) the autoplan outperformed the clinical plan and this difference was beyond clinical
thresholds, this is compared to 44 structures (3%) of endpoints for which the clinical plan
performed better and was beyond clinical limits. Of the 4% of endpoints for which the
autoplan provided an improvement at the dosimetric endpoint and this resulted in the plan
meeting clinical constraints whereas the clinical plan had not met that constraint, 91% came
from the population of patients treated on the clinical trial.
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Figure 10. Explanation of clinical and autoplan comparison. For structures with an upper DVH
constraint (i.e. spinal cord maximum dose less than 45Gy) (right), plan quality was improved if
the DVH metric of the autoplan was less than the DVH metric of the clinical plan, these plans
will be reflected in the shaded green regions. Plans for which an improvement was seen but
both plans met the clinical constraint (e.g. spinal cord maximum dose of 43 Gy in the clinical
plan and 42 Gy in the autoplan) are reflected in a, when both fail to meet the clinical
constraint (e.g. spinal cord maximum dose of 47 Gy in the clinical plan and 46 Gy in the
autoplan) in panel b. In the darker green region, panel c, the autoplan met the clinical
constraint but the clinical plan did not (e.g. spinal cord maximum dose of 46 Gy in the clinical
plan and 44 Gy in the autoplan). Similarly if the clinical plan outperformed the autoplan, this is
reflected in the red shaded regions. If both plans met the constraint in panel d and if both
missed the constraint in panel e. Importantly, if the clinical plan met the clinical constraint but
the autoplan did not, the plan will be reflected in panel f. On the left, the same schema is used
but for structures with a lower DVH constraint (e.g. volume of the PTV receiving 95% of the
prescribed dose). An improvement in plan quality, shaded green, are seen when the autoplan
has a higher value than the clinical plan. Color and letter definition are as previously
described.
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Figure 11. Distribution of autoplan and clinical plan performance at relevant dosimetric points.
Autoplan values are shown along the x-axis and corresponding clinical plan value along the yaxis. Shades of green indicate improvement in the dosimetric descriptor for the autoplan,
shades of red indicate poorer performance due to autoplanning. Darker shades delineate
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common clinical thresholds for each dosimetric descriptor, with darker green indicating an
improvement beyond the clinical threshold and darker red indicating a poorer performance
beyond the clinical threshold. Twenty nine patients treated on a clinical trial are shown in
magenta circles, and 54 patients from our institution shown in cyan squares. The number of
patients in each group are shown (continued of following pages).
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Figure 11, continued from previous page.

64 | P a g e

8

6

4

12

9
32
1
75

65
26

11

1

2

1

1

43

5
28
91

120

2

2
18

33

111

55

1

Figure 11, continued from previous page.

65 | P a g e

Finally, when considering DVHs curves of target and organs at risk, the autoplans
show significant improvement over clinical plans treated on a clinical trial. Shown in Figure 12
are average DVH curves for the two planning techniques and the negative of the log of the pvalue of the Wilcoxon signed rank test which is significant for values greater than or equal to
3. For all structures, the autoplans significantly outperformed the clinical plans in DVH
analysis.

Figure 12. DVH comparison of autoplans and clinical plans treated as part of a clinical trial .
The average DVH over all 20 patients is shown for both the clinical plan (red) and the
autoplan (blue). Overlaid is negative of the log of the p value of the Wilcoxon signed sum test,
significant in the green shaded region at values greater than or equal to 3. Autoplans routinely
outperform clinical plans.
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Physician Review of Autoplans
During the development of the planning approach, four head-and-neck site specific
radiation oncologists review the autoplans and assessed them for clinical utility. When
presented with 8 plans, 2 radiation oncologists from South Africa approved 100% of the
autoplans. Upon presentation of the autoplans for 20 patients treated on a clinical trial XX
were approved for use without and one required only minor edits. However, of 20 patients
treated at MD Anderson Cancer Center only 7 (35%) were approved for use without edit and
one required only minor edits. These patients included patients from subsites which differ in
treatment strategy from those primarily used for strategy development including patients with
disease of the oral cavity in which dose prescription levels (typically 60 ,57 and 54 Gy) are
much closer than, for example, for oropharynx cases (70, 63 and 57Gy or 66, 60 and 54 gy).
Further, the strategy was tested for patients with primary disease of the larynx for which, in
scenarios of low-resource, advanced techniques are unlikely to be used. While for this cohort
of patients, clinical dose constraints were met at rates similar to clinical plans as seen in
Table 5, other features of the plans including dose heterogeneity and relative location of
hotspots with underlying anatomy result in major modification needed for treatment planning.
This suggests that, while the strategy is high performing for some subsites (particularly
disease of the oropharynx), further investigation is likely needed for other subsites.

Discussion
In summary, we have developed an automated single-optimization approach for
VMAT planning in the head-and-neck. Using a full automated approach based on in-house
algorithms and commercial solutions, head-and-neck VMAT plans are created without human
intervention. After manual contouring of targets and organs at risk, algorithms are used to set
beam parameters including the jaw and collimator, identify the isocenter, and automatically
contour planning structures. Finally, using a validated RapidPlan ® model in combination with
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added population optimization objectives, VMAT plans were optimized and dose was
calculated automatically. The entre process takes, on average, less than 40 minutes.
This autoplanning technique represents the first fully automated approach which
requires no human intervention aside from the contouring of targets and organs at risk. DVH
analysis of 29 patients treated on a clinical trial showed considerable improvement to the
dose to organs as risk with limited impact of dose coverage and as rated by a head-and-neck
specific radiation oncologist, XX% of plans were clinically acceptable without edit. A decrease
in plan variability at clinically relevant dosimetric endpoints between plans was seen for four
organs at risk when the autoplanning approach was used. A reduction in plan variability is
often cited as desired for quality management purposes (82), though a reduction in variability
should not come with a reduction in quality. The plans are generated in less than 40 minutes
and this represents time during which the user does not need to intervene or be present and
during which other tasks (i.e. contouring, plan approval, etc.) may occur. This time includes
that needed for the autocontouring of structures not included in the treatment plan, which if
supplied by the attending physician would not be required. Built on clinically implemented
tools including the Eclipse Treatment Planning system (VMAT optimizer, dose calculation
engine) and autocontouring algorithms the autoplanning technique can easily be expanded
for use with other treatment machines and at other institutions. Evaluated on 20 patients from
international partner institutions, the autoplanner performed well and radiation oncologists
from these institutions found the plans clinically acceptable.
This autoplanning approach does, however, have limitations. First, when compared
against clinically delivered plans from our institution, the clinical plans outperformed the
autoplans for 10 of 26 DVH metrics analyzed, including having a lower maximum dose to the
spinal cord, brainstem, optic chiasm, nerves, eyes and lens, better coverage at the 95% dose
level of the low dose PTV and a lower hotspot to 1cc of the high dose PTV. The autoplans
only outperformed for 6/26 including volume receiving 30Gy to the ipsilateral and contralateral
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parotid glands, mean dose to the ipsilateral parotid gland, and maximum dose to the brain. It
is known, and a fundamental characteristic of knowledge based planning, that the autoplans
will represent the quality of the knowledge base on which the approach was designed. Also,
as rated by a head-and-neck specific radiation oncologist, all rated plans for disease of the
oral cavity and salivary glands needed major edit for clinical use, it is likely a subs-site specific
optimization strategy is needed. A model built based wholly or partly on the sample of the 54
MD Anderson patients herein, may represent an improvement in plan quality over the current
knowledge base and therefore allow for an improvement in the autoplans.
Similarly, while the current knowledge based schema does consider the spatial
geometry of the patients’ targets and normal tissues the use of a single model for the planning
of many head-and-neck subsite may limit to performance of the autoplanner. Investigation in
subsite specific knowledge based planning techniques for the head-and-neck may allow for
incremental improvement in plan quality. Finally, the autoplanner performance was noticeably
poor for patients which met certain criteria including very large tumor volumes, tumor volumes
which include large volumes with very low density, and targets in very close proximity to
critical normal structures. Many times, in these cases, compromises in plan quality must be
identified by highly trained staff and therefore are not suitable to a fully automated approach.
This could be implemented through a feedback system which analyzes spatial geometry of
the plan prior to optimization.
In addition to general performance, the autoplanning schema used here has
fundamental limitations. The limitation of 3 discrete target volume prescriptions which, while
acceptable for the majority of patients, may exclude some patients who have disease very
close to the brain or brachial plexus and generally require a fourth prescriptions volume to
shape the dose around these critical structures. Additionally, as seen for one patient, the use
of the current autocontouring technique requires consistent CT slice spacing, a requirement
which does not apply to manual contouring or traditional treatment planning approaches.
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As with any automated approach rule base objectives and tradeoffs must be
implemented which may need revising over time. It is critical that characteristics of the
incoming data are known and systems, which warn the user or may halt the process when a
result is outside of standard values are implemented. For example, herein we implemented a
normalization approach meant to ensure adequate coverage of all target volumes, which was
realized by normalizing the final plan such that at least 98% of each target volume received
95% of the prescribed dose. However for some patients this resulted in very small
normalization values and unacceptable plans. Evaluation of the characteristics of the target
volumes used for normalization revealed the normalization to very small or very low density
target volumes could drastically effect the plan quality. Towards this, pre-normalization rules
were implemented to avoid these scenarios and over time new scenarios may arise which
require the revaluation of the assumptions on which the algorithms were developed.
There are many opportunities for further study concerning this automated treatment
planning approach. As mentioned, refinement of the knowledge based model may improve
plan quality or may allow for tailoring to each individual site for implementation. Further, an
iterative approach which may involve re-optimization with added constraints on hot or cold
spots has seen success (83) and could be implemented without requiring human intervention.
Additionally, though the current use of 3-4 arcs is not desired as the use of additional arcs
increases the time needed for delivery, dose calculation, and plan quality assurance.
Optimization of the planning approach including jaw and collimator selection algorithms may
allow for the use of two arcs. Further refinement of the normalization algorithm to
accommodate additional head-and-neck subsites, and not yet encountered circumstances,
and in order to satisfy individual treating physicians may be required. The time needed for
plan development may also be reduced by increasing processing power or using improved
dose calculation algorithms including Acuros® (84) which is available in the Eclipse TPS but
requires additional investigation including how to handle dental artifacts. Other considerations
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for planning/overrise structures such as dental artifacts or bridges may be required and result
in an improvement plan quality. Finally, and most importantly, the clinical use of the
autoplanning approach will reveal how the system will be integrated into a radiation oncology
clinic, will likely reveal the need for further refinement, and may prove to be an essential tool
to help reduce the human infrastructure burden of radiotherapy in low-resource settings.

Conclusion
In conclusion, a single optimization treatment planner along with automatic field
settings can generate clinically acceptable autoplans in under 40 minutes without the need for
human intervention.
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Chapter 5: Automatic Contours of Normal Structures in the
Head-and-Neck
A substantial portion of this chapter is written or based on the following publications:
Placeholder – Paper under 2nd round revision.

In this chapter we describe the results for Specific Aim 3 in which, through four
experiments, we evaluate the feasibility of automatic delineation of normal structures for
treatment planning in the head-and-neck. Our working hypothesis is automatically contoured
normal structures can be used for treatment planning purposes without significant impact on
plan quality.

Introduction
Advanced techniques including 3D conformal radiotherapy, IMRT, and VMAT which
have been widespread in high-resource clinics since the 1990s, have made the process of
contouring an essential step in the treatment planning process. Contouring, however, is
known to be time consuming, plagued by considerable inter-physician variability (85-89), and
the component of radiation therapy treatment planning which introduces the most error (90,
91). For head-and-neck cancer, the contouring of 3 or more target volumes and as many as
25 normal structures may be required (92). For any clinic, but particularly for those in lowresource clinics the enormous time, human resource, and training burden of contouring may
prohibit the transition to these advanced techniques, which are particularly critical for the
treatment of head-and-neck cancer.
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In the context of an automated treatment planning approach for head-and-neck
cancer, automatic contouring would increase the time savings, reduce plan variability, and
may eliminate some of the barriers prohibiting the transition to advanced delivery techniques.
Many efforts to automate the contouring process for normal structures have been reported –
techniques include image registration atlas based segmentation, machine learning, and
shape modelling (57). Findings indicate that for head-and-neck treatment plans, automatic
segmentation of normal structures can significantly reduce inter-observer variability and
contouring time (93-95). Authors have reported on the limited implementation of automated
contouring for small structure sets (e.g., brachial plexus(96), heart chambers(97),etc.) and for
other anatomical sites (e.g. the prostate(98)). However, use of autocontouring for only a
subset of structures requires a deviation in workflow, if contours require manual editing the
time saving advantages are partially lost, and importantly, and the long term clinical use of
autocontoured normal tissues has not been reported.
Further, reports on the clinical implementation of automatic contouring methods note
that automatic contours should be carefully reviewed and edited by the physician (99), which
may take up to 60 minutes (100). The use of automatically contoured normal structures for
treatment planning without edit would offer increased time savings and would be interest not
only for a fully automated treatment planning approach but also for adaptive planning in which
treatment plans are made under tight time constraints and for general clinical practice.
However, using unedited automatically contoured normal structures should be considered
with great caution and after comprehensive analysis.
In this chapter we describe four experiments which assess the viability of using
unedited normal structures in the head-and-neck for treatment planning. First, several
autocontouring algorithms were retrospectively assessed for accuracy compared to physician
drawn structures and were qualitatively rated by head-and-neck radiation oncologists. Then,
the best performing algorithm was implemented into our head-and-neck clinic with careful
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physician review and editing for clinical use. Next, a technique to ensure safe use in an
automated process was developed in order to detect both gross errors in autocontours and
autocontours which required physician edit for clinical use. Finally, treatment plans were
created on autocontours without edit and DVH analysis revealed the impact planning on these
structures, as opposed to physician derived structure, had on the treatment plan.

Methods
Analysis of Autocontouring Algorithms
In this first experiment we sought to evaluate automatic contouring algorithms for
normal structures in the head-and-neck.
Patient Cohort
For this study, we collected 128, the latest in our database, treated for head-and-neck
cancer at MD Anderson Cancer Center, and who had physician approved contours. Normal
structure contours were identified manually by naming convention and visual assessment.
From the 128 patients, the 8 contours most often included in the final treatment plan, and thus
included in this analysis, were the brain, brainstem, cochleae, eyes, lungs, mandible, parotid
glands, and spinal cord. Limited analysis of the autocontouring of others structures, including
lens, optic chiasm, optic nerves, and submandibular glands was also performed.
A subset of 10 patients was randomly selected for initial review of four autocontouring
techniques. For the highest performing algorithm on initial review the 118 remaining patients
were selected to further analyze the autocontouring algorithm’s performance.
Autocontouring Algorithms
Of the four autocontouring algorithms used for this study, three are based on two
commercially available autocontouring algorithms available in the Eclipse Treatment Planning
system; Smart Detection® and Smart Segmentation®(101). Smart Detection® is a heuristic
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solution available for a select number of structures and requires only the selection of desired
contours. Available structures included brain, eyes, lungs, mandible, and spinal canal. The
second algorithm, Smart Segmentation®, is a deformable image registration based technique
which, in Eclipse TPS version 13.2, requires the user to select one of many available expert
cases from which the autocontours will be propagated. According to the manufacturer:
“Users match their patient case to one of the hundreds of expert cases in the
library, and through a sequence of co-registration and proprietary deformation
algorithms, the contours of an expert case are deformed to fit the CT images of
the patients”(101)
The Smart Segmentation software offers guidance on which expert case should be selected
through a 5 star rating system. Expert cases for each structure for each patient were selected
in order of star rating, with up to 14 expert cases selected for each structure for each patient,
though not all expert cases were available for all 8 normal structures considered. Later
versions of the Eclipse TPS software allows the selection of multiple atlas and fuses the
contours using a majority voting algorithm. To simulate this and based on physician feedback,
up to 12 individual contours were used as inputs to an in-house majority voting algorithm
outside of the treatment planning system, resulting in a single fused contour per structure.
The fused contours represent the third autocontouring approach.
The fourth autocontouring method was based on an in-house multi atlas deformable
image registration technique termed multi-atlas contouring service (MACS) (96, 97), was
previously developed (102, 103) and consists of three distinct steps. First, rigid registration is
performed between the test patient’s simulation CT and the CT of each of twelve atlas
patients, using 2D sagittal and coronal projections. Second, the test patient is deformably
registered to each of the atlas patients using dual-force Demons deformable registration
(104). Using the resultant deformation vector fields, the contours from each atlas patient are
mapped to the test patient(105); resulting in a number of individual contours equal to the
number of atlas patients. Finally, the STAPLE algorithm with a built-in tissue appearance
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model(106) is used to combine the individual segmentations, generating a fusion contour
approximating a true segmentation. Central to the MACS algorithm is the building of an atlas
of patient CTs, which is representative of the patients for which the algorithm will be used. To
build the atlas used in this work, 12 patients recently treated at our institution for head-andneck cancer were selected. The contours used for atlas building were either extracted from
patient treatment plans (reviewed prior to treatment by head-and-neck quality assurance peer
review clinic (107)) or created using thresholding tools (brain, lung, and mandible). All
contours were carefully reviewed by a medical dosimetrist and head-and-neck radiation
oncologist with 13 and 8 years of experience, respectively. The autocontouring process of
multi-atlas DIR based methods can be seen in Figure 13.
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Figure 13. Schematic of the multi-atlas deformable image registration autocontouring process.
For each new patient, a deformable image registration algorithm is used to link the test patient
to each of the chosen atlas patients, which have validated contours already drawn. The
deformation vector field is used to map the contours from each of the atlas patients to the test
patients, which results in a number of contours for each structure equal to the number of atlas
patients. A fusion algorithm is used to combine the contours into a single contour. The inhouse contouring algorithm uses 12 atlas patients, a deamons dual force DIR algorithms and
STAPLE as the fusion algorithm. For the fused Smart Segmentation contours a proprietary
DIR and contours from up to 12 patients were used with a majority voting algorithm. A third
algorithm, discussed in the next sections, used a Deeds deformable image registration
algorithm, 10 atlas patients, and a majority voting algorithm.

Quantitative Contour Assessment
Contours of the 8 normal structures from each of the 4 autocontouring techniques
were quantitatively compared to independently physician drawn contours, when available.
The Dice similarity coefficient, mean surface distance, and Hausdorff distance were
measured to assess contour accuracy. The Dice similarity coefficient (DSC) measures the
volume overlap of the physician drawn contour, P, with the autocontour, A, as a ratio to their
total volume, with a minimum value of 0 when the contours have no overlap and a maximum
value of 1 when the contours agree perfectly, as in Equation 1.
Equation 1 – Dice Similarity Coefficient
𝐷𝐷𝐷𝐷𝐷𝐷(𝑃𝑃, 𝐴𝐴) = 2

|𝑃𝑃 ∩ 𝐴𝐴|
.
|𝑃𝑃| + |𝐴𝐴|

The mean surface distance was calculated as a symmetric 3D mean surface distance
between two volumes (P and A) and has a minimum value of 0 when the contours agree
completely and no maximum value, as in Equation 2.
78 | P a g e

Equation 2 – Mean Surface Distance
1
1 1
� min(𝑑𝑑(𝑎𝑎, 𝑝𝑝))�.
𝑀𝑀𝑀𝑀𝑀𝑀(𝑃𝑃, 𝐴𝐴) = � � min(𝑑𝑑(𝑝𝑝, 𝑎𝑎)) +
|𝐴𝐴|
2 |𝑃𝑃|
𝑝𝑝∈𝑃𝑃

𝑎𝑎∈𝐴𝐴

The Hausdorff distance (HD) was used to measure the maximum Euclidean distance
from the points both contours to the nearest point in the other and has a minimum value of 0
when the contours agree completely and no maximum value, as in Equation 3.
Equation 3 – Hausdorff Distance
𝐻𝐻𝐻𝐻(𝑃𝑃, 𝐴𝐴) = 𝑚𝑚𝑚𝑚𝑚𝑚 �max min 𝑑𝑑(𝑝𝑝, 𝑎𝑎) , max min 𝑑𝑑(𝑎𝑎, 𝑝𝑝)�.
𝑝𝑝∈𝑃𝑃 𝑎𝑎∈𝐴𝐴

𝑎𝑎∈𝐴𝐴 𝑝𝑝∈𝑃𝑃

For two of the eight normal structures (lungs and spinal cord) we performed the quantitative
analysis using a modified structure which included only slices of the contours of the
autocontour between the most superior and most inferior contours drawn by the physician.
This analysis better represents the contouring accuracy of the algorithm (compared to wholestructure quantitative analysis) as it eliminates errors that arise owing to differences in CT
scan extent both between the test and atlas patients and among the atlas patients, and takes
into consideration incomplete contouring of structures at distance far from the treated
volumes, see Figure 14.
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Figure 14 - Modified structures considered for analysis of autocontour performance. For
spinal cord and lung (shown), a modified autocontour was created for analysis. This structure
only includes slices of the original autocontour between the most superior and most inferior
slices of the corresponding physician drawn structures. In this example, the physician drawn
lung structure (brown) was only contoured for part of the true lung. The original autocontoured
lung (cyan) extended for many slices below the physician lung, when modified (lavender) the
slices extended below the most inferior slices of the physician drawn lung were removed. This
is appropriate for many reasons including, as shown in this example, often the autocontour
will extend further even than the dose grid (green dash) and is therefore irrelevant in the
treatment planning process.

Physician Review of Autocontours
A radiation oncologist was asked to rate the normal structures on a five-point scale,
Table 8. For contours receiving a score indicating minor or major edit would be needed for
use in dose volume histogram (DVH)-based planning (scores 1-3), the physician was asked
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to note the main failure mode. This allows for analysis of potential improvement of the
algorithm.

Table 8. Five point scale for physician rating of normal structures. For structures receiving a
score of 1, 2, or 3, which indicates either minor or major edit is needed for use in DVH based
treatment planning, the physician was asked to cite the main failure mode.
Rating

Description

5

Perfect; indistinguishable from physician-drawn contours for DVH based planning
purposes

4

Within acceptable inter-physician variation for planning purposes, as described
above

3

Good; needs minor edits if normal structure is near a target

2

Fair; needs significant edits to be used for the planning purposes described above

1

Poor; large areas need minor or major edit. Is unusable for planning purposes
described above

For the top performing algorithm the remaining 118 patients were rated on the same
scale and, to assess the possibility of rater bias, contours from this top performing algorithm
for 10 patients were reviewed by five additional radiation oncologists from four international
institutions. Physician agreement was assessed by grouping each pair of ratings (one rating
from the primary physician and one from an outside physician) into one of three categories.
Category I agreement includes instances when the primary and outside physician agreed as
to the degree of edit needed, Category II agreement indicates that the physicians agreed that
the contour required either no more than minor edits or required major edits. The final
category, Category III agreement, includes those contours where the physicians disagreed on
the acceptability of the contour, with one physician indicating that the contour needed major
edit with the other indicating no or minor edit for use. Additionally, inter-physician variability in
ratings was assessed using a Wilcoxon signed rank test.
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Additional Contour Analysis
Exploratory analysis of the autocontouring of additional structures including optic
chiasm, optic nerves, submandibular glands, esophagus, and lens using the previously
described algorithms and others including a commercially licensed algorithm (108) using (1) a
proprietary atlas (2) the same atlas used in MACS and (3) the proprietary atlas in combination
with a shape model supplied by the vendor (only available for some structures) were also
performed results of which can be found in the appendix.
The results of this first experiment are found on page 100.

Clinical Use of Normal Tissue Autocontours
In the second experiment we investigated the clinical use of an autocontouring
algorithm for normal structures in the head-and-neck.
Clinical Implementation
After retrospective validation of the contouring algorithms, we began a limited
introduction of the top performing algorithm, MACS, into our head-and-neck clinic. The
automated contouring algorithm was already in use for a limited number of sites and
structures in our clinic prior to the implementation of this atlas for normal structures in the
head-and-neck. The software based on the MACS algorithm is accessible via a script in the
Pinnacle3 Treatment Planning System (Philips Medical Systems, Milpitas, CA). Initially, use of
the software was limited to a select number of radiation oncologists for review, which
prompted standardization of the contour color to match that already in clinical practice, and
inclusion of a script to overwrite empty structures already in the treatment plan (our clinical
workflow involves the population of a standard set of empty structures through a script).
Additionally, due to algorithm limitation as discussed, the inferior portion of the lung was often
either not contoured or was contoured in many segments per slice, which prompted renaming
of the lung structure to “lung_avoid,” indicating its use for treatment planning purposes rather
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than anatomical definition. After the automated contouring workflow was finalized, the
software was released for use by all attending physicians. Typically, the clinical workflow of
automated contouring involves the initialization of the algorithm by a dosimetrist using a script
in the treatment planning system, import of the structures into the treatment plan, followed by
review and any needed editing of the contours by the attending radiation oncologist. All final
contours were reviewed and edited by the attending physician, see Figure 15, in the same
way that initial resident contours would be reviewed. The final contours reflected approval by
the physician, with or without editing as deemed appropriate.
Quantitative Analysis of Autocontour Edit
To assess the degree of edits made of the autocontours for clinical use, the contours
generated by the algorithm were compared to the contours edited for treatment planning by
the physician using the DSC (Equation 1), MSD (Equation 2), and HD (Equation 3). In
addition to analysis of the eight clinically implemented normal structures, we also
quantitatively compared edits of two modified contours, as previously described.
Additionally, in order to elucidate possible planning margins needed if autocontours
are used without edits, we determined the minimum uniform expansion to the autocontour
needed to cover 95% or 100% of the edited contour for 90% or 95% of the population. These
margins may reveal that for some structures a planning at risk volume (PRV) may be added
to the autocontoured normal tissue in order to compensate for potential errors in contouring.
This expansion may ensure the safety of using unedited structures in treatment planning. This
may be especially true for structures with a maximum dose constraint for which, if the
modified structure meets constraint, any structure completely encompassed would also meet
constraints.
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Finally, to assess the possible motivation for contour edits outside of anatomical OAR
definition, we used a one-sided t test to assess the association between automatic contour
edits and the minimum distance to target volume.
The results of this second experiment are found on page 107.

84 | P a g e

Autocontoured
Structures
Physician
Edited/Approved
Structures

Figure 15 - Example of physician edits to clinical autocontours. Shown for one patient are
autocontours of the brain, brainstem and cochleae (panel A) and spinal cord mandible and
parotid glands (panels B and C) in blue and the physician edits and/or approved structures
which remained in the patient’s treatment plan in red. For this patient, no edits were made to
the cochlea structures, and some boundaries of other structures remained unedited.
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Machine Learning Model for Prediction of Autocontour Errors
In the third experiment we sought to develop of a random forest model for assessment
of anatomical errors in autocontours of normal structures in the head-and-neck
Contour QA technique
Necessary for implementation as part of a fully automated treatment planning
approach is a method to detect autocontouring errors. Detection of gross and simulated errors
represents a check of safety and catching of significant autocontouring errors. The detection
of smaller, potentially necessary clinical edits to autocontours would allow for the possibility to
flag to the user of an automated treatment planning approach that autocontours presented
may require editing. Other investigations of contour QA have been reported using historical
data with heuristically selected metrics and thresholds to predict simulated contouring errors
(109), mislabeled contours, and the effects of noise (110). These studies introduce the
important topic of contour QA and demonstrate the feasibility of automated techniques in
detecting some errors. However a comprehensive or optimized prediction model was not
used to differentiate cases of automatic contouring failure and manual detection of errors is
still heavily relied upon.
To predict contour errors, we implemented a random forest (RF) method in Matlab
(Mathworks, Natick Massachusetts). RFs are machine-learning models proposed by Breiman
(111) that do not require a priori information about any relationship between input metrics and
output predictions (unlike, for example, regression models, which typically assume linearity)
and provide a measure of predictor importance, and have low susceptibility to overfitting.
Random forest models have proven successful in other contour QA approaches (49, 110) as
well as non-linear approaches such as radiation toxicity (112-115).
Three RF models were trained for each of the eight normal structures, one model for
each of the three classes of automatic contouring errors (simulated errors, and two degrees of
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true errors), as described below. Each model was then tested on an independent dataset.
The RF models were trained for 1,000 decision trees with a minimum leaf node size of three.
The number of patients and error types for each training and testing dataset are detailed in
the following sections.
Engineered predictive metrics, developed to assess the contour accuracy, were
extracted from each contour and corresponding CT dataset. A summary of the metrics can be
found in Table 9. The predictive metrics included volumetric (e.g., Dice similarity coefficient)
and distance agreement metrics (e.g., mean surface distance) with contours generated from
three independent contouring techniques. For the first technique, a commercially licensed
algorithm (108) (Varian Medical Systems, Palo Alto, CA) was implemented in a multi-atlas
deformable image registration contouring approach, whereby contours from 11 atlas patients
were deformably registered to the test patient and the resultant contours were fused using a
majority voting algorithm, a schematic is shown in Figure 13. For the second technique,
contours were generated using the heuristic algorithm Smart Detection®, as implemented in
the Eclipse treatment planning software (Varian Medical Systems). Owing to algorithm
limitations, only the brain, eyes, lungs, and mandible contours were generated and thus
compared with the corresponding contour from the test patient. For the third technique, 11
atlas patients were rigidly registered to the test patient and the most accurate registration (as
measured by the mutual information between atlas and test patient data set over the whole
image) was used for contour propagation.
Other predictive metrics included the volume of the contour, metrics extracted from the
Hounsfield unit (HU) distribution within the contour, and the spatial relationship of the contour
with other automatically contoured structures (i.e., other normal structures). Additionally, we
analyzed the highest order coefficient of first-, second-, and third-order polynomial fits to interslice distance measures, both between adjacent slices and between bony tissues and the
inter-slice area Figure 16. Because several of the available metrics were derived from the
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same primary data (e.g., metrics from the HU distribution, agreement with secondary
techniques, and polynomial fits to slice measures), a univariate selection was performed by
choosing the metric within the group with the lowest average misclassification probability in a
small (10-tree) forest using only the predictor in question. The full list of predictive metrics can
be found in Table 9.

Mean Distance to Bone
Superior

A

Inferior

0.5 1.0 1.5 2.0

B

2.5 3.0

Distance [cm]

Slice Area

0

2

4

6

2

Area [cm ]

8

C

10

Figure 16. Inter-slice metrics for autocontour error detection. Contour features for a
representative patient are shown in panel A and include polynomial fits to inter-slice metrics
such as the mean distance to bone (in panel B) and the slice area (panel C).
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Table 9. Engineered metrics used for the prediction of errors to automatic contours.
Size/Hounsfield unit (HU)Positional metrics
Shape metrics
derived metrics
Metric/metric
Metric/metric
Metric/metric
Definition
Definition
Definition
group
group
group
Inter-slice
slice area
statistics
Inter-slice
slice area
polynomial
fits*
Inter-slice 3D
Hausdorff
distance
Inter-slice 3D
Hausdorff
distance*

Inter-slice 3D
mean surface
distance

Mean, maximum,
minimum, and
standard
deviation

Volume

Highest order
coefficient of first, second-, and
third-degree
polynomial fits
Mean, maximum,
minimum, and
standard
deviation
Highest order
coefficient of first, second, and
third-degree
polynomial fits

Lower extreme
of HU
distribution
within contour*

Mean, maximum,
minimum, and
standard
deviation

% of contour
with HU below
given HU
values

HU statistics

Upper extreme
of HU
distribution
within contour*

(no. of voxels
in contour) ×
[voxel size
(cm3)]
Mean,
standard
deviation of
HU of pixels
within contour
HU at 1%, 2%,
5%, and 10%
cumulative
probability
HU at 90%,
95%, 98%,
and 99%
cumulative
probability
-500, -100, 0,
40, 300, 500

Highest order
coefficient of first, second-, and
third-degree
polynomial fits
*Univariate selection was performed within the metric group.
Inter-slice 3D
mean surface
distance*

Inter-slice
minimum
distance to
bone statistics
Inter-slice
minimum
distance
polynomial fits*
Inter-slice
maximum
distance to
bone statistics
Inter-slice
maximum
distance
polynomial fits*
Separation of
contour
centroids in X,
Y, and Z
directions

Mean, maximum,
minimum, and
standard
deviation
Highest order
coefficient of first, second-, and
third-degree
polynomial fits
Mean, maximum,
minimum, and
standard
deviation
Highest order
coefficient of first, second-, and
third degree
polynomial fits
Seven other
automatic
contours

Metrics showing agreement with
independent automatic contours
Metric/metric
Definition
group
Independent
deformable atlas
Volume ratio, true
approach,
positive ratio,
volumetric
false positive ratio
agreement*
Independent
deformable atlas
approach, distance
agreement*

Hausdorff
distance, mean
surface distance

Independent
heuristic approach,
volumetric
agreement*

Volume ratio, true
positive ratio,
false positive ratio

Independent
heuristic approach,
distance
agreement*

Hausdorff
distance, mean
surface distance

Independent singlepatient rigid
approach,
volumetric
agreement*

Volume ratio, true
positive ratio,
false positive ratio

Independent singlepatient rigid
approach, distance
agreement*

Hausdorff
distance, mean
surface distance

89 | P a g e

Simulated failure models
In the RF models for simulated errors, prediction classes included unedited clinical
automatic contours and simulated failures, including automatic contours that had been shifted
or expanded by amounts that varied by structure. Contours were expanded uniformly in three
dimensions or shifted in a random direction by a known amount. The size of the shifts and
expansions varied by structure according to the average volume of the structure. Contours for
small structures (eyes and cochleae) were shifted and expanded to a lesser extent than those
for medium-sized structures (brainstem, mandible, and parotid glands), which were shifted
and expanded less than that for large structures (brain, lungs, and spinal cord). For RF
training, eight shifted structures from each of four size shifts and 10 expanded contours from
each of three size expansions were combined with 62 unedited clinical contours, providing a
total of 124 contours. See Table 10 for details of the training data-set, including the sizes of
shifts and expansions. Predictor importance was assessed by summing the change in the
mean squared error due to splits on that predictor divided by the number of branch nodes
after the split.
For testing of the simulated error RFs, 50 contours from each of the aforementioned
error types (shifts and expansions) were combined with contours propagated on 13 patient
scans of other anatomical locations (seven patients with cervical cancer and six patients with
breast cancer), and contours from nine patients in nonstandard positions for which the
automatic contouring algorithm was grossly incorrect, as well as contours from one patient
who had a very large primary tumor volume that impinged on nearby normal structures.
Figure 17 shows representative examples of contours with simulated errors and for a patient
not in a similar position to the atlas patients.
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Brain
Left Eye
Right Eye
Mandible
Right Parotid
Spinal Cord
Left Parotid
Clinical Contour
Automatic Contour
Expanded Contour
Shifted Contour
Figure 17. Contouring errors for building and testing of QA models. Simulated errors included
autocontours which had been shifted and expanded (left) and autocontours propagated on
patients for which the atlas based technique is not suitable (right). The atlas used for the
current study included patients positioned supine on the treatment table; when autocontours
are propagated on patients in significantly different positons automatic contouring errors arise.

91 | P a g e

Table 10. Number of type of simulated failure modes used for building of the random forest models. In the prediction of simulated errors,
four sizes of shifted contours and three sizes of expanded contours were used for each structures. The sizes of the shifts and
expansions varied by structure in accordance with the structure size, classified into three groups. Contours for smaller structures (eyes,
cochleae) were shifted and expanded less than those for medium-sized structures (brainstem, mandible, parotid gland), which were
shifted and expanded less than those for large structures (brain, lung, spinal cord).

Structure
Brain
Brainstem
Cochleae
Eyes
Lungs
Mandible
Parotid glands
Spinal cord

Shifted,
size 1
Size, cm No.
1
8
0.5
8
0.2
8
0.2
8
1
8
0.5
8
0.5
8
1
8

Shifted,
Shifted,
size 2
size 3
Size, cm No. Size, cm No.
2
8
3
8
1
8
2
8
0.3
8
0.5
8
0.3
8
0.5
8
2
8
3
8
1
8
2
8
1
8
2
8
2
8
3
8

Shifted,
size 4
Size, cm No.
5
8
3
8
1
8
1
8
5
8
3
8
3
8
5
8

Expanded,
size 1
Size, cm No.
3
10
2
10
1
10
1
10
3
10
2
10
2
10
3
10

Expanded,
size 2
Size, cm No.
5
10
3
10
2
10
2
10
5
10
3
10
3
10
5
10

Expanded,
size 3
Size, cm No.
8
10
5
10
3
10
3
10
8
10
5
10
5
10
8
10
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Prediction of clinical edits
For the prediction of true errors, a group of RF models (two for each of the eight
OARs) were trained and tested on autocontours that were reviewed, and, if necessary, edited
for clinical use. RF models were trained to differentiate contours that had been edited
clinically from those that had not been edited. Two thresholds were chosen to determine
whether the contour was edited: first, a Hausdorff distance (see Equation 3) between the
edited contour and the contour in the patient’s final treatment plan greater than 0 (i.e., any
clinical edit) and second, a Hausdorff distance between the edited contour and the contour in
the patient’s treatment plan greater than 5 mm, classified as a “significant” clinical edit.
To obtain the initial RF model, we used data collected from the first 104 patients
during clinical implementation. Following the initial modeling, and as the automatic contouring
software was used clinically, the results were collected and a prediction was obtained for
each structure. After the prediction for 10 structures from at least five patients (because
bilateral structures, if all are left in the treatment plan, accrue 10 structures from five patients),
predictive metrics were calculated and the RF models were retrained to include the new
clinical results. This iterative machine learning mechanism was implemented to determine
whether model performance improved over time as the models learned from new failure
modes; the process of model building and rebuilding is illustrated in Figure 18. The final
analysis contained RF models tested on 120 independent patients. The number of
autocontours used for training and testing varied by structure because predictions were
generated only for structures that remained in the patients’ treatment plans upon treatment.
Predictor importance was assessed by summing the change in the mean square error due to
splits on that predictor divided by the number of branch nodes after the split.
The results of this third experiment are found on page 112.
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Figure 18. Workflow of the machine learning framework for the prediction of clinical edits to
automatic contours (i.e., true errors). After the initial model building (104 patients), the model
was used to predict clinical edits, and after prediction on 10 successive structures, the new
data were added and the models were updated. Data from 120 patients were used for this
prospective model testing and model updating.
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Dosimetric Impact of Normal Tissue Autocontours for Treatment Planning
In an ideal scenario, the autocontouring of normal structures would produce contours
which do not need edit for treatment planning, as they would be anatomically correct. While
we do not expect that we have achieved this ideal, we sought to investigate the possibility of
using unedited autocontours from the MACS autocontouring algorithm for treatment planning
and to assess the effect this may have on the treatment plan. Other investigations have
shown that for salivary glands the use of autocontoured or even simplified geometric
structures may be sufficient for treatment planning purposes(116) suggesting that the same
may be true for other normal structures.
Patient Cohort
For this analysis, two cohorts of patients were considered. Patients were selected as
to represent seven head-and-neck subsites; larynx, nasopharynx, oral cavity, oropharynx,
paranasal sinuses and cavity, and salivary glands. Selection criteria included a maximum of
three physician-drawn planning target volume dose levels and availability of the physician
approved contours.
In the first cohort, 54 patients treated at The University of Texas MD Anderson Cancer
Center had clinical normal structures which were derived from autocontours and either edited
to satisfaction or used with approval by the attending physician. The autocontouring of eight
normal structures (brain, brainstem, cochlea, eyes, lung, mandible, parotid glands, and spinal
cord) was implemented clinically and thus were considered in this analysis.
In the second cohort, normal tissue contours were drawn independently by the
attending physician who was blind to the autocontour. In this group, structures not included in
the clinical autocontouring atlas for 54 patients treated at The University of Texas MD
Anderson Cancer Center and for all structures from 30 patients from other institutions treated
on a clinical trial were collected. The clinical trial data were retrospectively collected through
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The Cancer Imaging Archive (75) and was originally derived from the Radiation Therapy
Oncology Group 0522 study (76).
Using a two sided t-test the distribution of differences of clinical structures compared
to autocontours was compared to the larger group of clinically edited patients, as presented in
the second aim (Page 43) to determine how they compare to a population of patients with
clinically edited contours.
Dosimetric Evaluation
Using the planning strategy presented in Chapter 4 - A Single Optimization Treatment
Planning Strategy in the Head-and-Neck – two treatment plans were created for each patient.
The first treatment plan was developed using the clinical normal structures and the second
plan was created using unedited autocontours of normal structures (including the brain,
brainstem, cochleae, eyes, lens, lungs, mandible, optic chiasm, optic nerves, parotid glands,
submandibular glands, spinal cord). For all patients, physician drawn PTVs were used for
treatment planning. Additional autocontoured planning structures were created as needed per
the treatment planning strategy. Treatment plans were normalized as in Chapter 4. A
schematic describing this investigation can be seen in Figure 19.
For both plans, dosimetric analysis at clinically relevant DVH points was performed
using the clinical normal structures, regardless of which structure (clinical structure or
unedited autocontour) was used for treatment planning. Comparisons were made only for
structures included in the clinical treatment plan. A Wilcoxon signed rank test was used to
compare the dosimetric impact at clinically relevant dosimetric endpoints.
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Dosimetric Analysis

Unedited
Autocontours

Automated
Treatment
Planning
Approach

Clinical Structures
(edited/approved)

Ratio of Total Structure Volume [%]
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Figure 19. Experiment to identify the dosimetric impact of using autocontoured normal tissues for treatment planning. Using both the
unedited autocontours (top) and clinical structures (bottom) the planning strategy described in Chapter 4 was used to create high quality
head-and-neck treatment plans. Evaluation of the plans was carried out on the “true” physician edited/approved structures, any
differences in the DVH curves identifiy the impact the chioce of planning structure may have on th treatment plan.
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Correlation Dosimetric Impact of Normal Tissue Autocontouring to Quantitative Predictors
Given the expected distribution of clinical edits and the knowledge of their impact on
treatment plan quality we wished to investigate the possibility of predicting, prior to plan
optimization and dose calculation, the potential impact of edits to normal tissue autocontours
for four key normal structures in the head-and-neck; the spinal cord, the brainstem, and the
contralateral and ipsilateral parotid glands. It may be expected that the relative importance of
edits to normal tissue contours is related to patient specific features. For example, if the
brainstem is close to the target volume, than edits to this autocontour may be more impactful
than if the brainstem was at a distance from the targets. The correlation of the patient and
structure features to the dosimetric impact of planning on these structures could provide the
user a pre-assessment of potential autocontour quality.
To investigate this, three dosimetric metrics including; the absolute dose to the clinical
structure, the absolute difference in dose to the clinical structure when planned on either
unedited autocontour or the clinical structure, and the relative dose difference when planned
on the two structures, were evaluated for correlation with several features of the structures.
Predictive metrics included the clinical edits to the structure, the prescription dose
levels of the (up to three) PTVs, the minimum distance between the autocontour and the
PTVs, the maximum distance of the closest 10% of points of the autocontour and the PTVs,
and the Dice Similarity coefficient between the autocontours and the PTVs analyzed in 3
ways (1) the autocontour and the original physician drawn PTVs (2) the autocontours and the
PTVs with a uniform expansion of 0.5cm and 1cm and (3) the convex hulls of the
autocontours and the PTVs. Examples of these structures and metrics can be found in Figure
20. The convex hull of the normal tissues are the smallest convex shape which encompasses
the contour. They, for example, may provide insight when a target is within the concave
region of a parotid contour.
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The results of this fourth experiment are found on page 119.

Planning Target Volumes

Expanded PTVs

High Dose

High Dose

Intermediate Dose

Intermediate Dose

Low Dose

Low Dose

Normal Tissues
Autocontours
Hulls

Figure 20. Patient specific metrics for correlation with the effect ofthe use of autocontoured
targets for treatment planning. For four normal structures (brainstem, parotid glands, and
spinal cord), in blue, metrics which quantify the spatial relationship to each of the patients’
target volumes were calculated and included the minimum distance and minimum 10% of
distances to each PTV (in colorwash, by dose level), the DSC and MSD with the PTV and
with expanded PTVs (solid line, corresponding color), shown here for 1 cm uniform
expansions, and the DSC and MSD of the normal tissue hulls (in maroon) with the PTVs.
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Results
Analysis of Autocontouring Algorithms
Pilot Test of 4 Contouring Algorithms
Considering the 10 initial test patients, the in-house MACS contouring algorithm was
best performing when considering all 8 normal structures. For some structures, the Smart
Segmentation® approach with and/or without fusion was not investigated owing to the
success of the other autocontouring techniques (see Table 11). For lung contours the Smart
Detection® algorithm performed the best with an average rating of 4.6 and a minimum of 3,
indicating minor edits. The lung was the worst performing structure for the in-house algorithm,
with an average rating of 3.5 and a minimum rating of 1. The main failure mode noted was in
the inferior portion of the lung, where, due to the deformation fields, the combining of several
contours in the STAPLE algorithm and the varying scan extent (and thus portion of the lung)
in each of the atlas patients, the contours often have small slices inferiorly or occasionally
islands. For many patients this part of the lung is distant from the treated volume, and given
that the whole lung is seldom included in the simulation scan and therefore whole lung DVH
metrics cannot be quantitated may not be included in the dose calculation region. For these
ten patients, the most inferior portion of the PTV was at an average distance of 11.5 cm from
the slices of inferior lung with noticeable errors, and for the patient with the closest PTV-toinferior-lung distance the dose grid was 3cm superior to the lung region with errors, see
Figure 21. Given these things, we feel that errors on these bottom few slices are acceptable
and may either be ignored or removed on post processing. For all other structures including;
brainstem, cochleae, eyes, mandible, parotid glands, and the spinal cord, the MACS
algorithm had an average rating better than all other algorithms.
Quantitative comparison of the autocontours from each of these 4 autocontouring
algorithm on the same ten patients in shown in Table 12. For all structures MACS had a
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higher average Dice similarity coefficient and lower average Mean surface distance and
Hausdorff distance indicating that these structure agree more closely with independently
drawn physician structures.

Dose Calculation
Region
Planning Target
Volumes
Autocontoured
Lung

Designated
Failure Mode

Physician Drawn
Lung

Figure 21. Example of autocontouring errors at the inferior structure extent. This patient, with
the lowest physician score had large areas for which the autocontoured lung (cyan) failed to
contour, as shown in the red circles. However, the physician drawn/approved structure
(brown) also had large areas of incomplete contour. However, these missed areas are at the
most inferior portion, or outside of, the dose grid (dashed green) and far from the contoured
planning target volumes (red color wash).
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A reoccurring failure mode of the smart detection algorithm, as cited by the rating
physician, was structures that the structures were too large or were offset. This feedback
prompted the decision to provide a third contouring approach in which these contours were
fused using a majority voting algorithm. Unfortunately, many of the fused contours were also
reported as being too large or offset, indicating that neither method was suitable for automatic
contouring purposes. For example, the average volume across the ten patients of the
physician drawn brainstem was 25.0 cc, the average volume of the MACS autocontoured
brainstems was 23.85 cc, the average volume of the single and fused Smart Segmentation
brainstem contours was 30.72 cc and 31.26 cc, respectively.
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Table 11. Physician ratings of four autocontouring algorithms on ten patients. The mean, standard deviation, and minimum and
maximum are shown for four autocontouring algorithms for ten patients. Contours were rated on a five point scale by a single physician.
For brain, spinal cord and lungs, due to the success of other algorithms, Smart Segmentation® with and/or without fusion were not
analyzed. The smart detection algorithm was not available for the structures with no reported statistics.

Physician Ratings of Autocontouring Algorithms
Smart Detection
Structure
Brain

N mean ± std
10

4.9

[minmax]

Smart Segmentation
N

mean ± std

[minmax]

Smart Segmentation +
Fusion
N mean ± std

± 0.3 [ 4 - 5 ]

[minmax]

Multi Atlas Contouring
Service
N mean ± std

[minmax]

10

5.0

± 0.0 [ 5 - 5 ]

Brainstem

91

3.1

± 0.6 [ 2 - 5 ] 10

3.1

± 0.7 [ 2 - 4 ] 10

4.6

± 0.5 [ 4 - 5 ]

Cochleae

95

3.0

± 0.4 [ 2 - 4 ] 20

2.8

± 0.5 [ 1 - 3 ] 20

5.0

± 0.2 [ 4 - 5 ]

3.6

± 0.6 [ 2 - 4 ] 20

3.6

± 0.6 [ 3 - 5 ]

10

3.5

± 1.1 [ 1 - 5 ]

Eyes

20

3.4

± 0.9 [ 2 - 5 ] 185

3.3

± 0.9 [ 2 - 5 ] 20

Lungs

10

4.6

± 0.7 [ 3 - 5 ] 93

3.0

± 1.0 [ 1 - 5 ]

Mandible

10

2.8

± 1.5 [ 1 - 5 ] 101

2.8

± 0.8 [ 2 - 5 ] 10

2.9

± 0.7 [ 2 - 4 ] 10

4.7

± 0.5 [ 4 - 5 ]

172

2.9

± 0.8 [ 1 - 5 ] 20

3.2

± 0.9 [ 2 - 4 ] 20

4.5

± 1.1 [ 1 - 5 ]

± 0.4 [ 4 - 5 ] 93

4.1

± 0.4 [ 3 - 5 ]

10

5.0

± 0.0 [ 5 - 5 ]

Parotid Glands
Spinal Cord* 10

4.2

*Smart detection only allowed for the contouring of spinal canal
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Table 12. Quantitative comparison of four autocontouring algorithms with independently
drawn physician normal tissue contours. The Dice similarity coefficient, the mean surface
distance, and the Hausdorff distance were used to compare the normal tissue autocontours
for 8 structures generated on the same ten patients rated by the physician. The in-house
multi-atlas contouring algorithms most closely matched the physician drawn structures with
the highest average DSC and lowest average MSD and HD.
Dice Similarity Coefficient
Smart
Multi Atlas
Smart
Smart
Segmentation +
Contouring Service
Detection
Segmentation
Fusion
Structure
N mean ± std N mean ± std N mean ± std N mean ± std
Brain
10 0.98 ± 0.00
10 0.98 ± 0.00
Brainstem
91 0.74 ± 0.05 10 0.79 ± 0.04 10 0.88 ± 0.04
Cochleae
95 0.38 ± 0.09 20 0.38 ± 0.07 20 0.65 ± 0.09
Eyes
20 0.75 ± 0.05 185 0.74 ± 0.08 20 0.78 ± 0.06 20 0.87 ± 0.03
Lungs
10 0.96 ± 0.01 93 0.92 ± 0.06
10 0.92 ± 0.02
Mandible
10 0.67 ± 0.07 101 0.68 ± 0.08 10 0.71 ± 0.06 10 0.90 ± 0.03
Parotid Glands
172 0.67 ± 0.10 20 0.72 ± 0.10 20 0.84 ± 0.05
Spinal Cord* 10 0.57 ± 0.05 93 0.67 ± 0.07
10 0.81 ± 0.03
Hausdorff Distance (cm)
Smart
Multi Atlas
Smart
Smart
Segmentation +
Contouring Service
Detection
Segmentation
Fusion
Structure
N mean ± std N mean ± std N mean ± std N mean ± std
Brain
10 1.13 ± 0.24
10 0.80 ± 0.29
Brainstem
91 0.98 ± 0.27 10 0.83 ± 0.17 10 0.68 ± 0.24
Cochleae
95 0.84 ± 0.21 20 0.69 ± 0.19 20 0.30 ± 0.07
Eyes
20 0.58 ± 0.11 185 0.70 ± 0.27 20 0.57 ± 0.09 20 0.44 ± 0.12
Lungs
10 2.35 ± 0.89 93 2.30 ± 0.88
10 1.90 ± 0.66
Mandible
10 2.40 ± 1.06 101 1.71 ± 0.48 10 1.13 ± 0.27 10 0.63 ± 0.19
Parotid Glands
172 2.00 ± 0.76 20 2.00 ± 0.85 20 1.25 ± 0.75
Spinal Cord* 10 5.27 ± 1.98 93 2.90 ± 2.04
10 1.48 ± 1.18
Mean Surface Distance (cm)
Smart
Multi Atlas
Smart
Smart
Segmentation +
Contouring Service
Detection
Segmentation
Fusion
Structure
N mean ± std N mean ± std N mean ± std N mean ± std
Brain
10 0.08 ± 0.02
10 0.07 ± 0.02
Brainstem
91 0.28 ± 0.05 10 0.24 ± 0.05 10 0.14 ± 0.04
Cochleae
95 0.25 ± 0.05 20 0.23 ± 0.04 20 0.09 ± 0.03
Eyes
20 0.20 ± 0.04 185 0.23 ± 0.07 20 0.20 ± 0.05 20 0.11 ± 0.02
Lungs
10 0.10 ± 0.02 93 0.21 ± 0.22
10 0.25 ± 0.14
Mandible
10 0.39 ± 0.18 101 0.29 ± 0.09 10 0.24 ± 0.06 10 0.08 ± 0.02
Parotid Glands
172 0.38 ± 0.14 20 0.34 ± 0.14 20 0.18 ± 0.06
Spinal Cord* 10 0.53 ± 0.17 93 0.31 ± 0.13
10 0.14 ± 0.06
*Smart detection only allowed for the contouring of spinal canal
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Further testing of in-house multi-atlas contouring service (MACS)
The MACS contouring algorithm was best performing on initial review and was
therefore selected for comprehensive analysis. Central to the MACS algorithms is the atlas of
patients from which contours are propagated. Of the 12 patients in the contouring atlas, nine
were male and 11 had primary oropharynx disease, one patient had unknown primary. The
mean age was 72 years. Ten were AJCC 7th edition clinical stage IVa, one IVb and one stage
III; all were treated with curative intent.
For all 128 patients the distribution of physician ratings of the 8 normal structures on
the same 5-point scale can be seen in Figure 22. One patient had a surgically removed
parotid and for five patients the lungs were not visible in the patient CT, thus no rating was
recorded for these structures. Of the eight normal structures, six were, on average, indicated
as clinically acceptable for use without edits in DVH-based planning, scoring either a four or a
five. The remaining two structures had ratings indicating the need for minor edits for use in
DVH-based planning, depending on their spatial relation to the target volume. For all normal
structures, 87% received ratings which indicate no need for edit for use in treatment planning
(a score of 4 or five). Furthermore, 97% of normal structures received a rating which indicates
that, at most, only minor editing is needed for use in DVH based planning.
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Figure 22. Distribution of the primary physician ratings of the in-house MACS algorithm.
Contours of eight normal structures generated from the MACS algorthms were reviewed by a
physician on a five point scale for 128 patients. The mean (± standard deviation) physician
ratings are displayed in the graphs and the % receiving each rating overlaid on the bars

Inter-observer variability
To assess inter-observer variability, a subset of 10 randomly selected patients was
reviewed by five additional radiation oncologists from four outside institutions. The radiation
oncologists, per a self-reported questionnaire, had an average of 8.25 years of experience
(range, 3.0-12.5 years) and contour and/or review an average of seven patients per week
(range, 2-15 patients), spending an average of 95 minutes per patient on contouring (range,
45-180 minutes). For all structures except parotid glands, the scores assigned to the 10
patients differed significantly (Wilcoxon signed rank test, p<0.05) between the primary
physician and at least one outside physician. However, no structure was significantly different
between primary and all of the outside physicians.
For all structures, 45% (245/547) of the ratings by the outside physicians matched
those of the primary physician and were classified as Category I agreements. Considering
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5

Category II agreements, the physicians assigned an additional 48% (262/547) of the contours
to same group, either as needing no or minor edit for use (48%) or as needing major edit for
use (0%). Finally, only 7% of contours received scores indicating the need for major edits by
one physician while needing no or minor edits by the other physician. In Table 13 the
percentage of contours classified into each of the three agreement categories can be found
for the eight normal structures assessed.

Table 13. Percentage of normal tissue rating pairs in three agreement categories. Category I
indicates the scores by the two physician matched, Category II indicates that the ratings did
not match but the contours were rated into the same “group” (either as needing no or minor
edit or as needing major edit) by both physicians. Category III represents disagreement
between two revewing physicians. Due to rounding, not all rows sum to 100.

Structure
Brain
Brainstem
Cochleae
Eyes
Lungs
Mandible
Parotid gland
Spinal Cord
Total

% of agreements in
Category
I
II
III
22
76
2
48
32
20
46
49
5
47
42
11
60
36
4
40
58
2
57
38
5
22
68
10
45
48
7

Clinical Use of Normal Tissue Autocontours
Due to its success on retrospective evaluation, the MACS autocontouring algorithm
was implemented into the head-and-neck clinic at MD Anderson. During 10 months of clinical
implementation, 22 radiation oncologists used the automated contouring software to generate
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normal structure contours for 166 patients treated at our institution. Inclusion criteria included
availability of the approved treatment plan and record of the requesting of the autocontours
through the script in the treatment planning system. The 7 attending physicians who used the
tool the most accounted for 23, 15, 14, 9, 7, 7 and 5% of the total use. The mean (± standard
deviation) time required for generation of the autocontours was 11.5 ± 3.1 minutes when run
on a Windows 2012-based PC with an 8-core Xeon E5-2697 v3 2.6-GHz CPU and 16 GB of
memory. Multithread computing was enabled in the deformable registration algorithm, and 2
registration tasks were allowed to be run simultaneously on the server. This time does not
require oversight by a physician or dosimetrist and can therefore occur simultaneous to other
required treatment planning tasks. The distribution of autocontour edits, as measured by the
Dice similarity coefficient, mean surface distance, and Hausdorff distance is shown in Figure
23. We measured edits only for structures which remained in the treatment plan at the time of
treatment with the same naming convention as the automatically contoured structures.
Notably, radiation oncologists did not edit 49.8% of the contours for treatment
planning. As shown in Figure 2, 31%, 40%, and 48% of automatically contoured brainstems,
parotid glands, and modified spinal cords were not edited for clinical use. The structures
edited least often were the eyes (69% were not edited) and modified lungs (74% were not
edited). The Dice similarity coefficient was lowest for the cochlea (0.79±0.26). The maximum
mean surface distance edits were seen for the unmodified lung avoidance structure (3.29
mm) and unmodified spinal cord (2.65 mm), due primarily to inferior CT scan extent
discrepancy. However, considering edit to the modified lung avoidance and spinal cord
structures, the maximum mean surface distances were decreased for lungs and spinal cord to
0.33mm and 0.20mm, respectively. This reduction is shown in Figure 23 as a reduction in
both the medians and interquartile ranges of edits to the modified lungs and spinal cord
structures relative to those edits of the unmodified versions.
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A non-paired, one-sided t test showed that for all structures, contours that were edited
for clinical use were significantly closer to the target volume than contours that remained
unedited in the treatment plan (p < 0.003).
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Figure 23. Distribution of the clinical edits to autocontours. The red line within the box plot
represents the median and box edges represent the 25th and 75th percentile. Outliers are
indicated by red crosses and are values outside the 25th or 75th percentile by more than 1.5
times the interquartile range. Between the boxplots are the percent of unedited contours and
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the means (± standard deviations) of the Dice similarity coefficients and the mean surface
distances for each for the automatically contoured or modified structures. Abbreviations: DSC
= Dice Similarity Coefficient, MSD = Mean Surface Distance, HD = Hausdorff distance.

Given these clinical edits, we sought to identify the minimum uniform expansion to the
autocontours needed to encompass either 95% or 100% of the clinically edited contour for
90% or 95% of the patients. Table 14 lists the minimum uniform expansions needed for each
of the eight normal structures examined in our study, including the inferiorly modified lung and
spinal cord contours. If autocontours are used without edit, our findings show that a uniform
expansion between 0 and 5 mm would provide coverage of 95% of the physician edited
structure for 90% of the population. To cover 100% of the physician edited structure for 95%
of the population the minimum uniform expansion needed ranges from 4mm (cochlea) to
more than 15 mm (lungs, mandible, parotid).
Table 14. Minimum uniform expansion to autocontoured normal tissues needed to cover a
given fraction of the structure for a given fraction of the population.
Patient population
90%

95%

Contour coverage
Structure

95%

100%

95%

100%

Brain

0.00

7.53

0.00

10.64

Brainstem

3.55

7.22

4.51

8.88

Cochlea

2.28

3.02

3.42

4.00

Eye

1.64

3.34

2.06

5.28

Lung (modified)

0.64

>15

4.20

>15

Mandible

1.74

12.80

3.59

>15

Parotid gland

4.67

>15

9.05

>15

Spinal cord (modified)

0.98

3.74

1.63

4.81
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Machine Learning Model for Prediction of Autocontour Errors
As necessary for the implementation of autocontouring as part of a fully automated
treatment planning approach a method to detect autocontouring errors was investigated.
Detection of gross and simulated errors represents a check of safety and catching of
significant autocontouring errors. The detection of smaller clinical edits represents the
possibility to flag to the user of an automated treatment planning approach that autocontours
presented may require editing.
Simulated failure models
The performance of the RF models to predict simulated and gross errors is
summarized in Table 15. The overall sensitivity and specificity of the models to gross and
simulated error prediction were greater than 0.85 for all structures. When considering
simulated errors due to small shifts and expansions, we found that the sensitivity was greater
than 0.9, and this improved with the size of the shifts and expansions.
When considering patients in non-standard positions, we observed that the model
sensitivity was slightly lower for some structures; a minimum sensitivity of 0.5 was seen for
the cochlea, lungs, and mandible, although the size of the test set was small (2-14 patients).
For one patient, a large primary gross tumor volume (637 cm3) resulted in substantial
automatic contouring errors for the surrounding contours, and for contours with a Dice
similarity coefficient of less than 0.8 compared with the clinically edited structure (right eye
and mandible), the contouring errors were successfully detected by their respective RF
models. When considering the test patients in nonstandard positions plus the patients with
other scan sites, we observed that at least half of the structures were predicted to have some
contour errors in all patients. This suggests that if automatic contouring is predicted to fail in
more than half of the structures, the patient is not a good candidate for this in-house
autocontouring technique.
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Table 15. Random forest model performance for the prediction of simulated and gross errors. Sizes of shifts and expansions can be
found in Table 10.

Structure

Overall model Shifted, size
performance*
1

Shifted,

Shifted,

Shifted,

size 2

size 3

size 4

Expanded,
size 1

Expanded,
size 2

Expanded, Nonstandar Other scan
size 3
d positions locations

N, test
N, test
N, test
N, test
N, test
N, test
N, test
N, test
N, test
Sens
Sens
Sens
Sens
Sens
Sens
Sens
Sens
Sens
set
set
set
set
set
set
set
set
set

Sens

Spec

0.88

0.95

50

1.00

50

1.00

50

1.00

50

1.00

50

0.94

50

1.00

50

1.00

7

0.71

13

0.46

Brainstem 0.90

1.00

50

0.96

50

0.98

50

1.00

50

1.00

50

0.74

50

1.00

50

1.00

5

0.80

13

0.77

Cochleae 0.87

1.00

50

1.00

50

1.00

50

1.00

50

1.00

50

0.84

50

1.00

50

1.00

14

0.50

26

0.38

Brain

Eyes

0.89

0.94

50

0.98

50

1.00

50

1.00

50

1.00

50

0.84

50

0.98

50

1.00

16

0.94

26

0.77

Lungs

0.88

1.00

50

0.98

50

0.98

50

1.00

50

0.96

50

1.00

50

0.98

50

1.00

2

0.50

13

0.54

Mandible 0.90

1.00

50

1.00

50

1.00

50

1.00

50

1.00

50

1.00

50

1.00

50

1.00

8

0.50

13

0.77

Parotid
glands

0.85

0.98

50

0.92

50

0.96

50

1.00

50

0.98

50

0.96

50

1.00

50

1.00

15

0.60

26

0.69

Spinal
cord

0.91

1.00

50

0.96

50

0.98

50

0.96

50

0.98

50

1.00

50

1.00

50

1.00

3

0.67

13

0.77

*Sens, sensitivity; spec, specificity.
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For all structures a metric derived from the HU distribution or an agreement metric
with the independent deformable image registration contouring technique was the most
important predictor. Other important predictor classes were derived from the autocontour
distance to bony structures and the quantitative comparison to an independently and
heuristically derived autocontour.
Prediction of clinical edits
Table 16 shows results of the overall performance of the RF models for the prediction
of clinical edits to automatic contours (i.e., true errors), in which the thresholds of Hausdorff
distances greater than zero (any clinical edit) or greater than 5 mm (significant clinical edit)
were considered for contour errors. On average, 40% of contours (including modified
structures) were edited for clinical use and 26% were edited such that the Hausdorff distance
was greater than 5 mm. Models were not trained to predict significant (≥5-mm Hausdorff
distance) edits to the brain, lung, or spinal cord contours owing to the very small proportion of
contours edited and available for model building and testing purposes.
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Table 16. Random forest model performance for the prediction of clinical edits to
autocontours. Two random forest models were trained for each structure, in which automatic
contour error was defined as a Hausdorff distance (compared with the edited automatic
contour) of greater than 0 (i.e., any clinical edit) or greater than 5 mm (i.e., significant clinical
edit).
Any clinical edit

Significant clinical edit

Structure

No.
No.
No. edited Accuracy Sensitivity Specificity edited Accuracy Sensitivity Specificity

Brain

113

63

0.56

0.71

0.36

Brainstem

109

60

0.55

0.92

0.10

39

0.56

0.54

0.57

Cochleae

220

79

0.57

0.39

0.67

31

0.57

0.48

0.58

Eyes

205

58

0.68

0.07

0.92

16

0.73

0.75

0.72

Lungs

71

14

0.79

0.00

0.98

Mandible

113

36

0.62

0.36

0.74

29

0.57

0.59

0.56

Parotid gland 214

102

0.61

0.80

0.44

96

0.63

0.63

0.63

Spinal cord

38

0.53

0.68

0.44
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The model performance over time, both for any clinical edit and for large clinical edit
can be seen in Figure 24 and Figure 25, respectively. Little model improvement was seen
over time and performance plateaued for most structures after 10 rounds of testing.
Generally, the RF models to predict any autocontour edits did not perform as well as
expected, with an average accuracy of 0.61. The RF model for the prediction of edits to the
lung contours did not correctly identify any edited contours, though only 14 of 71 were edited
and had Dice values with an average and standard deviation of 0.96±0.04.
The RF models to predict significant clinical edits performed, on average, better than
those to predict any clinical edit; the best performing model for the prediction of significant
clinical edits was for the eyes. Model performance improved when only contours that had
significant clinical edits were considered. The RF models for the prediction of significant
clinical edits were 100% sensitive to edits with Hausdorff distance greater 12 mm to the
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brainstem, 7 mm to the cochlea, 6 mm to the eyes, and 22 mm to the mandible contours and
were 76% sensitive to edits with Hausdorff distance greater than 2.2 cm to parotid contours.
This indicates that the size of edit to which the models are sensitive may be larger than for
edit size for which it was built.
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Figure 24. Performance of QA models to detect any clinical edit. Models with high sensitivity
(red) (e.g. brainstem, parotid) generally had low specificity (yellow). The accuracy (blue) of
the detection of clinical edits to normal tissue structures was generally low, less than 0.6 for 4
of 8 structures. (Previous page)
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Figure 25. Performance of QA models to detect large clinical edits. Models were rebuilt after
ten patients. Model accuracy (blue) was above 0.55 for all structure, with the model to detect
errors in the eyes having the highest accuracy at 0.73. Model performance plateaued over
time.(Previous page)

Among the most important predictors were a quantitative comparison to the
independent deformable image registration contouring technique and metrics from the HU
distribution. After the initial RF was built, the models were updated after every 10 structures.
The accuracy, sensitivity, and specificity of the models were tracked over time, although an
improvement in model performance was not observed.
Insight into model performance may be had by understanding the reasons for which
contours were edited. A non-paired, one-sided t test showed that for all structures, contours
that were edited for clinical use were significantly closer to the target volume than contours
that remained unedited in the treatment plan (p < 0.003). For the RF models least sensitive to
contour editing (lungs, eyes, and mandible), the edited contours were on average 1.9 cm
(lungs), 1.9 cm (eyes), and 0.4 cm (mandible) closer to the target volume than contours that
were not edited for clinical use. This result may indicate that reasons other than anatomical
accuracy (e.g. potential dosimetric effect) are used for contour edit decision making.

Dosimetric Impact of Normal Tissue Autocontours for Treatment Planning
Patients Cohort
For the eight structures implemented for autocontouring into our clinical practice, the
distribution of clinical edits seen clinically were compared using a two sided t-test to both the
group of 54 patients selected from this larger cohort and to the group of 29 patients treated on
a clinical trial. The results are shown in Table 17. For all structures, except eye, we found no
significant difference in the mean of the distribution of dice similarity coefficients or Hausdorff
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distances between the cohort of 54 patients and all patients with clinically edited normal
structures. For eye, the mean Dice similarity coefficient for 289 clinical edited eye structures
was 0.96±0.11, for this cohort the edits were slightly less with a mean and standard deviation
of DSC of 0.98±0.04.
Considering the 29 patients treated on a clinical trial and when normal tissues were
drawn independently there was a significant difference in the distribution of clinical and
autocontour agreement. The difference between autocontours and physician structures was
larger for this group of patients than for those with clinical edited autocontours indicating that
the use of these for planning would represent a worst case scenario, as clinical edits would be
expected to be smaller.

Table 17. Comparison of contour disagreement in the dosimetric cohorts with clinical edits to
autocontours. A two sided t-test was used to test the hypothesis that the distribution of edits
sizes for both the cohort of 54 patients with clinical edited autocontours and the cohort of
patient with independently contours normal structures had the same mean as all patients with
clinically edited normal structures, as described in the previous section.

Structure
Brain
Brainstem
Cochleae
Eye
Lungs
Mandible
Parotid Glands
Spinal Cord

p-value, two sided t test
Independently Drawn Contours
Edited contours
(n=29)
(n=54)
Hausdorff
Hausdorff
Dice
Dice
Distance
Distance
0.60
<0.01
0.28
0.38
<0.01
<0.01
0.43
0.16
<0.01
<0.01
0.48
0.68
0.01
0.06
0.03
0.01
No Structures
0.94
0.99
<0.01
<0.01
0.56
0.23
<0.01
<0.01
0.87
0.83
<0.01
<0.01
0.33
0.89
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Dosimetric Impact
A paired Wilcoxon signed rank test was used to compare the treatment plans using
the physician drawn/edited structures with those created on unedited normal tissue
autocontours. The comparison was done independently for the two patient groups (1) clinical
structures derived from autocontours and (2) structures drawn independently from the
autocontours.
Considering the group of patients from which physician structures were derived from
autocontours, DVH metrics which showed a significantly worsening effect on the DVH metric
included the mean doses to both the ipsilateral and contralateral parotid glands and the
volume of the ipsilateral parotid gland receiving more than 30Gy (p=0.01). The p-values of the
Wilcoxon signed rank test for all structures can be found in Table 18. These results suggest
that for most structures using unedited autocontours generated using the method described in
Chapter 4, results in no significant dosimetric effect on the treatment plan. The exception to
this is for the parotid glands which are often in very close proximity to targets in the head-andneck.
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Table 18. Comparison of DVH metrics to true structures when planned on unedited structures
and clinically edited structures for 54 patients with clinical edited normal structure
autocontours. Shown are p-values of the paired Wilcoxon signed rank test. In green are
parameters for which having planned on unedited autocontoured normal structures showed
an improvement in the DVH metric compared to having planned on the true physician
edited/approved structure. In red are metric for which planning on the unedited structures
caused a significantly poorer performance at the clinical DVH point. All plans were evaluated
on physician edited/approved structures.
Clinically Edited /Approved Structures
p-value, paired
Structure
N
Test Point
Wilcoxon rank
sum
D_max
0.08
Spinal Cord
54
V_45Gy
1.00
D_max
0.68
Brainstem
53
V_54Gy
1.00
D_mean
0.01
Ipsilateral Parotid
53
V_30Gy
0.01
D_mean
0.06
Contralateral Parotid
50
V_30Gy
0.01
D_max
0.49
Cochleae
106
V_35Gy
0.68
D_max
1.00
Eyes
88
V_50Gy
0.13
D_max
0.16
Brain
50
V_54Gy
0.95
D_1cc
0.18
High Dose PTV
54
V_95%
0.68
Intermediate Dose PTV
45
V_95%
0.98
Low Dose PTV
42
V_95%
0.09
Detriment to DVH Metric

Improvement in DVH Metric
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Considering the group of patients treated on a clinical trial, and for which normal tissue
contours were contoured independently, there was also limited dosimetric impact due to the
use of unedited autocontours compared to physician drawn contours, Table 19. A significantly
worsening effect due to the use of the unedited autocontoured normal structures was seen for
the maximum dose to the brainstem (p<0.01) and both the maximum dose (p<0.01) and the
volume receiving more than the maximally allowed dose of 45 Gy (p<0.01) for the spinal cord.
However, for some patients, there is a clear discrepancy in the naming of structure and its
contoured anatomy, this is especially easy to detect for the spinal cord contour. Common
were two errors, either the physician drawn spinal cord either more closely represents a
spinal canal contour, or is clearly not a contour of the spinal cord (i.e. includes part of the
spinal column or brainstem. Examples of these errors can be seen in Figure 26. This analysis
underlines the importance of assumptions which are made about the development of
treatment plans and their retrospective analysis.
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Table 19. Comparison of DVH metrics to true structures when planned on unedited structures
and independently drawn physician contours. Shown are p-values of the paired Wilcoxon
signed rank test. In red are metric for which planning on the unedited structures caused a
significantly poorer performance at the clinical DVH point. All plans were evaluated on
physician drawn structures.
Independently Physician Drawn Structures
Structure

N

Spinal Cord

29

Brainstem

27

Ipsilateral Parotid

29

Contralateral Parotid

26

Ipsilateral Submandibular Gland
Contralateral Submandibular Gland

16
21

Cochleae

8

Optic Chiasm

21

Optic Nerves

46

Lens

56

Eyes

6

Brain

1

High Dose PTV

29

Intermediate Dose PTV
Low Dose PTV

29
14

Detriment to DVH Metric

Test Point
D_max
V_45Gy
D_max
V_54Gy
D_mean
V_30Gy
D_mean
V_30Gy
D_mean
D_mean
D_max
V_35Gy
D_max
V_54Gy
D_max
V_54Gy
D_max
V_7Gy
D_max
V_50Gy
D_max
V_54Gy
D_1cc
V_95%
V_95%
V_95%

p-value, paired
Wilcoxon rank
sum
<0.01
<0.01
<0.01
1.00
0.55
0.77
0.12
0.08
0.21
0.57
0.84
1.00
0.14
1.00
0.44
0.50
0.34
0.46
0.44
1.00
1.00
1.00
0.38
0.87
0.17
0.95

Improvement in DVH Metric
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A

B

C

D

E

F

G

H

I

J

45 Gy Isodose Line
Autocontoured Structures
Clinical Structures

Figure 26. Ten patients with clinical spinal cords exceeding clinical constraints when planned
using autocontours. For these ten patients, the maximum dose to the clinical spinal cord (red)
exceeded 45Gy (cyan) when the autocontoured spinal cord (blue) was used for treatment
planning; the maximum dose when the physician drawn spinal cord was used was less than
45Gy. In panels A-C, the clinical contour exceeds more superiorly than the autocontoured
spinal cord. In panels D-J, the clinical spinal cord more resembles a spinal canal. In panel F,
the clinical spinal cord contour extends very far superior to include the brainstem, which was
not included as a separate structure for this patient.
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In Figure 27, the dosimetric impact of the choice of planning structure can be seen.
For 898 physician drawn normal structures, 474 showed a decrease in plan quality and 424
showed a dosimetric improvement due to planning on unedited autocontours. For spinal cord,
13 of 83 plans (12 of which were drawn independently from autocontours) had a spinal cord
which exceeded clinical dose constraints when planning was done on autocontoured spinal
cords. Though, as discussed, and shown in Figure 26, all of these structures have physician
edited/approved/drawn spinal cords which are not reflective of their naming. Considering all
other normal structures, in only five cases (three parotid gland, one optic nerve, and one eye)
did planning on an unedited autocontour result in an exceedance of the corresponding clinical
threshold. The relative percentage difference of these five structures can be found in Table 20
and were all less than 15%, indicating that while the structure did exceed clinical thresholds,
the relative difference as small.
The results above should be considered with the understanding that comparisons
were made only on structures which were included in the original treatment plan. It is likely
that structures not included in the clinical treatment plan were not of significant dosimetric
interest because, for example, the structure may be far from the target. In these cases using
an unedited automatic structure in lieu of a clinically approved structure is likely to have very
limited dosimetric impact and therefore results herein represent the expected dosimetric
impact for a subset of patients for which accurate contouring is expected to be of
consequence in the treatment plan and therefore these results may overestimate the impact
on the population as a whole.
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Table 20. Dosimetric Impact of structure which exceed clinical structure when autocontours
are used for treatment planning. Of 815 structure s 5 exceeding corresponding clinical
constraints when autocontours, instead of clinical structures, were used for treatment
planning.

Structure
Parotid
Gland
Parotid
Gland
Eyes
Optic
Nerve

Dosimetric Value when planned on
Clinical
Automatic
Structures
Structures
25.9 Gy
27.5 Gy
24.7 Gy
26.0 Gy

Dosimetri
c metric

Clinical
Threshol
d

Relative
Difference
(%)

Mean
Dose

26 Gy

V_30Gy

50%

47.0%

53.6%

14

Max Dose

50 Gy

48.2 Gy

51.4 Gy

6.6

Max Dose

54 Gy

52.1 Gy

54.4 Gy

4.4

6.3
5.5
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1

44

3

2
39

28

Edited
Independently Drawn

49

19

39

37

35

1
25

33
13

44

47

Figure 27. Distribution of relevant dosimetric points when planned on clinical structures and
autocontoured structures. Along the x-axis, the DVH metric to true physician approved
structures when planning on autocontoured structures and along the y-axis for the same
patients the DVH metric when planned on the true clinical structure. Shades of green indicate
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improvement in the dosimetric descriptor when planned on the autocontours, shades of red
indicate poorer performance due to use of the autocontours for planning. Darker shades
delineate common clinical thresholds for each dosimetric descriptor, with darker green
indicating an improvement beyond the clinical threshold and darker red indicating a poorer
performance beyond the clinical threshold. In cyan squares, for 54 patients, clinical structure
originated from autocontours with physician approval/editing for clinical use. In magenta
circles, other normal structures were independently drawn for clinical use (continued on
following pages).
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24
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Edited
Independently Drawn

2

1

14
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1
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8
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1

Figure 27. (Continued from previous pages)
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1

2
1

7

22
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Figure 27. (Continued from previous pages)
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Correlation to Patient Features
Considering four structures of particular importance to the treatment of head-and-neck cancer
(spinal cord, brainstem, and contralateral and ipsilateral parotid glands), there were few
examples when the use of unedited autocontoured structures impacted plan quality or dose
delivered to true clinical structure as measured by clinically used dose metrics. However,
variations in impact including positive and negative impact as well as a limited number of
cases for which clinical constraints were exceeded in autocontours were used for planning
indicate a possibility of detecting these patients for the warning to the user of a fully
automated system or for further investigation. Three dosimetric metrics; the absolute dose to
the clinical structure, the absolute difference in dose to the clinical structure when planned on
either unedited autocontour or the clinical structure, and the relative dose difference when
planned on the two structures, were evaluated for correlation with several features of the
plans, as shown in Table 21.
For the spinal cord, brainstem, and contralateral parotid the absolute dose to the
clinical structure when planned on the unedited autocontour was significantly correlated to the
size of clinical edit, quantified as the Dice similarity agreement, Hausdorff distance, and mean
surface distance. This indicates that the degree of clinical edit is correlated to its relative dose
region. Unfortunately this data, the size of clinical edit, would not be available for incoming
patients for which the need for clinical edits partly motivates the model prediction itself. The
dosimetric impact for these three structures was also positively correlated to the prescription
dose level of all three PTVs, and both the minimum distance and the distance of the 10%
closest points to one or more PTVs. These correlations indicate that the higher a prescribed
dose and the closer a normal tissue is to the PTVs, the higher the dose to the true normal
structure will be.
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The dosimetric impact due to the use of unedited autocontoured structures for
treatment planning was assessed using the two remaining metrics; the absolute and relative
dose differences. Significant correlation between features of the treatment plan and the
dosimetric impact of the choice of planning structure was found for a limited number of plan
features. For example, the absolute difference in the mean dose to the contralateral parotid
was significantly correlation to both the minimum distance and the distance of the 10%
closest points to the low dose PTV, this may be expected given that edits to the parotid may
be more impactful if the target is near the structure. Considering the very limited impact the
choice of planning structure had on the resultant plans, as presented in the previous section,
strong correlations would not be expected.

Table 21. Correlation between dosimetric impact of using unedited autocontoured normal
structures and patient and plan features. P-values of the hypothesis that there exist no
relationship between the dosimetric impact (rows) and plan features (columns), significant
established at <0.05 and shown in green. The absolute dose to the clinical structure of four
key normal structures in the head-and-neck were significantly correlated with the size of
clinical edit (although not available for prediction of new patients), the PTV prescribed dose
level and the minimum distance to the target. The absolute and relative dose difference were
less often correlated to plan features. No dosimetric features were correlated with the DSC of
the targets or target variations.
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p-values of Correlation
Coefficient
Structure
Spinal Cord
Brainstem
Absolute
Dose
Ipsilateral Parotid
Contralateral Parotid
Spinal Cord
Absolute
Brainstem
Dose
Ipsilateral Parotid
Difference
Contralateral Parotid
Spinal Cord
Relative
Brainstem
Dose
Ipsilateral Parotid
Difference
Contralateral Parotid

PTV1

PTV2

PTV3

Prescription Dose
Level
PTV1 PTV2
PTV3
<0.01
0.03
<0.01
0.01
0.03
<0.01
0.35
0.71
0.86
<0.01
0.01
<0.01
0.04
0.19
0.08
0.61
0.61
0.45
0.97
0.54
0.46
0.28
0.75
0.30
0.29
0.25
0.10
0.48
0.87
0.28
0.82
0.34
0.68
0.07
0.38
0.15
Dice of Structure Hull
with PTVs
PTV1 PTV2
PTV3

0.03
0.61

0.22
0.61

0.99
0.08

0.03
0.65

0.18
0.63

0.98
0.07

0.26
0.23

0.19
0.05

0.73
0.04

0.31
0.23

0.25
0.06

0.75
0.04

0.22
0.14

0.15
0.13

0.54
0.06

0.25
0.14

0.18
0.13

0.55
0.06

Clinical Edit
Dice
<0.01
<0.01
0.68
<0.01
<0.01
<0.01
0.23
0.20
<0.01
<0.01
0.37
0.17

HD
0.01
<0.01
0.72
<0.01
0.01
<0.01
0.55
0.33
0.03
<0.01
0.94
0.21

MSD
0.02
<0.01
0.74
<0.01
0.04
<0.01
0.43
0.35
0.07
<0.01
0.76
0.23

Dice with PTVs

Absolute
Dose
Absolute
Dose
Difference
Relative
Dose
Difference

Structure
Spinal Cord
Brainstem
Ipsilateral Parotid
Contralateral Parotid
Spinal Cord
Brainstem
Ipsilateral Parotid
Contralateral Parotid
Spinal Cord
Brainstem
Ipsilateral Parotid
Contralateral Parotid

Minimum Distance
PTV1 PTV2
PTV3
<0.01
0.01
0.02
<0.01
0.05
0.07
0.98
0.66
<0.01
<0.01
0.24
0.09
0.01
<0.01
0.09
0.52
0.77
0.42
0.36
0.09
0.81
0.56
0.18
0.68
0.04
<0.01
0.10
0.47
0.76
0.64
0.17
0.04
0.90
0.46
0.24
0.87
Dice with 0.5 cm
expanded targets
PTV1 PTV2
PTV3
0.81
0.49
0.22
0.09
0.49
0.03
0.04
0.15
0.27
0.14
0.86
0.54
0.94
0.42
0.02
0.17
0.26
0.26
0.30
0.44
0.72
0.02
0.53
0.97
0.45
0.05
0.24
0.21
0.21
0.18
0.39
0.72
0.05

Max Distance of 10%
closest points
PTV1 PTV2
PTV3
<0.01
0.01
0.01
<0.01
0.04
0.05
0.68
0.70
<0.01
<0.01
0.23
0.07
0.01
<0.01
0.05
0.58
0.78
0.41
0.34
0.09
0.90
0.66
0.16
0.73
0.06
<0.01
0.07
0.53
0.75
0.65
0.15
0.04
0.83
0.56
0.25
0.92
Dice with 1cm
expanded targets
PTV1 PTV2
PTV3
0.23
0.18
0.74
0.36
0.30
0.54
0.36
0.88
0.13
0.17
0.58
0.12
0.74
0.36
0.23
0.94
0.83
0.03
0.09
0.15
0.62
0.17
0.69
0.44
0.12
0.79
0.95
0.06
0.14
0.26
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Discussion
We have investigated the use autocontoured normal structures in the head-and-neck
for treatment planning purposes. We first evaluated retrospective and prospective algorithm
performance including the clinical implementation of the 8 normal structures into our headand-neck clinic. In an effort to ensure the safe use of autocontoured for automated treatment
planning, which may or may not include the careful review of contours, we developed an
approach to QA autocontours in order to flag them to the user. Finally, we investigated the
potential use of unedited autocontours for treatment planning. The results show that
autocontouring is a viable method to save time, reduce required infrastructure, while
maintaining a high standard of care, and that the use of unedited autocontours has limited
dosimetric impact.
In an analysis of four autocontouring algorithms, an in-house methods, MACS, was
highest performing. Two commercial algorithms were also analyzed –Smart Segmentation® a
deformable image registration technique which performance was not found to be adequate for
clinical use and Smart Detection® a heuristic approach which worked well but is only
available for a limited number of structures, and Smart Segmentation® a deformable image
registration approach which performed poorly with or without the use of multiple atlas
patients. While the heuristic approach slightly outperformed the in-house technique for a few
structures, the advantages of using a single algorithm which include a reduction in the time
needed to contour, a simplification in workflow, and the availability to modify the contours
which is not possible using the commercial approach the in-house method alone was selected
for further analysis. Interest in other automatic contouring methods are increasing, including
the use of edge detection, image gradient, and voxel intensities, which do not require prior
information or model building as well as shape model and machine learning techniques which
use the contours of prior patients to inform the contour of new patients and have performed
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well on select patient data sets (99). These techniques may offer advantages and the
validation and assessment of these algorithms both in the clinic and for planning purposes
may be evaluated using the principles presented here.
Given the known inter-physician variability in contouring(88, 117) and as the atlas for
contour generation was derived from patients from the primary rating physician we sought to
present autocontours from MACS to 5 physicians and, as expected, the acceptability of the
contours, especially for use without edit, varied among physicians, however only 7% of
contours received contours which indicated physician disagreement (i.e. outside of their own
opinion of acceptable inter-physician variability). We expect similar results for a larger group
of physicians.
We successfully implemented into routine clinical the autocontouring of 8 normal
structures (11 total contours as three were bilateral). These 8 structures were chosen as they
were the most often contoured structures in a sample of head-and-neck cancer patients. This
clinical implementation provides ongoing data at the size of edits of autocontours and
possible trends into normal tissue contouring practices. Other structures are also required and
include the submandibular glands, optic structures, esophagus, and others (92). A limited
analysis of these structures, presented in the appendix, show less success for their
contouring compared to independently drawn physician structures and therefore these
structures may warrant further analysis.
While no formal analysis of time savings or systematic method for physician feedback
was developed, we believe that, in line with previous findings, autocontouring saves time
(118-120) and that the continued use of the software indicates that it has been well received,
with over 1000 patients having had these contours requested through the script in the
treatment planning system. Upon implementation a description of the tool as well as guidance
for its use was sent to the attending physician, however due to software limitations we were
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unable to track approval and/or editing of the structures on a patient-by-patient basis and it
was assumed that if normal structures were requested for the patient and image set of the
final treatment plan and if the contours remained in the final treatment plan with the same
naming as the autocontours (which is the same as our clinical naming) then the contours
were edited and/or approved for clinical use. These assumptions likely have an impact of the
fidelity of the data, and a limited number of instances which highlight the impact they may
have were encountered. In one such example, for the patient and image set in question, the
contours were requested through the script in the treatment planning system and remained in
the final treatment plan, however, upon analysis of the cochlea structure it was found that the
naming was inconsistent with the structure location (i.e. the left cochlea was on the right side
of the body, and the right cochlea on the left). These structures were removed from analysis
but other, less obvious examples, may have remained. Generally, clinical implementation was
considered a success as nearly 50% of structures were not edited for clinical use and
physicians appreciate and use the tool.
In the third experiment, a method to ensure the safe use of autocontours in automated
treatment planning was investigated. Random forest models were developed such that a
patient with grossly incorrect autocontours would not be allowed to continue in the automated
treatment planning process. Additionally, the possibility of warning the user to suspected
contour inaccuracies was investigated. Due to the success of the autocontouring algrotihm,
there were few “true” autocontouring failures and simulated failures were therefore used to
supplement. It is unlikely that these simulated errors (e.g. shifts and expansions) accurately
represent the potential failure modes of an autocontouring algorithm. However, models to
detect gross errors successfully identified patients in non-standard positions, for a patient with
a very large gross tumor, and for a limited number of other gross contouring errors. For all
patients in nonstandard positions and of other disease sites, at least half of the normal
structures were flagged as failing by their respective models and therefore we suggest that if
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more than half of the structures are flagged as failing by the gross error models then the
patients should not continue in the autoplanning process.
Unfortunately, efforts to detect smaller contour edits found only limited success, with
average accuracy just over 60%. The reason for the poor performance is likely multifaceted,
though a driving reason is likely the (mis)alignment of the data collected with underlying
assumptions. During clinical implementation it was assumed that contours which remain in
the treatment plan represent the anatomical structure which corresponds to their name. An
extension of this is the idea that edit of an autocontour indicates autocontouring error and also
the inverse; lack of contour edit indicates perfect anatomical agreement. However, numerous
examples which do not support this idea were identified. Further, the significance of the
correlation between contour edit and distance to target suggest that contours are not edited
solely for the purpose of anatomical accuracy. If a model to detect anatomical accuracy of
contours is desired then vetting and careful development of a data set which matches this
desire should be curated. While strict adherence to anatomical boundaries of normal
structures for treatment planning purposes is ideal, contours for the purpose of treatment
planning may serve other purposes which are not tracked, noted, or otherwise identifiable.
To investigate the impact that the use of unedited autocontours may have on the
treatment plan we developed treatment plans on both clinically used structures (both edited
and/or approved autocontours and independently drawn structures) and unedited versions.
The results of this experiment indicate that the automated treatment planning strategy as
presented in Chapter 4 is robust to edits on the size of those seen clinically and even larger
differences seen when the contour is drawn independently and that using unedited structures
for treatment planning, which may save up to an hour of editing time, may be a feasible
option. Through this, again, we saw the impact of structures which do not align with their
naming (121); for at least seven of ten patients with a spinal cord dose which exceeded
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clinical constraint when the treatment plan was developed on unedited structures there was
some error in the spinal cord contour.
There are several limitations and opportunities for further study. Generally, the
curating of a data set which explicitly meets the needs of the hypothesis is desired, though
the use of real clinical data exposes the purposes and methods with which a clinical tool may
be utilized and therefore, should be considered. The structure set implemented clinically
included only 8 normal structures, and though others were investigated including their impact
of plan dosimetry, further investigation is needed. The study of the dosimetric impact of
autocontours was completed for a cohort of only 54 patients, from 6 sub-sites in the head and
neck, and the accrual of additional patients may reinforce the conclusions or may identify
specific scenarios (e.g. groups of patients) for which the current conclusions may not apply.
Finally, if we are to suggest that true anatomical structures are not required for high-quality
treatment planning we must be cognizant of the impact or doing so. First, the naming of such
structures should always be in line with their physician description (121). Second, normal
tissue contours routinely serve purposes beyond that for treatment planning (e.g. for the
analysis of normal tissue complications, in the case of retreatment, etc.), and if anatomically
defined contours are not routinely generated there is a risk of losing new and clinically reliable
data which may be used.
Over all, we believe this work represents the first comprehensive assessment of
automatic contouring for a large set of normal structures in the head-and-neck, including over
2 years of use. Further, we have developed a technique to identify contours with gross errors
which may jeopardize the safety of a fully automated treatment planning approach. Finally,
this is the first study to evaluate the potential of using unedited autocontours of normal
structures for head-and-neck treatment planning, and the results show that unedited
autocontours do not significantly impact plan quality at clinically relevant dosimetric endpoints,
and compared to clinical edited or approved autocontours. The use of autocontouring in the
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head-and-neck, with or without editing, could dramatically reduce the time needed to headand-neck treatment plan development, possibly allowing for the transition to advanced
techniques in low-resource settings.

Conclusion
The automatic contouring of normal structures in the head-and-neck is a promising
avenue, producing accurate contours which are suitable for use without edits for treatment
planning.
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Chapter 6: Automatic Contours of Intermediate and Low
Dose Clinical Target Volumes and Their Use in an
Automated Planning System
In this chapter we describe the results for Specific Aim 4 in which, through three
experiments we evaluate the feasibility of the use of automatically countered intermediate and
low dose target volumes in the head and neck. Our working hypothesis is that automatically
contoured clinical target volumes can safely be used for treatment planning purposes.

Introduction
Towards a fully automated treatment planning system for the head-and-neck, we have
presented the validation of the planning technique and optimization algorithms in Chapter 4
and the use of fully automated normal structure contours in Chapter 5. The next step towards
full automation is the implementation of automatically contoured target volumes. Intermediateand low- dose clinical target volumes are good candidates for automatic contouring as they
are often based on anatomically defined tissues rather than, as for the high dose treatment
volume, the cancerous tumor.
In the treatment of head-and-neck cancer, the irradiation of subclinical disease in the
lymphatic system of the neck to between 45 and 60 Gy has long been shown to improve
patient outcomes (1, 2). Historical records of patient reoccurrence reveal likely patterns of
disease spread of each sub-site in the head-and-neck (3-6) and advise physicians on the
nodal levels which would benefit from prophylactic radiation coverage. While irradiated nodal
levels and prescribed doses may vary between patients and physicians (7, 8) there is some
consensus on which to base standardized nodal selection according to stage and disease
sub-site (9, 10). An atlas of nodal levels on a contrast enhanced CT of one patients is
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available on the RTOG website
(https://www.rtog.org/CoreLab/ContouringAtlases/HNAtlases.aspx).
Once the intended nodal volumes for irradiation have been selected, they must be
delineated. Contouring of these elective targets in the head-and-neck faces the same burdens
as does the contouring of normal structures; contouring is time consuming and even with
published guidelines and publically available atlases of nodal volumes there exists significant
inter-physician variability(11-14). Further, target definition represents a major contributing
factor to geometric inaccuracy in radiotherapy (15). To reduce cntour variability as well as
save time and standardize treatment, methods for the automatic delineation of these
anatomically based nodal volumes have been investigated and are promising techniques (1619), though small patient cohorts and limited or patient specific nodal volume selections limit
their applicability more broadly.
We seek to provide a set of atlas based automatically contoured nodal volumes which,
with post processing, can provide clinically usable clinical target volumes for elective neck
coverage of many head-and-neck subsites and stages. In the context of an automated
treatment planning system for the head-and-neck, we envision a process by which the
attending physician is required to provide information about the location of gross disease (by
identifying the head-and-neck subsite) and the location of gross nodal disease, if present.
This information along with the physician drawn primary and nodal gross tumor volume (GTV)
contours will be used to provide a preliminary clinical target volume, divided by dose level,
which the physician will then have the opportunity for edit for treatment. This process can be
seen in Figure 28.
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Physician Provided Information:
1. Head-and-neck subsite
2. Nodal involvement
3. Prescription dose levels

4. Patient CT

5. Primary and
Nodal GTVs

Patient CTVs ready
for physician
editing/approval

Automatic Contouring

Nodal Volume Atlases
(Left and Right)

Nodal Volumes on
Patient CT

Figure 28. Workflow of the propagation of automatically generated CTVs. Using 5 user
provided inputs, patient specific CTVs are created. The patient CT is used in a multi-atlas
autocontouring algorithm and information provided about the disease type and stage is used
to select the appropriate nodal volumes based on templates. From the patient GTV, the high
dose CTV is created and then combined with the nodal volumes to provide patient specific
CTV contours. In a contouring workspace the physician then has the opportunity to edit and
the obligation to approve the contours for clinical use.
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Methods
Autocontouring Algorithm
Autocontours of four anatomically defined nodal level groupings, as described in Table
22 and Figure 29, were created using the in-house multi-atlas deformable image registration
approach known as MACS as described in Chapter 5. Two separate atlases were developed,
one for left sided nodal volumes and one for right sided nodal volumes. The left and right
sided atlases were comprised of 10 and 12 patients without gross disease on the
corresponding side and who were previously treated patients at The University of Texas MD
Anderson Cancer Center. Contours of the four target volumes were collected from the
patients’ treatment plans or drawn by a resident radiation oncologist; all contours used in the
atlas were reviewed and approved for use by an attending radiation oncologist with 13 years
of experience.

Retrospective Autocontouring Performance
Physician Review
For this study, 115 patients were selected from the most recent 128 patients stored in
the database of patients treated at our institution for head-and-neck cancer; the remaining 13
patients were used for atlas development. A radiation oncologist was asked to rate the nodal
level contours as seen in Figure 29 on a five-point scale, Table 8, with a score of 1 indicating
major edits are needed and a score of 5 indicating a perfect autocontour. To assess the
possibility of rater bias, nodal level contours for 10 randomly selected patients were reviewed
by five additional radiation oncologists from four international institutions. Physician
agreement was assessed by grouping each pair of ratings (one rating from the primary
physician and one from an outside physician) into one of three categories. Category I
agreement includes instances when the primary and outside physician agreed as to the
degree of edit needed, Category II agreement indicates that the physicians agreed that the
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contour required either no more than minor edits or major edits. The final category, Category
III agreement, includes those contours where the physicians disagreed on the acceptability of
the contour, with one physician indicating that the contour needed major edit with the other
indicating no or minor edit for use. Additionally, inter-physician variability in ratings was
assessed using a Wilcoxon signed rank test.
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Table 22. Anatomical definitions of individual nodal levels used in this study. Individual nodal
levels were grouped allowing for four atlas derived volumes; the retropharyngeal nodes (red
arrow), nodal levels II-IV (green), levels Ib-V (dark blue), and levels Ia-V (light blue). This
table was adapted from published guidelines, Gregoire et al(9)
Anatomical Boundaries
Nodal
Level

Cranial

Caudal

Anterior

Posterior

Lateral

Medial

Retropharyngeal
Nodes

Base of skull

Cranial edge
of the body
of hyoid
bone

Fascia under
the pharyngeal
mucosa

Prevertebral
m. (longus
colli, longus
capitis)

Medial
edge of the
internal
carotid
artery

Midline

Ia

Geniohyoid
m., plane
tangent to
basilar edge
of mandible

Plane
tangent to
body of
hyoid bone

Symphysis
menti,
platysma m.

Body of
hyoid bone

Medial
edge of
ant. belly of
digastric m.

n.a.

Ib

Mylohyoid
m., cranial
edge of
submandibul
ar gland

Plane
through
central part
of hyoid
bone

Symphysis
menti,
platysma m.

Posterior
edge of
submandibu
lar gland

Basilar
edge/inner
side of
mandible,
platysma
m., skin

Lateral edge
of ant. belly
of digastric
m.

IIa

Caudal edge
of lateral
process of
C1

Caudal edge
of the body
of hyoid
bone

Post. edge of
submandibular
gland; ant.
edge of int.
carotid artery;
post. edge of
post. belly of
digastric m.

Post. border
of int.
jugular vein

Medial
edge of
sternocleid
omastoid

Medial edge
of int. carotid
artery,
paraspinal
(levator
scapulae) m.

IIb

Caudal edge
of lateral
process of
C1

Caudal edge
of the body
of hyoid
bone

Post. border of
int. jugular vein

Post. border
of the
sternocleido
mastoid m.

Medial
edge of
sternocleidomastoid

III

Caudal edge
of the body
of hyoid
bone

Caudal edge
of cricoid
cartilage

Postero-lateral
edge of the
sternohyoid m.;
ant. edge of
sternocleidoma
stoid m.

Post. edge
of the
sternocleido
mastoid m.

Medial
edge of
sternocleidomastoid

IV

Caudal edge
of cricoid
cartilage

2 cm cranial
to
sternoclavic
ular joint

Anteromedial
edge of
sternocleidoma
stoid m.

Post. edge
of the
sternocleido
mastoid m.

Medial
edge of
sternocleid
omastoid

Cranial edge
of body of
hyoid bone

CT slice
encompassi
ng the
transverse
cervical
vessels

Post. edge of
the
sternocleidoma
stoid m.

Ant-lateral
border of
the
trapezius m.

V

Platysma
m., skin

Medial edge
of int. carotid
artery,
paraspinal
(levator
scapulae) m.
Int. edge of
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Figure 29. Examples of automatically contoured nodal level group. Shown for a representative
patient are the retropharyngeal nodes (red), nodal levels II-IV (green), levels Ib-V (dark blue),
and levels Ia-V (light blue), on five slices (Panels B-G) at locations as seen in Panel A.

Quantitative Contour Performance
From the two patient cohorts as previously discussed, [1) 115 retrospectively collected
patients with reviewed nodal levels and 2) 54 patients from various head-and-neck subsites
and clinically edited normal tissues autocontours], inclusion criteria included clinical nodes
which visually resembled anatomically defined nodal regions, and were treated for one of the
7 head-and-neck subsites. This left 55 of the 115 retrospective patients and 24 of the
prospective patient cohort, for a total of 79 patients included in this analysis.
Physician drawn CTVs served as the gold standard in this study and were created by
combining physician drawn CTVs of all dose levels into a single “clinical CTV”. This was
necessary as often the division of clinical target volumes among many prescription doses can
vary dramatically among physicians and were not standardized according to our automated
planning approach. Atlas derived CTVs were generated by a visual matching of the
intermediate and low dose clinical CTV with one or more of the four autocontoured nodal level
groups, Figure 29, or one of three additional nodal level groups (including nodal level groups
Ia-IV, Ib-IV, or II-V), which were not included in the autocontoured structure set and were only
used for 2, 2, and 4, patients respectively. The selected nodal levels were combined with the
clinical high dose CTV which was copied directly from the clinical treatment plan to mimic the
anticipated automated planning approach to create the “atlas derived CTVs”. Two quantitative
comparisons of the clinical CTVs and atlas derived CTVs were assessed using the Dice
similarity coefficient, mean surface distance, and Hausdorff distance, as previously described.
First, the clinical CTV and atlas derived CTV were compared directly, as seen in Figure 30.
Second, to eliminate the bias introduced by including the physician drawn high dose CTV in
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the atlas derived CTV, the physician drawn high dose CTV was removed from both the
clinical CTV and the atlas derived CTV to create atlas derived and clinical “nodal CTVs”, see
Figure 31.
The results of this experiment can be found on Page 156.

Atlas derived CTVs

A

C

B

CTV1
CTV2
CTV3

Clinical CTVs

CTV1
Atlas
Nodes

Figure 30. Quantitative comparison of clinical and atlas derived CTVs. In panel A, all clinical
CTVs (here three dose levels indicated in red blue and yellow) were combined to create a
single clinical CTV (green). IN panel C, atlas derived nodal volumes (light blue) were
combined with the physician drawn high dose CTV (red) to create atlas derived CTVs
(orange). In panel C, these two volumes were compared using the DSC, MSD, and HD.
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Figure 31. Quantitative comparison of clinical and atlas derived nodal CTVs. The high dose
physician drawn CTV was removed from the clinical CTVs (panel A) and the atlas derived
CTVs (panel C). The two volumes were compared the DSC, MSD, and HD.

Dosimetric Impact of Planning on Autocontoured Target Volumes
For this study, of the 54 patients used for evaluation of the treatment planning strategy
and impact of normal tissue autocontours, 40 were selected because they met the inclusion
criteria of at least 2 physician drawn CTVs and or PTVs, bilateral treatment, and intermediate
and/or low dose CTVs based on anatomical nodal levels. For comparison, two treatment
plans were developed. In the first strategy, plans were optimized to deliver dose to two
physician drawn planning target volumes. Clinical PTVs were reduced to two such that the
high dose physician drawn target was copied form the original treatment plan and any lower
dose PTV was combined into one target volume. For planning purposes the prescription to
this volume was chosen to be either equal to the original volume (if there was only an
intermediate dose target) or between the two remaining target volumes (if there were both
intermediate and low dose target volumes). See Figure 32 for an example of the reduction of
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target volumes from three to two dose levels for two patients. In the second strategy, plans
were optimized to deliver dose the atlas derived PTVs which were generated from atlas
derived CTVs with either 3 or 5 millimeter margin. The atlas derived high dose CTV was a
copy of the physician drawn high dose CTV. The second atlas derived CTV was derived by
combining the selected nodal levels which best matched the physician drawn nodes and
subtracting the high dose CTV, this volume was prescribed the same dose as the
intermediate dose level in the first strategy. Atlas derived CTVs were expanded by a margin
of either 3 mm or 5mm to create atlas derived PTVs. Both planning strategies used physician
drawn normal tissues, when present, for optimization. If physician drawn normal structures
were not included in the clinical plan MACS was used to generate these structures. For
optimization, planning structures were also generated using the MACS software as needed
for the planning strategy.
The dose delivered to the clinical CTVs and PTVs was evaluated when the two
planning strategies were used. In the first strategy, the clinical PTVs were the targets for
which the plan was optimized, the second strategy aimed to deliver dose a different target,
the one that would be used if atlas derived nodal volumes were used as target volumes
without edit. Coverage at the 95%, 98% and 100% isodose levels were evaluated.
The results of this experiment can be found on Page 161.
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Figure 32.Clinical and atlas derived targets used for treatment planning. In panels A (patient
1) and C (patient 2) intermediate and low dose clinical PTVs (blue and yellow colorwash)
were combined to create a single secondary PTV (pink line). The two physician derived PTVs
were used for treatment planning and represent the true planning scenario. Atlas derived
CTVs (orange lines panel B,C,E, and F) were used with 3 mm (lavender line, panels B and E)
and 5 mm (blue line, panels C and F) for comparison.
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Evaluation of an Independent Technique for QA of autocontoured Target Volumes
If automatically generated targets are to be used for treatment planning, similar to the
strategy proposed for normal structures, it is necessary that automatically generated target
volumes be verified independently. Towards this, we assessed the use of a second
independent target volume contouring approach as a QA check of atlas derived CTVs.
Second Clinical Target Volume Contouring Approach
As developed by a member of our group, a machine learning approach has been
shown to be successful in the contouring of a combined target volume structure in the headand-neck (CARDENAS – In Submission – Segmentation of Oropharyngeal Clinical Target
Volumes using a two-channel 3D U-Net Architecture MICCAI). This approach uses a 3D
variant of a two channel U-Net architecture and requires the user to input the patient CT
volume, the physician drawn gross tumor volume(s), an external body contour, and two
anatomical landmarks, as seen in Figure 33. The anatomical landmarks are used to identify
the extent of the area of interest in the machine learning algorithm and include the fusion of
sphenoid bone and basilar part of the occipital bone and most cranial extent of the sternum;
the landmarks were manually identified for this study but their identification could be easily
automated. The model was developed using 210 head-and-neck cancer patients treated for
oropharynx disease with bilateral treatment. Assessed on 85 patients not included in the
training set, this machine learning approach agreed with independent drawn physician CTVs
with an average and standard deviation in the Dice similarity coefficient of 0.78±0.05. In this
study, to assess the quality of the CTVs generated using this approach, CTVs for 79 patients
were compared with both the clinical CTV and the clinical nodal CTV as previously described
and as shown in Figure 34
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Figure 33. Secondary technique for the generation of CTVs. This approach requires as input
(panel A) the primary and nodal GTV, an external contour in the region of interest, and
anatomical landmarks which define the superior and inferior region of interest. The technique
outputs a combined CTV volume (panel B).
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Figure 34. Quantitative comparison
of CTVs from the secondary
technique to clinical and atlas derived
CTVs. Shown for three slices are the
CTVs from the independent

A

technique which were compared to
both the clinical CTVs (green) and
atlas derived CTVs (blue) for both the
whole CTV volume (left panels) and
the nodal CTV only (right panels).

B

C
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Independent Clinical Target Volumes as a QA Approach
In order to assess the use of these secondary contours for QA purposes we evaluated
the correlation between the quantitative agreement as measured by the DSC, MSD, and HD
between 1) the atlas derived CTVs and the CTVs generated using the independent machine
learning technique and 2) the atlas derived CTVs and the physician drawn CTVs. Correlation
was established using the correlation coefficient with a p-value less than 0.05 establishing
significant correlation. If correlated, the agreement of the contours generated for the
automated planning approach (the atlas derived CTVs) could be compared with the
secondary technique and this result provided to the user of the system to guide the need for
edits.
The results of this experiment can be found on Page 163.

Results
Retrospective Autocontouring Performance
Physician Review
For 115 patients with atlas derived nodal volumes, the distribution of physician ratings
of the 4 nodal volumes on the 5-point scale according to Error! Reference source not
found. can be seen in Figure 35. The average rating of the four nodal volumes was between
3.5 and 3.9, and 75% of contours [686/920 contours (4 volumes bilaterally on 115 patients)]
were rated as needing no edit for clinical use. One quarter of the nodal contours (230/920)
were rated as needing minor edit and only 0.4% (4/920) received a score of a 2 and were
indicated as needing major edit for use in treatment planning.
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Figure 35. Distribution of physician scores of the atlas based nodal volumes. A score of 4 or 5
indicates no edits are needed for use in treatment planning.

To assess inter-observer variability a subset of 10 randomly selected patients was
selected for review by five additional radiation oncologists from four outside institutions. The
radiation oncologists, per a self-reported questionnaire, had an average of 8.25 years of
experience (range, 3.0-12.5 years).
For all nodal volumes the scores assigned to the 10 patients differed significantly
(Wilcoxon signed rank test, p<0.05) between the primary physician and at least one outside
physician. However, no volume was significantly different between primary and all of the
outside physicians. The average score across the subset of 10 patients for each of the four
nodal volumes and each of the 5 physicians can be seen in Table 23. Some systematic
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differences in contour ratings are seen; for example the third outside physician rated on
average, all volumes lower than the primary physician. The fifth outside physician, however,
rated, on average, all volume as high as or higher than the primary reviewer. This supports
the known presence of inter-physician variability in contouring studies.
Of 399 total ratings by outside physicians (4 bilateral structures on 10 patients by 5
outside physicians with one structure not rated by one physician) 49% (195/399) of the ratings
matched those of the primary physician and were classified as Category I agreements.
Considering Category II agreements, the physicians assigned an additional 47% (186/399) of
the contours to same group, either as needing no or minor edit for use (47%) or as needing
major edit for use (0%). Finally, only 5% of contours received scores indicating the need for
major edits by one physician while needing no or minor edits by the other physician. In Table
24 the percentage of contours classified into each of the three agreement categories can be
found for the eight normal structures assessed.

Table 23. Average scores of the four nodal volumes by the primary and 5 outside physicians.
Three physicians rated at least half of the contours, on average, higher than the primary
physician. Two physician rated all contours, on average, worse than did the primary
physician.

Nodal Volume
Nodal Levels
Ia-V
Nodal levels
Ib-5
Nodal Levels
II-IV
Retropharyngeal
Nodes

Average Contour Rating
Outside
Outside
Outside
Physician 2 Physician 3 Physician 4

Primary
Physician

Outside
Physician 1

Outside
Physician 5

3.7

3.0

4.0

3.1

4.0

4.4

3.9

3.1

4.0

3.1

4.0

4.4

4.0

3.1

3.9

3.1

4.0

4.5

4.0

2.7

3.7

3.7

2.9

4.0
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Table 24. Inter-physician agreement in the rating of automatically contoured nodal levels.
Category I indicates the scores by the two physicians matched, Category II indicates that the
ratings did not match but the contours were rated into the same “group” (either as needing no
or minor edit, or as needing major edit)) by both physicians. Category II represents
disagreement between the two physicians. Due to rounding, not all rows sum to 100.
% of agreements in
Category
Structure

I

II

III

Retropharyngeal Nodes

39

55

6

Nodal Levels II-IV

55

41

4

Nodal Levels Ib-V

54

42

4

Nodal Levels Ia-V

47

48

4

Total

49

47

5

Quantitative Contour Performance
Compared to clinical CTVs, atlas derived CTVs had an average (± standard deviation)
DSC of 0.81±0.05. When considering only the nodal part of the CTVs (i.e. with the high dose
CTV removed) the dice similarity coefficient decreaseD to 0.63±0.10. The results of both
analyses are found in Table 25 and the distribution of value for all 79 patients are found in
Figure 36. The analysis without the high dose CTV better represents the quality of the atlas
contours in mimicking the clinical CTV contours, but the whole CTV analysis more closely
represents the true treatment scenario in the RPA whereby the final treatment volume would
include the physician drawn/edited high dose CTV. The results should be taken with some
consideration given that chosen atlas derived nodal volumes may not have accurately
reflected the attending physician’s intention when contouring the targets for each patient.
Generally, the atlas contours agree well with physician drawn contours compared to
previously published whole CTV agreement metrics (11, 19, 20).
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Table 25. Quantitative agreement between atlas derived CTVs and clinical CTVs.
Comparisons were made for both the whole CTV and the nodal CTV only, for which the high
dose CTV was removed.

Dice Similarity Coefficient
Mean ±
std

[min - max]

Hausdorff Distance (mm)
Mean ± std

[min - max]

Mean Surface Distance
(mm)
Mean ± std

[min - max]

Nodal
CTVs

0.63 ± 0.10 [ 0.34 - 0.85 ] 4.52 ± 1.56 [ 1.57 - 10.33 ] 0.55 ± 0.27 [ 0.04 - 1.53 ]

Whole
CTVs

0.81 ± 0.05 [ 0.69 - 0.91 ] 2.33 ± 0.82 [ 1.06 -

4.80 ] 0.30 ± 0.07 [ 0.14 - 0.46 ]

Figure 36. Distribution of the quantitative agreement between clinical and atlas derived CTVs.
Shown are the distributions of the Dice similarity coefficient (left) the mean surface distance
(middle) and the Hausdorff distance (right) for both the whole CTVs (in blue) and the nodal
CTVs only (red).Whole CTVs has better agreement due to the use of the original high dose
CTV from the clinical plan in the autoplan.
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Dosimetric Impact of Planning on Autocontoured Target Volumes
Coverage of the clinical CTVs and PTVs was poorer if atlas derived PTVs were used
for treatment planning (i.e. optimization and normalization) than if the clinical PTVs were used
for planning. Coverage was improved, however, if 5mm margins were used when compared
to 3mm margins for the expansion of atlas derived CTVs to PTVs. RTOG trial 1016, in which
the investigators studied the benefit of adding a chemotherapy drug cetuximab to a
radiotherapy treatment strategy for patients with oropharynx cancer, required that for the
intermediate dose target, prescribed 56Gy in the trial, volume should receive at least 45Gy
(80% of the prescribed dose) to 95% of the target volume(21). Considering this threshold of
80% of the prescribed dose to 95% volume, if 3 and 5mm margins are used 32% and 54% of
the 40 treatment plans considered here meet that constraint, respectively. The average and
standard deviation of the volume of both the clinical CTVs and clinical PTVs receiving 95%,
98% and 100% of the prescribed dose for each of the two margin values are shown in Table
26. Coverage of clinical PTVs was significantly poorer as measured using a Wilcoxon signrank test when comparing the volume receiving 95%, 98%, and 100% (p<0.001) of the
prescribed dose when 3mm margins were used as compared to 5mm margins. In Figure 37
are the average DVH curves to the high dose and intermediate dose CTVs and PTVs given
the two margins While the curves are similar for doses above 100% of the prescribed dose,
the DVH curve of the true physician drawn intermediate dose PTV has a noticeably rounder
shoulder when using either a 3 or 5 mm margin as compared to when the true structure was
used for planning.
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Table 26. Average coverage of the clinical CTVs and PTVs when atlas derived PTVS were
used for planning.
3 mm Margin

PTV

CTV

5 mm Margin

mean±std

[min-max]

mean±std

[min-max]

V95%(%)

81.1±13.4

[45.7-98.9]

86.9±11.1

[56.4-99.8]

V98%(%)

78.0±14.0

[41.7-98.1]

84.7±12.0

[52.1-99.5]

V100%(%)

74.9±14.1

[38.9-96.7]

82.3±12.5

[49.3-98.5]

V95%(%)

86.6±10.8

[58.4-99.2]

91.3±8.4

[67.1-99.8]

V98%(%)

84.1±11.8

[56.0-98.4]

89.6±9.3

[64.8-99.5]

V100%(%)

81.7±12.3

[53.7-97.1]

87.9±9.9

[63.0-99.1]
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Figure 37. Average DVH curves to clinical PTVS when using atlas derived PTVs for planning.
Atlas derived CTVs with 3 mm (green line) and 5 mm (blue line) were used for expansion to
the PTVs. Coverage of clinical PTVs is noticeably poorer when clinical PTVs are not used for
treatment planning.

Evaluation of an Independent Technique for QA of Autocontoured Target Volumes
Quality of the Second Independent Target Contouring Technique
The second independent target contouring technique performed well in the contouring
of CTVs for 79 patients, see Table 27. The contours agreed with a mean (± standard
deviation) Dice similarity coefficient of 0.80±0.07 when considering the whole target volume
and with an average of 0.66±0.11 when considering only the nodal CTV. Using a Wilcoxon
signed rank text, the atlas based technique had a significantly better DSC (p=0.02), MSD
(p<0.01), and HD (p<0.01) when considering the whole target volume.
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Table 27. Quantitative agreement of independently derived CTVs with clinical CTVs. Whole
and nodal only CTVs were compared using the Dice similarity coefficient, mean surface
distance, and Hausdorff distance.
Dice Similarity
Coefficient
Mean ±
std

[min - max]

Hausdorff Distance (mm)
Mean ± std

[min - max]

Mean Surface Distance
(mm)
Mean ± std

[min - max]

Nodal
CTVs

0.66 ± 0.11 [0.35 - 0.89 ]

3.07 ± 1.25 [ 0.75 - 6.37 ] 0.35 ± 0.16 [ 0.09 - 0.83 ]

Whole
CTVs

0.80 ± 0.07 [0.64 - 0.94 ]

2.64 ± 1.10 [ 1.01 - 6.37 ] 0.35 ± 0.11 [ 0.11 - 0.63 ]

Independent Clinical target Volumes as a QA Approach
In order for the independent target contours generated using a machine learning
technique to be useful as a QA check of the atlas based targets we first sought to establish if
the agreement between the two contours are correlated to the agreement of the atlas based
targets to the physician target. In Table 28 are the correlation coefficient and corresponding p
values for 3 quantitative metrics between the atlas based and physician targets and the atlas
based and independent targets. Significant correlation was established for all metrics
indicating that agreement between the two contouring techniques is correlated to the ultimate
agreement of the atlas based technique to the physician technique. The distribution of values
can be seen in Figure 38.

Table 28. Correlation of the agreement between the atlas derived CTVs with the clinical CTVs
and the independent CTVs. Correlation coefficients and p-values are shown for the
agreement between both the whole volume CTVs and the nodal CTV only for three
quantitative metrics. All metrics were significant, with the strongest correlation between for the
nodal CTVs using the mean surface distance.
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Correlation of Atlas and Physician and Atlas and Independent
Targets
Whole CTV
Correlation
Coefficient
p-value

Nodal CTV

Dice

HD

MSD

Dice

HD

MSD

0.44
6.0E-05

0.21
6.8E-02

0.27
1.6E-02

0.60
5.7E-09

0.78
3.1E-17

0.83
1.3E-21

The positive correlation coefficients indicate that the larger the disagreement between
the two contouring techniques the larger the disagreement between the atlas-based
technique and the physician CTVs is expected to be. This correlation was stronger for the
nodal CTVs which is expected as the subtraction of the high dose CTV removes the biased
introduced because the atlas based technique used this contour directly while the
independent technique does not. As seen in Figure 38, the identification of thresholds in the
agreement of the two contouring techniques may be selected in order to identify potential
disagreement with the physician drawn CTVs. For example, a threshold of 6 mm Hausdorff
distance between the two contouring techniques would identify all atlas based contours with a
Hausdorff distance of greater than 8mm and 82% of contours with HD greater than 6mm
compared to the physician drawn CTVs. These threshold represent this data set only and
should be further evaluated. The significant correlation supports the use of this second
independent technique for use a QA check of atlas based CTVs when , for example in Figure
39, when the atlas based CTVs do not agree well with clinical contours nor do they agree with
CTVs from the independent technique and which doesn’t agree well with the clinical CTVs
either.
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Figure 38. Distribution of the CTV quantitative agreement. Shown are the distributions of the
dice similarity coefficient (left), mean surface distance (middle) and the Hausdorff distance
(right) between the whole volume CTVs (red) and nodal CTVs (blue) between the atlas
derived CTVs with both the clinical CTVs (x-axis) and the independent technique (y-axis).
Clear trends are seen with the whole volume CTVs having better agreement.
.

Clinical CTV
Atlas Derived
Independent
Method

Figure 39. Example of disagreement between atlas derived CTVs, clinical CTVs, and CTVs
from the independent technique. This indicates that use of the independent contouring of the
CTVs may be useful as a QA tool in cases, like the one here, where all three contours
disagree
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Discussion
In this work we have investigated the use of atlas based automatically contoured
nodal levels for the definition of intermediate and low dose target volumes in the head-andneck. Upon physician review we found that the four nodal volumes considered were well
received by head-and-neck radiation oncologists with nearly half reviewed as needing no edit.
In an inter-physician analysis we found that there exists inter-physician variability in the
acceptability of these contours, though for only between 0.4% (as rated by the primary
physician) and 4% (as rated by outside physicians) would be expected to need major edits for
use in treatment planning.
Compared to clinical CTVs, we found good agreement with an average Dice value of
0.81, which is comparable to the agreement found in other studies (11, 19, 20). These results,
however, should be taken with the understanding that the physician drawn CTVs used for
comparison were copied from clinical plans directly, without consideration of the intent of the
physician when drawing the target. There are known exceptions to the general guidelines for
the treatment of elective nodal volumes in head-and-neck cancer and it is likely that for some
of the plans considered here the choice of atlas-derived nodal CTVs simply did not match with
what the physician delineated. Given this, this high DSC indicates that the atlas based
technique for the delineation of intermediate and low dose target volumes in the head-andneck performed very well.
Further, we sought to assess what impact planning on these atlas derived targets
would have on the coverage of the clinical targets. As expected, if the target of interest (in this
case, the clinical target) is not used for treatment plan optimization, then coverage suffers.
We investigated the use of both 3 and 5 mm margins for CTV to PTV expansion in order to, in
part, compensate for possible contouring errors. The CTV to PTV margin as used to
compensate for uncertainties in CTV contouring on the initial treatment scan is often not cited
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as a primary use, but, as it is to compensate for geometric uncertainties(22), if contouring
uncertainties are expected it may be wise to err on the side of safety and use a larger margin.
When a 5 mm CTV to PTV margin was used for atlas-derived intermediate dose targets,
slightly more than half of plans met the RTOG 1016 coverage constraint to the intermediate
dose physician drawn PTV.
Finally, if automatically delineated target volumes are to be used for fully automated
treatment planning, it is advisable to assess and, ideally, ensure contour quality before
presentation to the user. Towards this, we investigated the use of an independent technique
for the delineation of target volumes and the agreement between the atlas-based targets and
this secondary technique to the agreement between the atlas-based targets and the physician
targets. The two were found to be strongly correlated indicating that in a fully automated
system, both techniques could be used to delineate the CTV contours, their agreement
assessed and this result provided to the user as guidance for the need for editing. However,
as before, the motivation behind the delineation of the physician drawn targets is not known
and this may influence the results found here. There are a few clear examples of
disagreement between all three contours, which would indicate promise for the use of this
independent technique as a QA tool, however further investigation into the usefulness of this
strategy should be conducted.
There are general limitations of this analysis and potential utility of automatically
delineated targets more broadly. First, given the prominence of extensive inter-physician
variability in the delineation of target volumes it may be ambitious to expect very high
agreement between any automatic contouring technique and single physician drawn volumes,
especially, as in this case, if (1) the physician intent in target delineation is unknown or
ambiguous and (2) the atlas derived volumes originated from contours approved by a single
physician. A detailed record of physician intent in the delineation of CTVs and consensus
contours which match that intent would reveal the true ability of automated techniques for
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CTV contouring. Further, for multi-atlas autocontouring techniques, the presentation of the
atlas to multiple head-and-neck physicians or the development of a consensus atlas may
further reduce inter-physician variability in the reviews of contours propagated from such an
atlas and, ultimately, edits to such contours. Second, in the current strategy nodal levels are
limited to the four discussed here, though upon retrospective assessment approximately 10%
of patients required nodal levels not included in the currently available set of nodal volumes.
The need for additional volumes in a larger cohort of patients should be evaluated and, if
needed, the additional nodal level groups could be added to the atlas patients, but must be
accompanied by comprehensive analysis. Third, while the current autoplanning strategy is
limited to the use of three dose volumes, and the autocontouring supports this with the
intermediate dose level assigned to the ipsilateral neck and the lower dose assigned to the
contralateral neck, there exist examples where a fourth dose level may be required due to the
location of the disease, including when the disease is close to the temporal lobe or brachial
plexus. This division of the targets into multiple dose levels is likely to vary depending on
patient factors and physician experience. Therefore, a check of the target location should be
performed and the user made aware if an additional dose level is likely to be required. Fourth,
the use of the presented secondary technique, while proven to be correlated with the
agreement between the atlas-based targets and physician targets, needs adjustment in order
to be used in a fully automated system. In order to generate the contours a method to detect
the superior and inferior landmarks must be developed. Additionally, the current model was
intended and tested exclusively for patients with bilateral disease of the oropharynx by the
original authors and would require further development for use for many sub-sites in the
head-and-neck which systematically differ in the selection of nodal levels. Further, while the
correlation between atlas-physicians CTVs and atlas-secondary CTVs was established here,
the true ability of this technique to detect and warn physicians of possible inaccuracies in
atlas-based nodal level contours and or their use in CTV contours needs further development.
169 | P a g e

Finally, for use in an automated treatment planning strategy it is our recommendation
that atlas based nodal levels be generated using the presented autocontouring technique for
the initiation of CTVs but are used with physician approval and with the the allowance of
possible editing. The volumes, both prior to and after possible edits should be compared with
the secondary independent technique in order to further examine the use of this strategy for
QA purposes. Only true clinical implementation will reveal the extent to which these contours
are edited clinically and the extent to which QA is possible.

Conclusion
We have examined the use of automatically contoured nodal volumes for use as
intermediate and low-dose CTVs in the treatment of head-and-neck cancer with radiotherapy.
The contours were well received by head-and-neck radiation oncologists and agreed well with
independently drawn physician contours. An independent target contouring method proved
promising in the identification of contours requiring edits. We suggest the careful use of these
automatically derived nodal volumes as CTVs in a fully automated treatment planning system
with physician approval and editing as needed.
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Chapter 7: Discussion
The goal of this work as a whole was to investigate two initiatives which may help
alleviate the burden of radiotherapy in low resource settings. The dire need for radiation
therapy in low-resource settings, including for 135 of 139 LMICs whose population have
inadequate access to radiation therapy and for 55 countries in which no radiotherapy facilities
exist (1), demands attention. A multifaceted approach is necessary and collaboration with
professionals in these regions is central to success.

An Upright Radiotherapy Chair
The first method aimed to make more accessible the necessary high energy external
beam radiotherapy machines required for safe radiotherapy delivery. The concept involves
the use of a rotating patient treatment chair which, when paired with a fixed treatment beam
offers the same degrees of freedom as traditional treatment machines.
In the first aim, we have investigated inter- and intra- fraction setup reproducibility of
an upright radiotherapy chair with the hypothesis that an upright radiotherapy chair has
clinically acceptable inter- and intra- fraction reproducibility.
The use of such a chair, combined with a fixed treatment beam could greatly reduce
the upfront and ongoing cost of teletherapy machines and may be of interest in low-resource
settings or LMICs. While treatments in this seated position are not new to the field, the use of
treatment chairs has declined and are currently very rare due to the routine acquisition of
treatment planning images from CT scanners which, except for in a few rare exceptions, only
allow for horizontal or nearly horizontal acquisition. As technology improves and other
methods for the acquisition of planning images emerge (2, 3) the possibility of other
treatment positions is becoming a reality. If treatment chairs are to be reconsidered their
acceptability in the context of current treatment delivery must be re-examined. Accurate setup
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reproducibility is an important part of a robust treatment position. We found that the inter- and
intra-fraction reproducibility in the treatment chair was, on average, less than 3mm and this is
comparable to that in the traditional supine position. Given patient feedback, we
manufactured a second treatment chair which incorporates additional patient indexing
measures, increases the depth of the seat, and is built to limit the potential dosimetric impact
of inter and intra- fraction motion.
Limitations of this study include the use of a small patient set, all of whom were
relatively healthy and tolerated both the seated and supine positions well. Further, the
assessment of set-up reproducibility under conditions of image guidance were simulated
using pre-alignment of the images using select anatomy rather than true adjustment based on
pre-treatment images as is clinical practice. The treatment chair was only evaluated for headand-neck patients, due primarily to the tight geometry of the set-up using a traditional linear
accelerator.
The ultimate goal of this work is to support the development of a fixed beam system,
which would eliminate some of these challenges. Treatment of other sites in the seated
position, for example the cervix or prostate, may bring other challenges due to a difference in
patient anatomy in this seated positon. The current study, as it was limited to the head and
neck, would be expected to have little impact of internal anatomy between the supine and
upright positons. If a fixed beam-rotating patient system is to be developed, the impact of
other aspects of the radiotherapy process must be evaluated, including treatment delivery,
machine shielding, and patient throughput. Additionally, the compatibility of this treatment
positon including the import of planning images acquired in this position with treatment
planning systems and in concordance with DICOM standards must be evaluated. Finally, endto end testing of the entire treatment process must be completed both at the start and at
reoccurring intervals. Clinical implementation should be accompanied by appropriate clinical
protocols, FMEA and root cause analysis studies.
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Towards the development of a fixed-beam and rotating seated patient treatment
paradigm which could greatly reduce the cost of the teletherapy machinery necessary for the
delivery of both life-saving curative and symptom alleviating palliative radiotherapy in lowresource settings, we have shown herein that the set-up reproducibility of the treatment chair
is comparable to that in the supine position. Members of our group have previously showed
the capability of the onboard KV imagers to capture and reconstruct CBCT images (4), which
as reported by other investigators, can be used for treatment planning. This technology,
however, is not released for clinical use and represents the next step in the efforts to realize
this treatment paradigm. Other investigators are moving forward with this type of treatment
working towards commercialization of a fixed-beam upright system (LEO Cancer Care,
http://leocancercare.com).

Automated Treatment Planning
Our second proposal for the improvement of radiotherapy in low-resource settings was
that of a fully automated treatment planning process for head-and-neck cancers. Given the
extreme shortage of and growing need for trained radiotherapy personnel including medical
physicists in LMICs, methods and tools to reduce this burden are desperately needed.
Technological improvements have the ability to both improve the quality of care while
simultaneously reducing the required human involvement. However, the introduction of these
advanced technologies has the risk of further dividing those who have the resources and
infrastructure to encourage advancement and those who do not and therefore risk falling
further behind. In the case of advanced treatment planning techniques, the introduction of
IMRT and VMAT greatly improved outcomes for head-and-neck cancer patients, however the
introduction of these advanced treatment techniques requires improved equipment (MLCs,
availability of service personnel for complicated machinery, adequate dose rate to
compensate for beam modulation, etc.) and staff capable of implementing the techniques
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which include advanced treatment planning. Without the required infrastructure the gap in
treatment techniques only increases.
The aim of the second aspect of this work was to partially reduce the burden on staff
by automating the treatment planning process. Automated methods are proving beneficial in
many areas of radiation therapy and the automation of the treatment planning process would
be applicable in all clinics but may be especially useful in low-resource settings.
In Specific Aim 2, Chapter 4, we sought to develop and validate a treatment planning
strategy for the head-and-neck with the hypothesis that single optimization head and neck
treatment plans perform with equal quality to clinically acceptable plans and 90% are
accepted by radiation oncologists for use without edit. We found that a fully automated
approach can produce plans that perform as well as, and in some cases better than, those
plans as treated on a clinical trial with XX% rated as acceptable without edit by a dedicated
head-and-neck radiation oncologist. The automated approach utilizes the RapidPlan® tools
available in the Eclipse Treatment Planning System (Varian Medical Systems, Palo Alto, CA)
in conjunction with in-house algorithms and requires no user input outside of the patient CT
and treatment details including prescription and fractionation. The results were based on 54
patients treated for cancers of various head-and-neck subsites at The University of Texas MD
Anderson Cancer Center and 30 patients treated on a clinical trial.
In Specific Aim 3, Chapter 5, we sought to assess the feasibility of the use of
automatically contoured normal structures in the head-and-neck in a fully automated
treatment planning strategy with the hypothesis that automatically contoured normal
structures can safely be used for treatment planning purposes without significant impact on
plan quality. In an investigation of the use of four autocontouring algorithms we found that inhouse multi-atlas contouring approach performed well and upon its clinical implementation
half of contours were not edited for treatment planning. Further, we found that unedited

174 | P a g e

autocontours can be used without edit for treatment planning with very limited impact on the
treatment plan. While our hypothesis was confirmed, the use of contours without oversight is
far reaching and represents a significant change in practice and should be of further
investigation. Therefore, we conclude that automatically contoured normal tissues should be
reviewed by the radiation oncologist and approved for use in treatment planning though the
initialization of such structures will greatly reduce the manual input required and increase the
time savings offered of an automatic system.
Finally, in Specific Aim 4, Chapter 6, we sought to assess the feasibility of the use of
automatically countered intermediate and low dose target volumes in the head and neck with
the hypothesis that automatically contoured clinical target volumes can be safely used for
treatment planning purposes. We investigated the use of automatic contours for the
delineation of nodal levels which were then used as intermediate and low-risk clinical target
volumes. We found that, generally, the automatically contoured nodal volumes, generated
using the same in-house algorithm as the normal tissue autocontours, were well received by
radiation oncologists from five institutions. Quantitatively, intermediate and low-dose CTVs
agreed well with physician drawn targets. If automatic targets are used for treatment planning
than the coverage of physician targets is reduced, the results however suffer from a
fundamental difference in the intent of target delineation, for which the physician intent was
unknown, and thus the analysis of these results is limited. Finally, we found significant
correlation in the agreement between the atlas-based target contours with an independent
machine learning contouring technique and the physician contours suggesting that this
independent method may be a useful QA tool to aide users of the automated system in the
review of automatically contoured targets. We feel that the use of fully automatically
contoured intermediate and low-dose CTVs is not yet suitable for safe use and should be of
further investigation. We concluded that CTVs generated from the multi-atlas based
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automatically contoured nodal volumes can be used in treatment planning but should be
accompanied by physician editing and approval as deemed necessary.
Together, through these three aims we sought to investigate the extent to which the
development of head-and-neck treatment plans can be automated. We found, similar to other
investigators, that knowledge based planning approaches can be utilized successfully for
automatic treatment planning. Our group took automation further through the identification of
algorithms for the determination of treatment isocenter, collimator angles, and jaw settings
and through the use of the Varian API, the combination of all steps from the import of patient
DICOM files through to dose calculation without human intervention. We further automated
the process by automatically contouring normal tissues and anatomically based intermediate
and low dose clinical target volumes in the head-and-neck. We have showed that through
automation we can reduce the time needed for treatment planning to 40 minutes, most of
which time does not require supervision. The automation of normal structures represents an
important step in the treatment planning process and the algorithm described herein was
successful in the contouring structures which can be used without edit for treatment planning.
It is unlikely that clinicians are currently amenable to the use of unedited autocontours but it
has been shown that the review and editing of autocontours represents a significant time
savings. Together, the strategy is ready for limited clinical use and should be done so under
close supervision and with extensive data collection as to its impact on clinical workflow and
patient treatments.
The success of this work should be considered in the context of its limitations. First,
we found that the planning approach outperformed clinical plans for a cohort of patient treated
on a clinical trial, but, in general, did not perform as well as plans optimized by highly trained
dosimetrists at our institution or for plans of all head-and-neck subsites. The availability of
highly trained staff is limited to select clinics, however, and as the approach outperformed
plans treated on a clinical trial, we believe the quality of plans is sufficient for patient
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treatment. Improvement upon the clinical knowledge base used for treatment plan generation
including the optimization of the templated constraints could improve resultant plan quality
and should be of routine consideration. The development of multiple knowledge bases, for
multiple treatment subsites, may be considered and plans for which the strategy did not
outperform clinical plans may provide useful for the development of such a knowledge base.
Second, considering the automatic delineation of normal tissues, while a strategy was
presented which allowed for use of unedited contours in treatment planning it is not standard
practice to use unapproved contours for treatment planning and the consideration of such use
should be carefully considered, both in the context of the treatment of the individual patient
and if questions are to be asked of the dataset in which the patient may be included. As big
data and deep learning find use in radiation oncology it is essential that the data from which
these approaches are built can be traced back to thoughtful implementation. As an example,
unapproved contours should be tagged or named to indicate their use to future researchers.
We found many examples of contour and naming mismatches which, while likely irrelevant in
the individual patient treatment plan had an effect on the work herein.
Finally, the use of automatically contoured targets represents the aspect of this work
most in need of further investigation. There exist enormous variability in not only the
contouring of targets among physician but also in the choice of target anatomy when given
patient disease characteristics. These challenges will be underlined in a system for which a
simplified approach is desired. It is likely that additional nodal level groupings may be
required, the atlases may need further development for patients with gross disease, and/or for
patients from other demographics. The use of a second contouring technique as a check of
the atlas based contours represents a novel contribution but requires further investigations,
specifically the extension of the secondary technique for additional head-and-neck subsites
and stages.
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As a system, we envision the use of the automated treatment planning strategy as
follows; a user is required to submit an approved patient CT and patient plan order which
includes information about the patient’s acceptability for treatment (pregnancy status, prior
radiation, implants, etc) and treatment goals (prescribed dose and fractionation). This
information is then used to generate automatic normal tissues and nodal level groupings. The
process is then suspended for the manual delineation of primary disease. Then on a single
button click clinical and planning target volumes are generated using rules and the atlas
generated nodal volumes; the targets are then reviewed by the attending physician. At this
time the physician will also be presented with the results of the results of the random forest
models for the detection of normal tissue contour errors and should use this to aide in the
approval and editing of these structures as deemed appropriate. The automatic process then
resumes with the automatic identification of the marked and treatment isocenter, the selection
of beam parameters, plan optimization, dose calculation and production of accompanying
plan documentation. The whole process is estimated to take less than an hour, much of which
time is unsupervised.
Data concerning the editing of normal structures, targets, the results of the error
prediction models, the timing of each step, the acceptability of the final plan, and others
should be collected for all patients. This will allow in depth retrospect analysis of the
performance of the automated planning technique and improvement of the system.
We believe this system has the ability to greatly reduce the human effort needed for
one of the most technical and tedious aspects of radiation oncology. Automation of this
process, however, should be considered for use in low-resource settings in the context of
radiation therapy as a whole. Notably, while advanced techniques have been shown to
outperform older, simpler techniques for the treatment of head-and-neck cancer there exist
downstream effects due to this transition. Quality assurance process including that of
individual treatment plans as well as of the machines and even of the treatment planning
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process itself must reflect the transition to these advanced techniques. Further, the tasks
completed by an automated approach must be able to be accomplished by, ideally, a number
of trained staff; in the case of head-and-neck treatment this requires knowledge not only of
plan optimization but also of the contouring of normal tissues and targets. In circumstances
where the autoplanner may not be appropriate for patient treatment plan development, when
the system is not functional due to planned or unplanned circumstances, and for routine
quality assurance checks it is essential that treatment planning skills not be lost, or never
developed, in centers where autoplanning is used.

Conclusions
The work presented here represent efforts towards two solutions to reduce the great
and growing disparity of radiation therapy around the world. In LMICs, where 84% of the
world’s population lives and two thirds of the cancer population lives, there are only 30% of
the worlds radiation facilities; 11 countries of more than a million people have not a single
teletherapy unit. Improving access to radiation therapy is not a simple process, it requires
innovation approaches, collaborative efforts, and consistent reassessment of the needs and
status in the areas of interest. The approaches presented here represents efforts both to
reduce the upfront and ongoing cost of radiotherapy machines through the introduction of a
fixed-beam rotating patient paradigm and the automation of one of the most time-intensive
and technologically complex aspects of advanced radiotherapy – treatment planning. We
believe these efforts could benefit clinics in low-resource areas and partly address the
growing need for radiotherapy around the world.
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Appendix
Appendix A – Specific Aim 1
The following questionnaire was administered to patients after their participation in the interand intra- fraction setup study in the treatment chair. Participants were also encouraged to
give verbal feedback.
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This questionnaire evaluates your degree of comfort when in a treatment position.
The first 15 questions refer to treatments in a seated position

1. Getting on the chair was: Easy  Difficult (0-5)

2. When initially positioned on the chair, I felt: Relaxed  Tense (0-5)

DURING THE SIMULATED TREATMENT (ON THE CHAIR)…

3. …I felt like I needed to move. Not at all  Constantly (0-5)

4. …I felt: Restless  Calm (0-5)

5. …My body felt tense. Strongly DisagreeStrongly Agree (0-5)

6. …My breathing felt fluid and easy. Strongly Disagree Strongly Agree (0-5)

7. …My neck was: Not at allPerfectly Comfortable (0-5)

8. …My arms were: Not at allPerfectly Comfortable (0-5)

9. …My back was: Not at allPerfectly Comfortable (0-5)
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10. …My legs were: Not at allPerfectly Comfortable (0-5)

11. …Overall my body was: Not at allPerfectly Comfortable (0-5)

12. …I could have fallen asleep. Strongly DisagreeStrongly Agree (0-5)

13. …I had discomfort due to the chair I was positioned on. Strongly Disagree
Strongly Agree (0-5)

OVERALL (ON THE CHAIR)…

14. I felt stable and supported on the chair. Strongly Disagree Strongly Agree (05)

15. I felt absolutely safe on the chair. Strongly Disagree Strongly Agree (0-5)

The next 15 questions are about you regular actual treatments (lying down)

16. Getting on the patient couch was: Easy  Difficult (0-5)

17. When initially positioned on the couch, I felt: Relaxed  Tense (0-5)
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DURING TREATMENT (LYING DOWN, ON THE COUCH)…

18. …I felt like I needed to move. Not at all  Constantly (0-5)

19. …I felt: Restless  Calm (0-5)

20. …My body felt tense. Strongly DisagreeStrongly Agree (0-5)

21. …My breathing felt fluid and easy. Strongly Disagree Strongly Agree (0-5)

22. …My neck was: Not at allPerfectly Comfortable (0-5)

23. …My arms were: Not at allPerfectly Comfortable (0-5)

24. …My back was: Not at allPerfectly Comfortable (0-5)

25. …My legs were: Not at allPerfectly Comfortable (0-5)

26. …Overall my body was: Not at allPerfectly Comfortable (0-5)
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27. …I could have fallen asleep. Strongly DisagreeStrongly Agree (0-5)

28. …I had discomfort due to the chair I was positioned on. Strongly Disagree
Strongly Agree (0-5)

OVERALL (LYING DOWN, ON THE COUCH)…

29. I felt stable and supported on the couch. Strongly Disagree Strongly Agree
(0-5)

30. I felt absolutely safe on the couch. Strongly Disagree Strongly Agree (0-5)

FINAL: COMPARISON OF SEATED AND LYING DOWN POSITIONS

31. I prefer sitting up to lying down for treatment: strongly agreestrongly disagree
(0-5)

Please note any comments or feedback below.
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
_________________________________________________________________________
Thank you for completing this survey; we appreciate your feedback.
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Appendix B – Specific Aim 2
The contouring of small structures is often more difficult, as indicated by lower Dice
similarity coefficients and larger mean surface and Hausdorff distances, compared to larger
structures. Cochlea, the smallest structures implemented into the clinic had the largest
disagreement with the clinically edited structures and it was therefore decided that an
“uncertainty margin” of 5mm, similar to a PRV, would be added to the autocontoured cochlea
for treatment planning; In Table 14, we showed that a margin of 5mm would be sufficient to
cover 100% of the edited cochlea for more than 95% of the population.
Other smalls structures required for treatment planning but not implemented clinically
include the optic chiasm, optic nerves, and lens. The accurate contouring of these structures
is of particular importance with the tumor is close to the optic structures and because they are
serial structures (chiasm and nerves) or have particularly low clinical dose constraints (lens,
Dmax<7Gy). As data of the clinical edit to these autocontours was not available, we examined
the agreement between autocontoured structures using the MACS algorithm and
independently drawn physician contours for 37 patients. Occasionally, the MACS algorithm
would result in an empty structure due to insufficient overlap of individual contours from the
12 atlas patients, in this case automatic optimization could not continue and in the context of
the automated planning approach manual delineation of these structures would be required.
To compensate, for this we investigated the possibility of using structures which have been
expanded on the atlas patients in order to increase their volume and increase the likelihood of
overlapping anatomy as input into the staple algorithm. In Table 29 are the average volume,
Dice Similarity Coefficient, true positive fraction and false positive fraction as well as the
percentage of structure with true positive fraction of 100% and greater than 95% given preMACS expansion of 0-2mm in 1mm increments and with post macs (PRV-style) expansions
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of 1 to 5mm in 1mm increments. It was decided that structures with 1mm pre-MACs expansion would be used with 5mm post MACS
expansions for treatment planning.
Details of the final autoplanning strategy can be found in Table 30
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Table 29. Agreement of autocontoured optical structures with pre- and post- contouring expansions.
Volume (cc)
Pre-MACS
Post-MACS
Expansion (mm)
Expansion (mm)
Physician Drawn
0
0
0
1
0
2
0
3
0
4
0
5
1
0
1
1
1
2
1
3
1
4
1
5
2
0
2
1
2
2
2
3
2
4
2
5

Optic
Chiasm
1.25
0.70
1.12
2.41
3.12
5.25
6.56
1.26
1.83
3.62
4.50
7.26
8.86
2.99
4.06
6.58
7.93
11.63
13.84

Lens
0.37
0.12
0.27
0.66
0.98
1.81
2.48
0.34
0.62
1.26
1.74
2.97
3.87
1.08
1.70
2.81
3.65
5.57
6.96

Optic
Nerves
1.16
0.50
0.91
2.27
2.98
5.29
6.62
1.10
1.72
3.94
4.92
8.29
10.11
3.63
5.04
8.72
10.38
15.44
18.28

True Positive Fraction
Optic
Optic
Lens
Chiasm
Nerves
0.27
0.39
0.58
0.66
0.82
0.87
0.45
0.56
0.72
0.77
0.90
0.93
0.66
0.75
0.82
0.85
0.95
0.96

0.27
0.47
0.75
0.83
0.95
0.96
0.56
0.69
0.85
0.87
0.95
0.95
0.85
0.90
0.93
0.93
0.99
0.99

0.37
0.52
0.81
0.85
0.90
0.91
0.59
0.69
0.93
0.95
0.98
0.98
0.92
0.95
0.99
0.99
1.00
1.00

False Positive Fraction
Optic
Optic
Lens
Chiasm
Nerves
0.52
0.57
0.70
0.73
0.80
0.83
0.56
0.61
0.75
0.78
0.84
0.86
0.72
0.77
0.84
0.86
0.89
0.91

0.24
0.39
0.57
0.68
0.80
0.85
0.44
0.61
0.75
0.81
0.88
0.91
0.70
0.80
0.87
0.90
0.93
0.95

0.17
0.34
0.58
0.67
0.80
0.84
0.38
0.54
0.73
0.78
0.86
0.89
0.71
0.78
0.87
0.89
0.93
0.94
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Table 29. Continued from previous page.
Dice
Pre-MACS
Expansion
(mm)
0
0
0
0
0
0

Post-MACS
Expansion
(mm)
0
1
2
3
4
5

1
1
1
1
1
1
2
2
2
2
2
2

% with TPF > 100%

% with TPF >=95%

Optic
Chiasm

Lens

Optic
Nerves

Optic
Chiasm

Lens

Optic
Nerves

Optic
Chiasm

Lens

Optic
Nerves

0.34
0.39
0.39
0.37
0.32
0.28

0.38
0.49
0.51
0.44
0.32
0.25

0.50
0.57
0.54
0.47
0.32
0.27

0.00
0.00
0.00
0.00
11.11
14.81

0.00
0.00
18.42
34.21
69.44
86.11

0.00
0.00
0.00
0.00
13.89
22.22

0.00
0.00
0.00
3.45
22.22
33.33

0.00
2.63
28.95
52.63
83.33
88.89

0.00
0.00
13.89
25.00
44.44
50.00

0
1
2
3
4
5

0.43
0.44
0.36
0.33
0.27
0.23

0.53
0.48
0.37
0.30
0.21
0.17

0.59
0.54
0.42
0.36
0.24
0.20

0.00
0.00
0.00
6.90
18.52
29.63

2.56
20.51
53.85
69.23
83.78
86.49

0.00
0.00
11.11
30.56
50.00
72.22

0.00
0.00
6.90
20.69
51.85
66.67

5.13
23.08
64.10
76.92
86.49
89.19

0.00
2.78
58.33
66.67
86.11
86.11

0
1
2
3
4
5

0.38
0.35
0.26
0.23
0.19
0.16

0.43
0.32
0.22
0.17
0.13
0.10

0.44
0.35
0.23
0.20
0.14
0.12

0.00
3.45
13.79
17.24
29.63
48.15

35.90
58.97
76.92
84.62
97.30
97.30

11.11
38.89
61.11
86.11
97.22
100.00

3.45
13.79
27.59
51.72
66.67
77.78

53.85
79.49
84.62
89.74
97.30
97.30

52.78
66.67
97.22
97.22
100.00
100.00
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Table 30. Planning constraints of automated planning strategy. The origin of the contours in the RPA, in the evaluation of the planning
strategy and the constraints (if used for optimization) are listed. *Optic chiasm, nerves and lens are expanded by 1mm on the atlas
patients prior to MACS contouring. *
XXXXcGy indicates that the prescribed dose of the corresponding structure is embedded in the structure name and varies between
patients.

Structure

Structure Name

Origin (Prospective
RPA Use)

Origin

Primary and
Nodal GTV

GTVp, GTVn

Physician Drawn

Physician Drawn

High Dose CTV

zCTV1_XXXXcGy

Intermediate
Dose CTV

zCTV2_XXXXcGy

Low Dose CTV

zCTV3_XXXXcGy

High Dose PTV

zPTV1_XXXXcGy

Intermediate
Dose PTV

zPTV2_XXXXcGy

Low Dose PTV

zPTV3_XXXXcGy

Physician Drawn or
Edited and Approved
GTVp+1cm and
GTVn+0.5cm
Physician Drawn or
Edited and Approved
atlas derived nodes
Physician Drawn or
Edited and Approved
atlas derived nodes
High Dose CTV +
0.5cm, within 3mm
Contracted BodyAuto
Intermediate Dose
CTV + 0.5cm, within
3mm Contracted
BodyAuto
Low Dose CTV +
0.5cm, within 3mm
Contracted BodyAuto

Type

Volume

Dose

Priority

Physician Drawn

Physician Drawn

Physician Drawn

Physician Drawn

Physician Drawn

Physician Drawn
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High Dose
Planning PTV
High Dose PTV
Ring
5mm Ring 1 mm
from PTV1
PTV1 Minimum
Dose
assessment
structure

zpPTV1_XXXXcGy

zrPTV1_XXXXcGy
zWallPTV1_05

High Dose PTV
PTV1 - PTV1
contracted 5mm
PTV1+6mm PTV1+1mm

z8bodyPTV1

PTV1 within body
contracted 8mm

Intermediate
Dose Planning
PTV

zpPTV2_XXXXcGy

Intermediate Dose
PTV pulled 5mm
from pPTV1

Low Dose
Planning PTV

zpPTV3_XXXXcGy

Low Dose PTV
pulled 5mm from
pPTV1 and pPTV2

Body

BodyAuto

Automatically
Contoured

Normal Tissue
Avoidance

zNT_avoid

BodyAuto outside all
PTVs on slices within
1cm of PTV1

Non Target
Tissue

zNonPTVs

Brain

Brain

Brainstem

BrainStem

BodyAuto outside all
PTVs
Automatically
Contoured
Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)

Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

Upper
Upper
Lower
Lower

0
20
100
96

108%
103%
96%

400
400
400
400

Upper

0

103%

300

Upper

0

100%

120

Upper
Upper
Lower
Lower
Upper
Upper
Lower
Lower

0
0
100
97
0
0
100
97

108%+1Gy
103%+1Gy
97%+1.5Gy
100%+1.5Gy
108%+1Gy
103%+1Gy
97%+1.5Gy
100%+1.5Gy

190
190
190
250
190
190
190
250

Upper

0

106

900

Upper
Upper
Upper

0
10
20

45
35
30

70
70
70

Upper
Line
Upper
Upper

0

45

130
75
200
35

Model
0
1

45
Model
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Line
Brainstem 7mm
PRV
Brainstem 5mm
PRV

zBrainStem_07

BrainStem + 7mm

zBrainStem_05

BrainStem + 5mm

Left Cochlea

Cochlea_L

Right Cochlea

Cochlea_R

Expanded Left
Cochlea
Expanded Right
Cochlea

Automatically
Contoured
Automatically
Contoured

Model

75

Upper

0

50

300

Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

zCochlea_L_05

Cochlea_L + 5mm

Upper

0

45

75

zCochlea_R_05

Cochlea_R + 5mm

Upper

0

45

75

Esophagus

Esophagus

Automatically
Contoured

Esophagus
Avoidance
Structure

zEsophagus_avoid

Esophagus + 5mm
outside of all PTVs

Left Eye

Eye_L

Right Eye

Eye_R

Larynx

Larynx

Larynx
Avoidance

zLarynx_avoid

Left Lens*

Lens_L_A1

Right Lens*

Lens_R_A1

Right Lens
Avoidance
Left Lens
Avoidance

Automatically
Contoured
Automatically
Contoured
Automatically
Contoured
Larynx + 5mm
outside all PTVs
Automatically
Contoured
Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)
Line
Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

Model

75

Upper

0

40

130

Upper

0

40

130

Line

Model

70

Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

zLens_L_A1B2

Lens_R + 5mm

Upper

0

45

130

zLens_R_A1B2

Lens_R + 5mm

Upper

0

5

130
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Lung Avoidance

Lungs_Avoid

Mandible

Mandible

Left Optic
Nerve*
Right Optic
Nerve*
Optic Chiasm*
Right Optical
Nerve
Avoidance
Left Optical
Nerve
Avoidance
Chiasm
Avoidance
Oral Cavity
Oral Cavity
Avoidance
Left Parotid
Gland
Right Parotid
Gland
Left Parotid
Gland Planning
structure
Right Parotid
Gland Planning
Structure
Posterior Neck

OpticNrv_L_A1
OpticNrv_R_A1
Chiasm_A1

Automatically
Contoured
Automatically
Contoured
Automatically
Contoured
Automatically
Contoured
Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

Upper
Lines

2

105%
Model

150
75

zOpticNrv_R_A1B2

OpticNrv_R + 2mm

Upper

0

45

130

zOpticNrv_L_A1B2

OpticNrv_L + 2mm

Upper

0

45

130

zChiasm_A1B2

Chiasm + 2mm

Upper

0

45

130

Line

Model

100

OralCavity
zOralCavity_plan
Parotid_L
Parotid_R

Automatically
Contoured
OralCavity outside all
PTVs
Automatically
Contoured
Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)
Clinical Plan
(if DNE, autocontoured)

zParotid_L_sub

Parotid_L outside of
all PTVs

Line

Model

120

zParotid_R_sub

Parotid_R outside of
all PTVs

Line

Model

120

fsPostAvoid

Automatically
Contoured
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Posterior Neck
Avoidance

zPostNeck_avoid

Shoulders

Shoulders

fsPostAvoid outside
of all PTVs
Automatically
Contoured

SpinalCord

Automatically
Contoured

zSpinalCord_05

SpinalCord + 5mm

zSpinalCord_07

SpinalCord + 7mm

Spinal Canal

Spinal Canal

Automatically
Contoured

Left
Submandibular
Gland

Glnd_Submand_L

Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)

Right
Submandibular
Gland

Glnd_Submand_R

Automatically
Contoured

Clinical Plan
(if DNE, autocontoured)

Vertebral
Column

VeterbalColumn

Automatically
Contoured

Spinal Cord
Spinal Cord
5mm PRV
Spinal Cord
7mm PRV

Clinical Plan
(if DNE, autocontoured)

Upper

0

35

120

Upper

0

25

40

Upper
Upper
Line

0
1

Upper

0

50

300

Upper
Upper

10
20

35
30

70
70

Upper
Upper

10
20

35
30

70
70

40
Model
Model

300
35
75
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Appendix C – Specific Aim 3
Additional analysis of autocontour algorithm performance was performed and is
presented here. The deformable image registration known as “Deeds” was presented in 2013
and is currently licensed by Varian Medical Systems. This algorithm is used as the
independent method for normal tissue contouring used in the machine learning models for the
detection of autocontouring errors as presented in Chapter 5. In one version of the algorithm
active shape models have been implemented for improved contouring(1). A physician review
of the this algorithm, which includes the shape model and uses a Varian provided atlas, for
ten patients was conducted and the results can be seen in Figure 40. The algorithm was also
investigated for use with the same atlas as used in the MACS algorithm and with a second
atlas generated from 11 patients treated at MD Anderson Cancer Center, this independent
atlas was used for contour propagation for the machine learning models. The agreement to
independently drawn physician contours of these three algorithms based on the Deeds DIR
as well as for MACS can be seen in Table 31.
In the smart segmentation software, as described, there are vendor provided ratings of
the expected agreement between the test patient in question and each of the available atlas
patients. We sought to investigate if there existed trends in these ratings relative to physician
ratings or quantitative agreement with physician contours – no apparent trends were
observed, the results can be seen in Table 32. We also sought to investigate if the physician
ratings produced noticeable trends compared to both the average star rating and quantitative
agreement with physician drawn structures – no apparent trend was observed, the results can
be seen in Table 33.
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0

N
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6

1

0

1

2

0
3

4

5

6
1
1

0
2

9
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2

3
Optic Chiasm

3

19

20

4
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1
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4

5
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40
30
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10
0

3
1

1
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3

2

3

4

5

Parotid Glands

0
2

0

0

5

39

9

8

4

Mandible

22

2

8

0

5

34

30

Brainstem
25
20
15
10
5
0

40

15

20
10

19

20

4

50
40
30
20
10
0

5

Optic Nerves

41

12

6

3
1

2

3

0

4

5

Submandibular Gland

Physician Rating
Figure 40. Distribution of physician scores of Deeds based multi-atlas algorithm with shape models.
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Table 31. Quantitative analysis of additional normal structure autocontouring algorithms.

Contouring
Method

Structure

Deeds MDA
Independent
Atlas vs Phys

Brainstem
Mandible
Parotid Glands
Brain
Cochlea
Esophagus
Eye
Lungs
Spinal Cord
Brainstem
Mandible
Parotid Glands
Brain
Cochlea
Esophagus
Eye
Lungs
Spinal Cord
Brainstem
Mandible
Parotid Glands
Brain
Cochlea
Esophagus
Eye
Lungs
Spinal Cord

Deeds MDA
Original Atlas vs
Phys

MACS vs Phys

N

Dice Similarity
Coefficient

Hausdorff Distance (cm)

Std

Min

Max

75
39
140
26
94
29
58
12
70

Mea
n
0.81
0.80
0.72
0.97
0.59
0.51
0.79
0.88
0.71

Std

Min

0.90
0.92
0.90
0.98
0.85
0.80
0.93
0.97
0.88

Mea
n
0.92
1.89
1.74
1.53
0.45
3.59
0.46
3.75
5.37

0.12
0.13
0.10
0.04
0.17
0.16
0.08
0.09
0.12

0.24
0.29
0.33
0.76
0.11
0.10
0.63
0.74
0.24

0.62
1.36
0.55
1.21
0.22
1.74
0.11
2.42
3.92

75
39
140
26
94
29
58
12
70
75
39
140
26
94
29
58
12
70

0.79
0.81
0.74
0.98
0.57
0.51
0.79
0.84
0.74
0.80
0.85
0.79
0.98
0.50
0.64
0.84
0.76
0.73

0.13
0.13
0.09
0.01
0.16
0.14
0.07
0.14
0.11
0.12
0.06
0.07
0.00
0.17
0.12
0.07
0.21
0.09

0.24
0.27
0.34
0.96
0.13
0.12
0.65
0.51
0.28
0.25
0.64
0.44
0.97
0.06
0.37
0.56
0.39
0.30

0.90
0.91
0.88
0.98
0.83
0.76
0.93
0.97
0.87
0.91
0.93
0.89
0.99
0.88
0.83
0.93
0.94
0.86

0.97
1.92
1.65
1.37
0.47
3.54
0.49
3.80
3.90
0.98
1.83
1.47
1.33
0.48
2.32
0.47
4.56
3.75

0.69
1.29
0.47
0.94
0.22
1.46
0.11
3.47
3.23
0.62
1.12
0.64
0.86
0.19
1.21
0.15
4.23
2.91

Max

Mean Surface Distance
(cm)
Mean

Std

Min

Max

0.35 4.06
0.47 5.71
0.70 3.68
0.49 4.54
0.16 1.27
0.76 7.20
0.22 0.72
1.39 7.94
0.25 17.33

2.24
2.36
3.03
1.36
1.46
5.90
1.75
4.33
5.83

1.53
2.21
0.97
1.49
0.63
4.40
0.57
4.15
6.01

1.16
0.89
1.46
0.77
0.66
1.33
0.83
1.01
0.82

10.70
12.23
6.74
8.19
3.95
25.68
3.03
13.04
33.05

0.43
0.59
0.80
0.50
0.17
0.94
0.25
0.97
0.37
0.41
0.41
0.59
0.48
0.14
0.65
0.25
1.24
0.35

2.47
2.28
2.86
1.01
1.49
5.45
1.70
6.34
4.29
2.37
1.66
2.37
1.06
1.61
3.16
1.42
9.09
3.78

1.65
2.11
0.84
0.17
0.58
3.50
0.45
7.05
5.32
1.55
0.89
0.76
0.17
0.68
1.57
0.39
9.47
3.90

1.19
1.00
1.61
0.80
0.72
1.98
0.76
0.85
0.90
1.10
0.76
1.30
0.80
0.42
1.15
0.72
1.49
0.94

10.46
12.76
6.71
1.51
3.85
20.07
2.66
24.20
28.89
9.73
4.62
6.16
1.43
4.27
8.02
2.36
29.89
22.39

4.06
5.62
2.94
3.81
1.27
5.96
0.73
11.50
13.47
3.70
5.56
3.60
3.75
1.41
5.42
1.06
14.08
16.31
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Deeds Varian
Shape vs Phys

Brainstem
Mandible
Optic Chiasm
Optic Nerve
Submandibular
Glands
Parotid Glands

75
39
21
48

0.78
0.80
0.47
0.63

0.13
0.14
0.13
0.10

0.23
0.27
0.13
0.38

0.90
0.92
0.62
0.86

1.09
2.16
0.88
0.81

0.71
1.31
0.34
0.45

0.49
0.52
0.47
0.17

4.26
5.63
2.00
1.87

2.59
2.51
2.16
1.48

1.73
2.40
0.73
0.57

1.26
0.87
1.27
0.72

10.54
12.30
3.74
3.11

53

0.72

0.13

0.27 0.88

0.97

0.52

0.42

3.18

2.33

1.62

1.16

9.83

140

0.74

0.08

0.38 0.87

1.94

0.60

0.68

3.62

2.95

0.85

1.52

6.73

Table 32. Autocontour performance and Eclipse Star Rating. Mean and standard deviation of physician scores and agreement with
physician contours divided by Eclipse Smart Segmentation star rating.
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Structure
Brainstem

Cochlea

Eye

Lung

Mandible

Parotid

Spinal Cord

Star
3
4
5
3
4
5
3
4
5
3
4
5
3
4
5
3
4
5
3
4
5

Physician Rating
Dice
Hausdorff Distance (cm) Mean Surface Distance (cm)
Mean
Std
Mean Std
Mean
Std
Mean
Std
6
2.83
0.41
0.73 0.05
0.89
0.11
0.28
0.04
77
3.17
0.59
0.74 0.05
0.96
0.25
0.29
0.05
8
3.13
0.35
0.76 0.03
1.20
0.47
0.27
0.05
7
2.71
0.49
0.26 0.06
0.96
0.13
0.30
0.03
80
3.04
0.37
0.40 0.08
0.81
0.20
0.23
0.04
8
2.88
0.35
0.29 0.06
1.07
0.18
0.31
0.04
11
3.73
1.01
0.77 0.07
0.77
0.39
0.20
0.06
158
3.28
0.90
0.74 0.08
0.69
0.27
0.23
0.07
16
3.00
0.73
0.72 0.06
0.76
0.16
0.24
0.05
6
3.17
0.75
0.92 0.03
2.46
0.51
0.16
0.03
79
2.95
0.99
0.92 0.05
2.28
0.87
0.20
0.19
8
3.13
1.46
0.90 0.11
2.42
1.26
0.30
0.45
6
2.50
0.84
0.61 0.05
1.69
0.21
0.37
0.06
87
2.85
0.83
0.68 0.08
1.71
0.50
0.29
0.09
8
2.88
1.13
0.69 0.09
1.74
0.41
0.29
0.11
8
2.25
0.46
0.46 0.12
3.39
0.60
0.74
0.17
148
2.91
0.82
0.68 0.09
1.94
0.72
0.36
0.12
16
2.63
0.96
0.67 0.06
1.94
0.48
0.36
0.09
6
4.33
0.52
0.72 0.01
1.30
0.12
0.18
0.01
79
4.04
0.41
0.67 0.07
2.95
2.13
0.31
0.13
8
4.25
0.46
0.65 0.06
3.51
1.17
0.33
0.09
N
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Table 33. Autocontour performance and physician rating. Mean and standard deviation of Eclipse Stars and agreement with physician
contours divided by Physician Rating.

Structure

Brainstem

Cochlea

Eye

Lung

Mandible

Parotid

Spinal Cord

Rating

N

2
3
4
5
2
3
4
2
3
4
5
1
2
3
4
5
2
3
4
5
1
2
3
4
5
3

8
63
19
1
7
81
7
41
66
63
15
6
25
32
25
5
41
41
14
5
1
63
75
26
7
5

Star
Dice
Hausdorff Distance (cm) Mean Surface Distance (cm)
Mean Std Mean Std
Mean
Std
Mean
Std
3.88 0.35 0.70 0.07
0.94
0.08
0.32
0.05
4.03 0.44 0.74 0.04
1.02
0.31
0.29
0.05
4.05 0.23 0.77 0.03
0.85
0.16
0.25
0.03
4.00 0.00 0.79 0.00
1.00
0.00
0.24
0.00
3.86 0.69 0.33 0.06
0.99
0.17
0.28
0.03
4.02 0.39 0.39 0.09
0.83
0.21
0.24
0.05
4.00 0.00 0.40 0.07
0.83
0.11
0.23
0.03
4.07 0.35 0.69 0.11
0.90
0.44
0.27
0.11
4.06 0.43 0.74 0.05
0.68
0.19
0.23
0.05
4.02 0.34 0.76 0.06
0.62
0.12
0.21
0.05
3.80 0.41 0.78 0.07
0.62
0.14
0.20
0.06
4.17 0.41 0.78 0.10
3.82
0.98
0.77
0.50
4.04 0.35 0.91 0.06
2.72
0.51
0.23
0.17
3.97 0.40 0.93 0.03
2.27
0.85
0.16
0.08
3.96 0.35 0.94 0.02
1.74
0.58
0.14
0.06
4.40 0.55 0.95 0.01
1.44
0.32
0.09
0.01
4.00 0.45 0.61 0.07
1.92
0.52
0.36
0.09
4.02 0.27 0.72 0.05
1.52
0.36
0.24
0.06
4.00 0.39 0.71 0.06
1.67
0.36
0.27
0.08
4.20 0.45 0.76 0.02
1.67
0.73
0.21
0.02
4.00 0.00 0.29 0.00
2.57
0.00
0.68
0.00
4.06 0.50 0.60 0.10
2.37
0.63
0.47
0.15
4.01 0.26 0.70 0.07
1.86
0.75
0.34
0.10
4.08 0.27 0.75 0.04
1.68
0.69
0.27
0.07
4.14 0.38 0.76 0.08
1.39
1.01
0.26
0.14
4.00 0.00 0.56 0.05
3.47
2.98
0.42
0.19
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4
5

76
12

4.03
4.00

0.36
0.60

0.67
0.73

0.06
0.04

3.10
1.37

2.00
1.23

0.31
0.21

0.12
0.08
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